var title_f1_2_1056="Colpexin sphere pessary";
var content_f1_2_1056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Colpexin sphere vaginal pessary in situ",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1056=[""].join("\n");
var outline_f1_2_1056=null;
var title_f1_2_1057="Dog bite uninfected";
var content_f1_2_1057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uninfected dog bite",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 210px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This child was bitten multiple times by a dog in the back (Panel A) and thigh (Panel B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ludwig S (Ed). Bites and stings. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1057=[""].join("\n");
var outline_f1_2_1057=null;
var title_f1_2_1058="Algorithm - acute abdominal pain postmenarchal girls";
var content_f1_2_1058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Acute abdominal pain in postmenarchal girls",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 726px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1058=[""].join("\n");
var outline_f1_2_1058=null;
var title_f1_2_1059="Severe aortic plaque";
var content_f1_2_1059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe aortic plaque",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe aortic plaque (arrow) visualized by gastrointestinal endoscopic ultrasound (EUS) probe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Zamir Brelvi, Division of Gastroenterology, New Jersey Medical School, Newark, NJ.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1059=[""].join("\n");
var outline_f1_2_1059=null;
var title_f1_2_1060="Balanced salt solution: Patient drug information";
var content_f1_2_1060=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Balanced salt solution: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/62/30690?source=see_link\">",
"     see \"Balanced salt solution: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AquaLase&reg;;",
"     </li>",
"     <li>",
"      BSS Plus&reg;;",
"     </li>",
"     <li>",
"      BSS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      BSS Plus&reg;;",
"     </li>",
"     <li>",
"      BSS&reg;;",
"     </li>",
"     <li>",
"      Eye-Stream&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701586",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to balanced salt solution or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11140 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1060=[""].join("\n");
var outline_f1_2_1060=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138972\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138973\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023835\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023834\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023839\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023840\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023842\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023837\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023838\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023843\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023844\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/62/30690?source=related_link\">",
"      Balanced salt solution: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_2_1061="JXG multiple lesions";
var content_f1_2_1061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile xanthogranuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple scalp lesions in a young child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" style=\"FONT-STYLE: italic\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1061=[""].join("\n");
var outline_f1_2_1061=null;
var title_f1_2_1062="SLE with end stage interstitial fibrosis CT scan";
var content_f1_2_1062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F88486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F88486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    End-stage interstitial fibrosis on computerized tomography scan in systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 223px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADfAlUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3z4l+PNN+Hmh22qaxbX1zBcXS2iJZojPvKO+TuZRjCHv6V5v/AMNN+Ef+gN4k/wC/Nv8A/HqP2wv+SdaN/wBhqP8A9J7ivMfgp8KfDvjXwVq+v+I9U1WyFheSQsbWSJY1iSGKQsd0bHPzt36AcUAenf8ADTfhH/oDeJP+/Nv/APHqUftNeEjnGi+JeP8Aphb/APx6uJ+F3ws+G3xJ0y8vNB1bxhCLSYQyw3b2qSDK5VsLEw2nnHP8J4rwWyjH2OGS4LDzFU5UctxmgD6x/wCGmPCef+QL4k/782//AMeoH7THhMjjRfEn/fm3/wDj9fKhmVQQscYXGCCM/jSTpslwB8u3I9ge1AH1WP2mfCWM/wBi+Jcf9cbf/wCPUv8Aw0z4Sxn+xfEn/fm3/wDj1fKBIxwMgD9aCPQ8r7frQB9X/wDDTHhPj/iS+JB9Ybf/AOP0H9pjwmDj+xfEnrxDbn/2vXygiNIdqAs3qvp709oZFXdgH3ByAPTigD6s/wCGmPCf/QF8S/8Afm3/APj1H/DTHhP/AKAviT/vzb//AB6vk7qCBn3pQefXnnNAH1f/AMNM+Es/8gXxJ/35t/8A49Tv+GlvCnl7/wCxPEmzO3Pk2/X/AL/18oRxlzkfLGPvSdlH+NEriRgsY2oBtQd8f40AfVv/AA0z4S/6AviT/vzb/wDx6lH7THhIkD+xfEnXHMNv/wDH6+Tc45PTpS49SM/yoA+sn/aW8KI5VtE8Shh28m3/APj1J/w0x4TyR/YviTj/AKY2/wD8fr5SSQMoWXO0fdYdV/xpTbycCLbIhPBQigD6r/4aZ8Jf9AXxL/35t/8A49Tj+0t4UCBjoniTaTgfubf/AOP18pLDtGZiEXuOrH6D+tNlcyNnaABwFH8IzQB9W/8ADTPhLH/IF8Sf9+bf/wCPU7/hpbwphj/YniXC9f3Nv/8AH6+Thy3HTNPj5tZMHLBl4PXv/WgD6t/4aZ8JZx/YviXP/XG3/wDj1J/w0z4S/wCgL4k9f9Tb/wDx6vk889M460H0x1oA+sf+GmfCWf8AkC+JP+/Nv/8AHqT/AIaZ8Jf9AXxL/wB+bf8A+PV8nkHGM8dSB2pCe/f1oA+sv+GmfCWM/wBi+JP+/Nv/APHqT/hpjwl/0BfEn/fm3/8Aj1fJw4/HpmgdMDgUAfWX/DTPhLOP7F8SZ/642/8A8eoP7S/hQDP9ieJcf9cLf/49XynAqorSPhgvyhOzN7+wpy3k4bO7eO6kDH5UAfVX/DTHhP8A6AviT/vzb/8Ax+lH7S/hQoW/sXxJtBwT5Nv/APH6+ViLeUZcmJunHIPtUc8isqJEpCLnr1Y+tAH1Z/w0x4Tz/wAgXxJ/35t//j9OH7SvhUxlxoniXaOc+Tb+v/Xevk0Doc//AF6khlMWR94HnGcc/WgD6tT9pfwm7Kq6L4kyxwP3Nv8A/H6H/aW8KIQG0TxKCe3k2/8A8fr5YUwSktFG3mD5hHnAPfj/AApkjpcMsjSiNiPmGO/t/hQB9Sv+074QRWZtG8SBQMk+Rb//AB6vSviX48034eaHbaprFtfXMFxdLaIlmiM+8o75O5lGMIe/pXwBqSqIZzGCF2Hr9K+t/wBsL/knWjf9hqP/ANJ7igA/4ab8I/8AQG8Sf9+bf/49R/w034R/6A3iT/vzb/8Ax6vGvAHgbwvqPws1/wAZ+LLzX0i0u++zmHS2gyybIcECRDk7pT/EOB+fbeEfg/4E8Sa5f6OLjxvp2pWUEVzJDeS2RzHIMowaJHXkdiQfagDr/wDhpvwj/wBAbxJ/35t//j1H/DTfhH/oDeJP+/Nv/wDHq+RLdi8EbMcllBJ/CpkXceeFHU0AfWw/aZ8JHkaL4l/782//AMepf+GmPCeP+QL4k/782/8A8fr5RVWJCqCcjgelTxQ+YwjjDvMRkbBkE/3cdz9KAPqb/hpnwl/0BfEv/fm3/wDj1L/w0x4T/wCgL4k/782//wAfrwvw58J/FmtIkjWH9nWp/wCWt04Tj2U8mu80n4I6TbYOsa5PcMRylpDhf++m/wAKAO3P7TPhIDJ0XxJj/rjb/wDx6gftNeESCf7G8Scf9Mbf/wCPVDpvwv8ACFqN66DNeHOC11MTn6gYrXg8H6DCB5HhPSsejR5x+OaAM9f2l/Cbfd0TxKT7Q2//AMepT+0v4UABOh+JcH/phb//AB6r0/g/w9LgT+ENLb1xEVP4EGsu4+HHgm6Vh/wjUltnqbeZ0I/DkUASj9pjwn/0BfEn/fm3/wDj9H/DTHhP/oC+JfT/AFNv/wDHq5fUvgr4Xucix1bUrFzyBMiyAH36VyGq/AvxHAWfRr7TdTj/AIVEvlOfwPGaAPV/+GmfCX/QF8Sf9+bf/wCPUsf7SvhWRwqaJ4lJP/TG3/8Aj9fOWs+BfEui5Or6PfQIpyZBCXUD6rkVzzTJE2yPKydCX+U49MdqAPq0ftM+EiQBoviTn/pjb/8Ax+k/4aZ8Jf8AQF8Sf9+bf/49XycuKUjONoI4HJoA+sf+GmPCeP8AkC+JP+/Nv/8AHqVf2lvCjMFXRPEhJ/6Y2/8A8fr5M/l9afE4jKluVGPyoA+r/wDhpnwlx/xJfEvP/TG3/wDj1A/aY8JnpoviX0/1Nv8A/Hq+UHUxsVJGc/p601T1ycfX1oA+sf8Ahpjwn/0BfEn/AH5t/wD49Sn9pbwoFDf2J4l2nv5Nv/8AH6+TMjufyqWIygsIBISRyFBPtzQB9Wj9pjwmf+YL4l/782//AMep0f7SvhSQ4TRPEhJ7eVbZP/kevmG10zVbo4Gm6hMjcYFuxP4cdc1ft/Ani252mDwzqzZ6E25XP50AfRp/aX8Jg4OieJQfQwW4/wDa1H/DS/hPOP7F8Sen+pt//j9fPM3gfxlArNP4b1UxAZw1vvz+XNYl1p2o25P2rSLqE991vIv9KAPqEftL+EyM/wBi+JMf9cbf/wCP0f8ADTHhPOP7F8SZ/wCuNv8A/Hq+U3WMA7kmiA/vKT/Sk2I2RHIknf5Dz+XWgD6t/wCGmPCeQP7F8SZP/TG3/wDj9If2mvCQ66L4lH/bC3/+PV8o4IKhgQV6jHNIV3ja3A659KAPq7/hpvwj/wBAbxJ/35t//j1H/DTfhH/oDeJP+/Nv/wDHq+SSCDg0lAH1v/w034R/6A3iT/vzb/8Ax6kf9p3wgilm0bxIFAyf3Fv/APHq+Saiuv8Aj1m/3D/KgD9MaKKKAPCv2wv+SdaN/wBhqP8A9J7iuP8AgvoOs+KP2ffFeh+Hbm0tbu/1hoJJrlmVVhMFv5mNqkklcrj3PNdh+2F/yTrRv+w1H/6T3FfIrQROxLRIzHuVBoA+2vAnwy1DwP8AEKXUtK1Rbvw/d6ZFZ3UV1sScSwgLEyrFGqFQgC888knNfGVqQLO18wea3lLx0AG0YFNtdNW7uorW0sRPcykKkcUe5mPpgD9a9h8K/BLUriOCbxZcwaVaYBW3j/eXGPQgcLQB5KjL95UjU+sjZA/OtLSfDmt605/szT7u8Y/xRwsV6/3ulfQngvS/A1peyQaVpH2i6iLpFcamhk84I212jB4wrgg8ZHHGCpPeNeXbYSPKx7R8sYCqMDgYApRkpK8XcD5w0/4LeMroBprO0s165ublUP8A3yM1t23wH1TAF3rujw467N8hB+nFe2LmUhETzDuJYEZNTxWV2VBWMDIyAWwcf0pgeLv8DZCqxyeLLNAT92OzYDP58io/+FCTiQCDxVaeZ1x9nYYHboea92jspBjzJtpPIASny2cfzSSzuWXqGAoA8Cf4E37Z/wCKh0hzjn91IhB/xqI/AbVyR5WtaPJu6CR5F/pzXu0iwvIPIkdz6MhyPYGlMDMuYIJduOjDp9KAPA5PgT4kfCrrWghB2WRsA/l1+tMPwF8QDIbW9BwOpEjnH4Yr6Bis5xw8S5PG48D64/rU66efvM8Kcc7QTkev0oA8Ah+AmpYzP4l0lVPGUikYZ9PrV2D4D26j/SvFJfHXybT+RJr3GbTmUExYc5HGe30pkWnTDlsbM4GG/I4oA8bHwM0Xgf8ACRakW6Z+ypgn255qC4+BFoy5svFDggc+dZ9Pbg9K9yOmjdneFOMdOOPWlOmoRtGAR3CncfxoA+dbn4E62jE2Ou6PcegkDxH8iKx7r4L+OIP9Xp9ldD/p3u0OPzxX1D/ZgUfPIeD97b/jURsU/hZTzyQCSD+FAHylP8LvHEJPmeGb8n1j2uP0NVf+ED8YWzfvfC2rFCMEGA9Pwr67SzkbBjlC9wVY/L+FONveLlo7iZScE5k4NAHxxL4O8Rxlv+JFqpXd0Nq4YfpVVvDWupy+jX6c94GH9K+zlivwxK3Tcc5MhP8AWgnUtuwNKxIA++efrQB8VT6dcWn/AB82l5v/ALogdfpkkVTkktg+2TfC/wDe6/mDX2/u1MfxuVPZvmx+dVZ8udtzY2cm4f8ALW2Q5/SgD4pYDGUeORfVXB/+vTActs3fN/d719lzaVo9yred4b0R/XdZpkflzVU+GPC5J3+F9G3Y42w4/PB/SgD5BuHjQLGHX92Pm5/iPU/h0qLzEHBdR9DX2Ivhbw2MFfCmiL2x9mBp6aB4ZAAHhfSN3bFqpH+NAHxx5sf99PTG7inKynJDKR7GvsT+wPDy4B8NaGueoa2QEe1VX8K+Epcs/hbRXYcECEjP5GgD5H7e35UDjBP5n/PWvqO8+Gfge6X5tCNqTkB7S6ZCp/WuY1X4FaVOjNouv3drIcgJeRB0/Fl5oA8FjyJFwCG3Aj2omAE0ijGATgda7nxL8J/F+hI1x9jTU7VRu8/T38wDHcr94flXEsnmM5iOXz88R4ZT7j0oAqXpH2K4GCfkP8q+tP2wv+SdaN/2Go//AEnuK+Tb6Fls7gthf3bHk+3pX1l+2F/yTrRv+w1H/wCk9xQBx/wa8MXnjL9nTxnoGmS28V5e6sVje4ZljBWO1Y5Kgnop7GvU/hv8P9S8O+M7rWprfR9GsJNNjsf7L0eRnimlVgTcSExxgPgY4Xoevr8RNDE7FmjRie5UGmm3gAyYYgP90UAP0+N5ooI4lLMUHA+ldDoegXmr3SWenRSXdy3/ACyt13n/AIF2Fd58P/gzq+u6bYaje3Eem6XdrvOAfPCA8YXtmvf9D0Cz8M6XHpvhy2S1hI+eVv8AWSnuWbvQB5BoHwWKAP4m1FLMEDdb2v7yVh6Fug/CvSPDnhrQvDrH/hHtJWO4PH2mX97IR9Twv4V01vYDdvuCshH8IPPHv3q7GgjXEYCYH8PQ/WgCC0ilCyNdS+a7dpDnH59KsBEQfuVALDJwvFKfvDdkHOQQeGoOcqcAhsZbt7CgAVs85xjpg/40EANgAbsZGD+dRSTxxj55Bkclhzj/AD6U1bxX3JDE8h6kDgA+/v8ASgCfGVwMbecfNj9aa8ykjfKGIHfrj0yKiaC4mQb5I4wR0U5z7GlFrGhyZWOeDnj+XWgBszbtg8gS56F2Ax+dQyRw+U+2PgjpH3J/lVoRRxqxjgiOOc5yce1SRyAzCONtpPXkDH4UAZtu17EP9HadV/un+H2NVNR0Oy1ZSms6Fpl+rDDNLbqW+u4YNdZHbKVAY57Ahs4+tVb2CPzRKoIONrLHwPyoA8r1b4M+EdRcm206+0uVif8AjyuNyZx/cfPFcrqHwDtg2bHxPJEpHH2uy4H4qa9+0qQGOeFNiAuGyBywxxz6VpWRgWR0uo1JI4L8gf8A66APlmb4Ca2uRDr+iuOg3iRP6VCPgT4gON+t6CufWRyfTptr6sudHt3lEkZjt4s/OMZDLjg+xql9hhG7AUxqd27oT7+1AHzvp3wJbci6r4mtnjUbitraszD23MRXVWPwb8HWeDNbarekA/NNN5a49eBXqV5Zx28iyo4OflIbnmk8qR32NBE/I554+oPegDi7DwV4RsVxZeFbFmXA3T7pT156n6Vv20QtVH2PTrG1GeFhtkQfXNbB0xGyPJAP8QU9T/k1WnsFZc75B0UKy5/zxQBGsupErudlQ8YRhyPqP50yaC9aV8XTMp6lpT06DIp6WPlhxGqSZxyGI4HOKkiMUZIkDxtznzORj1HsBQBUjiuRJt+1SKwIHDnHHTn096txQXhBMl65HPJG4fgDUqBdhaFVJI4APHsBTkmWUEHcu37wJ/znJ/KgCotu7sfO8qRePleBDuH4isnWfCGgagrrdeHdKuQ2C+IdjfXcuDXSBVYbjt5z/Fjj3NAACj7vPHuaAPH9U+EfhS8BFo+p6U2CAobz0B+jcj86878Q/BrxHp6yTaT5Gs2w6G1bEuPeM8j9a+oJY4pULSIHBGQSOc/X6VSk03y2MlvM0bjplun0NAHxJqFnNaXDwXMUkM8f3kkXaR7YNUq+0PEGiaXrcPkeJdKhuNwwLhRtlU/74/rXzn8WPhvL4MaHUbG6+36JdTGJJNm14GxkLIOnPOD3xQB53UV1/wAes3+4f5VLUV1/x6zf7h/lQB+mNFFFAHhX7YX/ACTrRv8AsNR/+k9xXzv8OfAep+N9QkSz222n25Aub2QZSLPRQP4mPYV9D/thnb8ONHPprMf/AKT3FN+GWkSaB8OdH0+VfLuGBuJgR/y0k+Y5+gwKANHwr4a0bwbaGDQLVRcFFE19Iu6eTPXnsPYVrW6SSy735yeXIz2xUloY9ksjrG652j35qyl7nA8uJUBHc/060Acz4s8IllbUNHWQzgiWWGJgruyjAliJ4WYDjn5XX5H4wVf4M12C8QRX9wFvVjJQhSqXKA4LKD8ysDw0Z+ZG4PG0nplM1xLug/dRbR8xU/y7iuY8U+Esq+o6QJmu0dZpokIVpHUYEsRPCzAcDPyuvyPkEFeKrSlRk61FXvuu/mv7357Po1Sd9GdULlW4ht3II+YhRxz61aVZSGLLGF7LnJP/AOqua8I+Ko9SijtrxguoBSUMalEuVB2llVuVKnh4z8yNwcggno0m8xisKuxzhvmAAPX+ua6aVWNWKnB3TE1Yk29juyTn5TyPenbQMEduFyMgVGA7kkBQvU7f8KcQQV3GRi3CqF/oK0EPBYDhSoPXCnn6ignkkEjPO4ZH44qddOBkRLvcXbO2OIkuPq2cLUWoQWtvZkJGUud3KifcSo6luw/CgCNSABtLJntnrRuP3i7r698VQS7gMKyxNbuhUsCW+UqO+eRj3rldR+Jfhmx8sNqPnBtx3W/zgYOCPegDuCHC/NsAAB5Hb1zTgVHJHPQkNx/+quH034h+HtU3R2mtW0MkZGVuf3ec9wSK9DtZrO004pGyF3jXdNt++x6j8ulAFSNDKw8mGWQjuo6/4VM9ukPy3E2zp+7j5OfcngVd090WUBQiRkfOS2cjHH1NKZLKNQsbyOoRlPlqMDPfJFAEEb2u0eXbqrd/NO4j3HOPfFXIbhl35L8J8xXGxW/2f/1VTSe2UHZbOxBwTkbh9cDpTRfLCw/0J/m4O2bjNADnuY5nK3CRcjIJUevqOaheOLcSryQ8j/WktGB/vDp+NTi8hchJrd4027cowbBH4Z/KozbRXMziK4g2k7ijblOcccGgCCRJoQPNUqCAQV5Ujtg/lTV3Fcc88YHatuK2FjbsSco38HQZPas1reIvhi6owxkcBD1z9KAKbHacSYA/vFsYpcjbgsGDdcjOR9Kydb1ex0aWaWbUAtouShONxPfGevtiuSufiv4ftQ5ZrqcqCcABM89AfX0oA9D8tBtDYZh0AXJ/z9abJDFIuDEvHqmD9K4Pw/8AFPw5rGorZrI+nzO+2L7ThFlJ6bWzjP1xXUQ69pNxceRHqdn9oVymxpBnd/dB6Z/GgC6bKEnbvZcDgCQ/kKclswynmK4PYknn14606RjGNjbevQDv6Cp5lkgQLPFJErD7zABPzHT8aAIDAEUokMQBOcggY/OmupwA9srDGTtYEn1NTl1HGzAHTcOD+NIjbgwyxUnO5RwPagCi0Vs0bI0YjYjBbbg/UVUNlMAWjkDxg43dCa2iB0YH8Wz/ADqvNZW8xJMZVs4ynP6ZoAxy89qylXeNwMbl5z+PesLxR4T8OeL4iNesAl5jCX9quycfUjh/oa6aWwmgJ8oMwHGV+6Paqzb9427uefqenrQB8vfE/wCGur+DbW4uSw1PRmDBL+BcBTjgSL1U/pXvv7YX/JOtG/7DUf8A6T3FTePpZYPAPipd52vpV0rIV6/um/rzUP7YX/JOtG/7DUf/AKT3FAHyRXffBTwgni7xpEL0H+ydOAurs44cg/JH/wACI59ga4BiFUk9AM19XfBPw0ND8GQQypi91BBd3LBSGUtjan4Lj8zQB3lzfS3UyiCM7Dn7o5H+Aq3AGRMP06e/1xTbW3SBAIkQscnOOvvmnoMDKsNpPQHgUAOJOCc4YnBJ5/WlyFOSwVfU8D9aQ71U7GAbkZI5HH61SFqrnBJlfGSWOR19KALglVovlO5fQkY+uagMrSZMSMA3BYnCr/jWhaabGsAkmkENuw43kHeP9le1W3lhtoUuVaG0tiPmurlgrH6E0AZlnokrfM8Lk9egC/XHGahnv7e1tpJbqVLa0hGXmlYIie2awtc+LHh/TtJvGtbqe6+cwwzbeLqTuIzn7q9z06gc14T4y8TXusMkmuvNbyNbOq2cEx+zg5+UhTnB785oA9P134yeHbGSaPTo5tSnUgq8S+XGf+Bn+gridU+MPiK7J+wWtnZQyAqMAyDIHqcYPtXmIjRY3IIc7cbJVPX146+1WdLt7u5sdRitnURxRrcS24GfN2tj5fcZzigDtYfiv4tyuyS0uSAEMMlqDnuRwc9K6HTfjjcQ5OraBbygYXzLWcxt/wB8nNec6VaNb3a3LeXZyC1ljTdKNyzbSAWzyueTg0xNIsIdHW6HiSxlvuo0+2geRw3HBYgD+dAHudn8dPDcg23cOqWkgGSGhEv6qa04vin4Ovowza2kLnHE8DRkYPXp+vevmIs2xDuWaN/naNWxgg9/Tn/Cm5heBmLBJIwW+YE7yT0HYDFAH2F4c1fTNQleew1Gymt8D5kkVhn35zzXX2Aht0Mss8TK/ChWyB9K+N/Cfw/1nxNHFJa2bWWnOBm6mBVfcqo5bNe++DfDMXhrRk06G5uLiNWLmedizZOM47Ae1AHos+oRvH5VsGILZd2G0Ade/WqqyjALkA4BXP6Vli3BZvMZpWGBnqrexqVUThFCKCSCAM/kO1AD7yX7TJgKdqDAPb86LZzHgt0IweOeP6+1NIACARrkDOAf1HvQo6AYBIBz7fQ9KALrXsYJOR6f/Xqhf6lCzICDgHcMHr25p2AxBVWQ8444qFrVslgxdsZI/ib04+vP5UAULnWLG0jZ55fJjwSWOTgdaj0PxPo2tEJp2rWU8jdI/NUMcHgYPPv9alv7WKe0ms7m3SaN/vA44/qK8Q8d/Cm5humv/DMIu0zj7Kp2zK3qvr+FAH0DLboHIVmilAzlSQR9f0qNluEUmQCbaCc4+f8AEdK+Y9A+InirwzOljcTPdrbSFZLe/Us6n+7v+8uO3Wvffh98S/Dfi62gstsdlra8G1uzsMrDr5b9GP6+1AG0kizBRIWR85JjPf8A+t+pqwAyY3M0hJ+9kA4+npVy50+KViAGWc8CGZtrH/dYdaoJHLau0c+44y24r8y/Ud6AJmGSTK2ABnHXH40wD5A275ug+TlT/jSgoxLYbb1XIH5kf56VHcSyIFZFLPuxwOPegB7BtuGbaWzxyc+5/Oue8TaRZ67o19ourO7W91EYy6jaYz1V8f7JwRWvDfxswSQCJjwSTnPpmpbm1WcLuRgwz8gPGR/eoA+GtX0650fVrzTb4AXVpK0L46MR0YexGCPrWddf8es3+4f5V7h+0d4Ye3ubHxFHEy+bi0ueOCQMxvn6ZX8BXiF3/wAes3+4f5UAfphRRRQB5P8AtD6P/b+leD9N/hm8Qwl/9xbe4Zv0U1auS0UzHO3eeFOOB2AH0rT+Kas914NVOp1l/wD0gvKznuXP7tlixGcbyADQBLIm60SYy8ZyUQBQGNWLS03BJH4UD5FPt0NRTRIlnFH5okLsCzA8nHJxWoVBUbRjgDOOlACcBQfuqOi4yKYAu07gTgDPy8jJ9KkaMFjld3y8Hrx+NQzXkNsVR5BkHhU5IIH+eKAOB8c2VjHr9kLK5+z6reSLJ5e4RCRhhfNjkb5RMqnGOd6goykYK7Gm20/h7xIIbu4WUaxEZnmClVN3H98KMnAaMrtXJwITzW1cRpqVpJDdwwtZyZ3rMgYSD3U5GOnWsG88Gxb7IaPqV7ZJaXKTpaswuIdy9grcoCpZSEZRhjwa8itgsSsZDEUJpQ+1Hvpa9+69Fe2rNFJctmtTrWcNIiKm+V22qFXAY+megxWk0CacyNLLtkY4Lhd0j/7CDsPU1wd7488NaV4ghsbjXYF1IusQih+cKx4AYjgda8r8U/Fi/wBS8QXpga90+00uZW2oyO9ztkxhm7A44A7V65mel/EX4mW2i6bfwaQsF5qVu6RtpsDkyKWPWRh0x3HvXnOs/Eu01/wR4isNTivNF1ARxiNbMGRtu4ZyeAvPBHpXL6nqmi3V4fFOj6Jr9nPcXLXd4WukEHmB+YySM+/41oaFq3hh7XxO0Ol7b9rdhHNcTm78+NvmCuOBvDHr6D1oA0PHHi+7uPh9pFrpVnPZ6RqUSxm5liCtKigZQbeAM8+4rzGzjjSUtcbhbqpZ448Ak9sfjiuq1/xvr1/pf9iGaKLTFjjzDHCFxgdAT0GfSuVmlkmaFJWjYbQPMAxgehI64oApOgkG11VcdQRuC/8A166LSvGviTSZ7d7bUrl7e3RYo7a5YtC0f90jrg+ozVLTdF1HVoLn+zbCS5W1QyTSK4CqmcbiScVXbSr0Ex+T5zoDmOFw5H0AJ/SgD6i8CeK7LxH4VGoWhaOdG8ua1DbjC47E+ncHuK3IJ55J8yysqAZIU4Ix6f4189/BC7vbD4gQaf8ANHFfxOk8LL1KqWR8HuMH86+i4LZFw6OZMcgEcKfTjpQA62y8fmI0jCQbkZ+APr+VSInXJGWBY88fhnvTxktjaMdSCelCcsFJJIPIDZb3PpQAh6HDMDkkHcB3/WlMzouZRlRnqc9PahQWRQu0+gIyfwPc0FsEc47kNwcdv8KAJEu2a3ffORCefmB4x0xVTUHZYTJ5vlbBklzgMOpOfQf/AK6bJcpCxRxx1yvTFeIfHvxXdCSDw5aTtGkkazXbqdu9SSAg744JPrQBw/j/AFyw1jxVc3Wn3F1eQodiysQqH/dHYe/euf8APiYIkwCIckvtz9MjPSqyRgxO3moRGM8AqSM4wPf2q2moQJGiJZKQp+/I5dunY9Bz7UAP0eO0M4e/KpZK2bmbOGCeiY6sfSi9bTbDVLiPQ47m80rcpj+3sRIw6/MqnAPpVHbtmXzkcMOThTvYH27Ur5AwMKvJyR0/2aAO5sfip4k8Oa5FdxX0uo6JIEMVlcsDtVeNuQMq4wfrX0z4P8X6b4x0SDXNLmlhFxmI29wfk8xesZzxur41sb77ID5UcNwsqkSwzRgrgEYwT3//AFV6N8JfGdvpN7qNtfo8NpcW+9I4VMiRlWztWLuSDjjn60AfS91bJEsj26YjQ4lhP/LM+oz/AA1TeCJ23BcOOuDjFSaXqkdtJDBd3MSw3GFtWn+ViSM7MHk8djyKdqUDWVzsCloX+ZFQ8gdx74/rQBUKScZk8xR/CTg/nTmuQjFZQyEYw+3KnHr/AIU8OjHaCN3YE4J/A9KcwyCCRt+mQKAEUhuVwV68dOOvSo5bSGUMVGxuzqRyD/8AXpfJCyK8R8sluQnQjvmnqW4LHB7en6fyoA4j4mWckPgDxOduVOmXR3Y6nym/Kqf7YX/JOtG/7DUf/pPcV0HxOG34ceK8rkDSbr8zE/8AhXP/ALYX/JOtG/7DUf8A6T3FAHzt8J/DY8V+PtM06XItIybq5IGf3UeCR+JwPxr7I2qIwRtRN27A4wPb8uleJ/svaGkGi6trzq3nXcws4jg4EaYLY+rHt6V7cNh4Kgrnjb+eKAGj94CoViBzuyAD6Y/OnSkorBACwHTIH4VSu5i7PFC6hPXHU/h0p0dsFt2MkhJOT6A47n37UAFqskke0sxJ+9nB/AD0q4kZjGRGZmBB+c4HHXkGo4VRMImC4GORxn6V4x8VvHsl75mkeH7gRacCVuryIH5znBUY5Cj9aAOw8ffGaDSriTT9At7bUdXAIMuCYoT9f4iPbivEfEOq6j4hittW8Xag2pRG4EUMSzBR1+dMDhPbg1iblWMxwiRIOTwv+tI4z/8AWpsd8bCG4CLaqJEI/eWwcr03FR2JHWgDU8SafJe3MevLHbnS7xDDZ7GzHCqDBjYdQVPoOc1h3h8qR0aMMg4jZTwR6juOlb2sWwgsNNli1OR3iQvHC0e1YicZ2IOV9STz0rn23y5MisxZiWfqWzQBJawm6vrZJJWVJXCvKqbyB3O3vj2rWW8i0uZH0tHLsCzNMg3TxNxuUZ4B5+U88ZrKiUxjzY0kjaMYk2ycv2JT0PNS38Bt2hW9LhnAnJ3cbCO2Rn2NAC3kz3YY/aEKQBVj3BRK6Z4BxwdvXmqomuAySBpC0WArKcYAORgjkGiOETSuEZFcIShB278dRnvxTlW0a0XEd0bj7g2nKuc+g5B7cUAW9P0/Uby/iSw0Oe+lnYlI3jYqc5+YkYxjuc+9e0eAfhZYaRGl5rIXUNUHzlPvQQN6KD94jj5jxVr4PeBn8NWzarqryLqt2hRbcudtvC38PuzDGT26V6M/llGzt4wMMvA/HtQBFbIURR37HgHPpj+lXFHl8KThucCq8qqVKk7fXJxkelWdu0IVJPHy5/iH0/8A10AL94AgNtIzkjII7fSl+8UU5bPoMfgaQhcgkPuJznp05/E0Nz/ebJ64DL75FACHGfuIwz13ZwR3x9fSnckY3H5j1Jxke/oKR22kthSBgZJ4PoAf8ilO0O2cqw4I49O/19qAFTI5wVyM5zkY+mOnegtjONpce3B46fSmjAVuzd+madtyCFyADtAwRx7+5/woAaQ3Q7T3AI4H04NRNaq5EiEr/cPapgwzlXwO/H4Y/wD1U3I6kK5/iPf8PYGgDk/E/gXSfEbK2pQAXKc/aYMLMPYn+L6GvJfiL4Ev9L1J73yX1DSPKC+ZAm10YcDeozx6kV9DnI+Qgr6r6nrycUHnGEGcZHQkj1I649qAPn3wb8Xte0WOKyvvK13TkG0xXLFZ07YWQ/1z+Fe4eDvG/h/xgiWdldsLsDi0uyEuE9Sjchx9PSuM+IHw9sNanfVNOcWOsZ3CWNAUmx3dexHqK8T1fwzr2mXxuHPnPDID9qsJQ5RjyM4OVPsRzQB9Z6hYvDO0bscuMh0GVcfTuaz2QxF0G5h1I25DEddtcd8MPHM3iO0jsNXkEerwxlh/CLhBwSB2b+8PxruJ4wIy5DKO2O/p9Pp3oAoJZmSRx5mGH3G7Eemfb1rSijEUcce5H2Dlz071HbzCUujl0bHp8zf/ABP0q02Tz84APr/hQBieLtBh8TeFNU0a4YILyAqspH+rkHKNz6MB+FfDt8kkUNzFOu2aMOjr6MMg/qK++nBKMpUAnIwf518h/H/QV0HxzqBiUrb6hB9tTjjc2Q4H4j9aAPvGiiigDgviu7R3Hg1kxuGst1/68LuqCIk6MWZU2feJwN5Pr9Oav/FcZuPBox/zGm/9IbuqLDfsTaSyHsOOlAEtnbq06ANvVCcDsB2960Z7iO3UEgeYOAo6knpkH6VQia6FswhiMYBOW6H06VVht3liWT/WbSVPOcn1oAc13LcuUZwm5iCI/wCWe1aFtZJDIcnMmOSvIH+R3q5pljHkNPkwxHaNp++x/hq5qgjns2EMYgaOVUDJ3Unn9BQBlJI7yuMZiUAADr9OO1eWfHHXdctIjpWlTNa2V5bnMyKS8zZ+Zd/RAAPrzXmnjn4g654m8XqmhXtzptlZytHbJFJ5fKH5pZMdenQ9q6L4heOP+EmtdNswA1tHte6YRlWdgPvgfwg+tAHmkPhrVRYPLMy28KTKMs4Jz13Zqxr6SayJLmGK206yjkCiLt5mMFiwGSTjPPStTS729vbtNNhnMcExaMtIwKIueWbPXHr1q3q1kvh+R30y4i1mWd47RolhLJG/d2TvnPFAG7ceEriSFdDsbi0vFlg+1XM87MIFQqp85HHG5R/Cfetb4aWnhiS0uPDVxNam6ckpqEaeW0p6AKT94jqKo/E19X8L2Oi+HvtKHS2tGlWNISu5icOrn27DNeVXsiPKAUVCv3eowexAoA6bx94en8GeJW06W5ju2Keak2w5dT3IPG71H5VgF1llWSZIgsjh2jThBk9VxyM046lLPbG21CUXaY/cySSFpIT7Nzx22mojN5hUSNvVBtIx2/oKALD31zCl/bQfuI7j93MqEhWUHIQjocEDGapQM1syXMJUO6siseoPQ49+a09Pn0aK2J1Cwu57zzdwlgutiKnptI5qtqjq92yxFGthnyyibMD0Yevv3oAu+FNd/sPxLo2ryCWZLKcSsDJyydGA98E19a2F1b39nbX1lKLmyuE82GZDkMp7/X/PFfGnnyCJEfIReF+UZB6/l/jXq37PmrONVvdAlkdrZ1+2QJuIAIOHAHTkEce1AHt1zdSOQtuARnnGNwPr/wDXq7bBxCuWBLDccjj8e9Vb2RBbukQViRltq/c9ckVNaOJrdGXO1RtOTnGPSgCc/N97hjluf50hJ2ld2AeM4yR/nikUgKCWXbj7wx/PtQud3VkJ5yCD3/PigDPlVPsyrI2Zt+OnJIPpXyr8Rtbl8QeM9SvpcRBZfs8UWf8AVonygf1r6j128ks7K7lzkwW8rxlcZJCnnnv0r4/jikkZTM4WSX598/y5zySTQBGS5O3duwemeM1MjTLbSeWZ/JbHmYT5Sc8Z+lExikwyLINwwyP8y5HoR1/HFTWV9f2O82d3cQs3B8tsoR6UARI7tKzlpSQOWfO7HvnpVqKOI2Di5aRG3gxqrglhjnjrnP51Jf61qGoxLHqN7dTpGc4LYGfU8c/U1Tmmaa7lmBHzNuOcZoAllt08g3ENwksSsFYSYEhPsvf6ioNwKqJdy7Hz8pKlj9f1FTQWz3d0kenRSTSlMlUQnGByQBVrVdLu7OZo7+2msimMRS8HkZyfc+lAHey+KIfF/gOy0zXdXl0zVdDuUuorr/Wtcfwg5/vjP5V6Lf8AxS0e0v7MTyzXekmNY49Ut2LOkoHzLInYHrxXzaSi7kUZXIOXGCP/AK1aOnTQJFcwXaymOVd0ZhXcxI6Zz/DQB9eWtxaapZQ3VpLBc20q745oTncP8fbtRNczWx3OoIBwMHp7GvmX4c+NLrwRq6qWZ9GuXH2i3yTgH/lqnoR696+nrS4S6W3e0dZ4LmPfCUG4OvUfzoASzvY7k7AGWQc4PO7HpVzseMnleOOnqKzp7OOK5XekqyY+4ByD6/Sq8ElzHbSypHuAbczNxx6e9AFH4nkD4c+KRuIH9k3XfI/1L8Zrnv2xSV+G+jlRkjWY8Ad/9HuK1/iLc/avhr4qMmxMaZdAgHA3eS360/8AaR0z+2dG8G6dxi48S2yNlSw2+VPnIHOMZoAsfDvSF8PeBdC0xY3Uw2ivKQDzKw3uenq3f0rQOoPvYKCq4IUH+Zq3dzvbznajiIE5wOR6Y/SoHXzdS2MpPyqzHIxnvzQBLZxgKZnGCAGzgZPv610emWSwiOW4RnmYbgrDOz/6/vVHSYVmvEUnckY3sD7dMVd8V6zF4f8AD95qU5XdEhMan+J+ij8yKAOG+JlzrLahJpHhG2je/vFBuJ5VxFBDjB+bs5J4+hr598b6NPoOrDTow09ssaSrcRjEVyzfeZSPQ5GPavYY/E17ongie41mdNW16I+dNZhwkiiQjC/QA815R408QJfal53h68+z6dpw8q40y5RhGRkHIHXksQSPqKAOdt9R8mJktLS3SSQFGlKlzsYYOAen1xWYTLGykDDKc4Iy315611N7pumyRXi2FvcvPFgmNZgwB25IXIyQPzNYJspI7X7RcK8MROA0qcSHHIAPNAF3UfEV14gjjGqyW/2lAsf2jyhHJIi9NxHcdOO3WsaAFp1jETOxYjYDh2HoakMTlIlIA8wjBK44PTB7fWppLNHjkEN5F5qNzAQQxA43Keh+mc0AV44Z3njtxE0cjzKgBG0oxIAHqP5Vv+MdOn0vVmtrsTrPaSmB1kIcJ0Ybee4OcVn6VBbtqUEd35kLbgQ//POReRljyATivUfHei6j4ts9B1q6sk0Zr50hvTcvgo4Xas2AcYPTryCKAPM7bQrnUYJJIsAjMpllcJFt/LIavWfhL4e8Pyi2vbOQ3upWi7Zpw+5Vk7EJgbeDjceuK43xd4HvfA0a6pf3Nnf2/CKIHKO7noNnp3LdO3etj4A3Up8ZatD5TKt1ZeeybMYZGGOB/vGgD3dRhg+3D9SSfl+uR0pWGNqyKckcZ4OPx96Q8fMRtH8/xNKv3SBt24yVOeff36UANYhotsjYX3PHFIiBWdFznsAw/n/9enZOc5Xg4BDfrmkA2r8hX6L2/D8OlACgF/mwvzDLDjr7c/ypCRtAZQQx5GST6Yx3o5ByBjj5SFOfU59RwOOKUOyghn2Z5Ppn2NACg7ZN4xk85PU5PQ+n/wBelACBtrcJ97vikO9c85PTkdR6n07Up+UgtndnsOnt9PxoADnd/CBkDO4MPp/9emlVyBnKgEZPJz7e+KAdgbKAFjjBXjHvjNITlQSCYiOQT0+uelADi2Ojt04yOfwoB+6F59Ao4z6/544pOcZKgYGSp7Z75zQVz8+V56n7ufY9/wDGgAxtwnzcc4Q/f759qcAcNtJVDyxzkk+57/Smp83yqm7aSTtz8o75GadkZzwPRRwB6sfSgAkRpFOQpZjghwCenTpx3r578VaRd6ProttKt9VjtWuBbRyxDKysxJy2BnjOAT2r6EBDBflk24+43f3J7CsO6V01VLqIbJUUhHDFQo78A8jt70AeTaFf6jqVy9zpVw9vf6aD5rqsbCBMkKztjkcYOeea9e8J65H4i0eO8iltmnX5ZUgYsFP976HqK8y8cS6J4V0m4sNCtI7S+vWWe/VHGJYxn5SueASTwOlc58IPFC2fi26fVzbQaffWhSN7cEQRhW+U5PbJwaAPoGWATNujb98gDDB6jH/1sU6GVXG7OHHDKDnafTNW7PTm/s6Jzua7dTLtY/Lt9MZ64qlcb93nRFiNu122luOx9KAJi/ICnaCccD/Oa8S/aq0YXPg+w1iJCZLKdoXPUiOVeO3A3KOvrXtcTMEw4KvjaVXkk/h61x/xksBqXwq8TwMnEVk1wu4Zw0fz+vXA/CgD2WiiigDg/inGZbvwWinBOtNz6f6Dd1ZjQRYwSqqBubof8aq/FZzHc+DHAyRrTcf9uN3TzdgosoRmxwynGO35DvQBJLIYLUuzA7ckehJbt+dQWccODMI5AVHTOBnrxWfcSS3Ew3K4TJAGOBnuf/r1r+WILTytqpwQRzjPfrQBuxQObWGJFyCu+SQnaV3ck1yPjm71E+FtVj8Ix5vreBlsgCCXc8Fhn+LGcVrarfy3EKRqnlBQMoP+WhH06j2rNvbldH0q4uZYi4hRnwCMsQPegDxGx01/DXwjv7bxmkMOr6jcPJb2ciqLl0OMgsPmXJGTXIWkMesO8t20djjb5lyMhIR2UHPoPc1N4v8AFn/CQaomoXdpDNc7Chj5Ii9ge9czd3cl0qrM+5EHyoq4T8h3oA7DStN0wyXZtdatZVt4zPKq/K8yr1jiLY+c9s1vfDvxtpGgk3Ot28kPnzssEUeHa3Uf89eMM5z1FeZWUlkkU/2yIys0e2Extgo2R8x9KXakoCu8i4OQzcBc+vrQB03xK8aS+LtfDpH5Gn2uY7aNh87Du7Edz7dK4+VhkKN24jnceQc9vUfWrMNrC1heTNdRrJC0aJFuIMu4nJHsPaoMLuw2SvQEHBI9M9TQBC8iGVVRisaHcobAIPrVkQ/6Gbh0faJfLzwOcZK/1rZXXbPTobuDS9PgmS6cJuuLYCSCI8MitnJJ7t7V6/4vbwZo/wAH207SjBcWlzGFskVhJOZicmQnqCOcn0GKAPBnjVoSyuqndnyic7R3JNRS7FEW0liRlsjvniprizigtbRlnaSWRCzK4xs+bA5HrUh06c2lvcQKz27ggk4Chhn5cnrxzigCskhOwKIwAOBtXcf8+9egfAuGJ/GV5qF1N5Flp+nTXN3KP4UyM8+tedXEDxSO0DGSLjBU9B6H0PavRPCmm6ha/B74gaj5EkcV5b28ULsfvxh/3mPYZwfrQBneJ/jL4r1i/lfSrv8AsjS95NvBaoocL2MjHJJI5Nd/8GPihd69rH9i+KGt5LiVC1veKgQuw7OOmfcV88jdjgDGMZxwa7f4Jac+qfFDRYkYrHbl7qZlGNqIpJ/XA/GgD62ZCHGCd/oT14/kaZg5yM5+8do449QfzqC0lkaI+aGwDkeoHoKnOedxPzeoPX/61ADXjiuEMNxGGifIJK5yp4xzXyP4n01dH8WahpciPJa29yyoobDFc5GOuBzX12D3I3g4wSf8/nXzh8drP7P8QJ5zEGjuIY5DsPJ4x1/zmgDzi4CrO4iZMAkjB3fyHJpUhdQsrxyRqeEJyFY+x7Ypdyhw0SAqeArHBOf8KQSMIvJLjyg2fLY7hu9QKAJYPJluIGvpJVtzIBJIDnCZ5IP8XHvTtVSzS+kXSpXuLQEiOadAjsM9cDpXQeA/B934xuLy2tJViitYGlZs5XeeiAds4rmQrKpSWNzIrFVAHzAg88D6UAaGim/tHj1HT5J1aJ/LLJnMYI6/L2PTNSQwar4ivFSP7XqFydzbzmRlAySST1A9+lR6HPDbaxby3VzeRW4B8yS1AEhG0/KFPHPT2qfSribTI5dQsry7s4yGtZHgXLIHU4VznkHgZxQBlAoEkLsJJGHynafl9ST79s0+OUxr1YbhghB8uD7VAoKnayGPoMKDkfhWpp+nQvdXEV5JPGltF50hgUP8vGf0NAFGYQhkWKdpIgoBbZggemDx6817j+zf4tZL5vDN44B8qRtLdsd+ShPfpkfjXlZ0/QhDcS2uuGdFjJWGS0ZZs9jjpgetYttd3Wn3trqGmO6XVnIk8MinlWU5/I9MUAfb2pB7yykR932iEeYmeDwPmU/zFcw8rJaSLGwbcckDn9exro/CmpxeJtH0vW7AqLe7jEk0Y/hYrhh78/yrDhjEskkOcxq23nscnmgDC+Idtbp8NPE74DudKumDkZGfKbA/Kup+JsbS3/goJkOutM6kHGCthdsD+lcn49R4Phx4ridVGdKuiu4c/wCpfp/nvXV/FGUwXngyQLuI1l+P+3C8FAFa5hW2WJi0hkPLE9cY69elXbTLbpWKKzjkFOduBWYpeWRzKVYsBuYjoP6c1p2zZhiyNrNn5SeOOlAE8V9LaOzRbWYrg5Xj68V4x8evFt5b6rpWmTsJrVoxdXkeMCQbhsQdxjGfevXn2bUEhyGO0fNzXy/8TtQW++IfiB2lLKkwgQFf7gA2+nHP1oA1vjNq0FpcW9vb2dndPq1rFey30kRB2/wIgz25ye5rjL3xFdXmmaTLJp0E01s3lSXMYP2h5OiliP8AZxjII4rf1bRP+Eg8I+ErzzpYXgjnsJbiTHlRojlkByQd5yQAKwfDOsyrfLpulsLK2kRoyXUeZLgEkO2DgnnGOlAGvPpzve6nDdxSJawgvlZCvmAKNx92PoPesrVp2vb0Ss7TIigKi5wE9Mnv2zVvUg9t/Y9zIgF1BGzxoTlSpJ2tg9eD1zzT5rOC80e3u9LaRFV/LvombBDnlWVe6noBnqMUAZuo6iNQddtsIESNYkWLoAo4Jz1PvTrHS7i+RpbW2nuWjOXWAEmMH+I+1LqtoLEoudzOC2GZs7e2R2NWPDWtXmiapHqNhO0F1CDgrhQykY2lehB9DQBN9uls5LFLq2SKyRsOojOJFJ5Lf3jgfpXWXfij+ydDeHw/rV3qWlX5bzba9twTH15wx+XnBAHGBVrxVJpF4+iFZIla5thPcRsoktmcnIRyCGicdiODwDXKG5sdVubttVmELOAkYhU7Qy4CfQY4oAxftUsiI5uJZJ9xIL52pnuM8da0fCevPoPjLT9YdW2RTj7Rg4DRN8r9frn8K29P8Pyajol7r1kIGuvNwukIRvSIfKXIPIXI4459a5CdUSx3PPEPMY4t05YD1bIIA+pz7UAfYO6NsPHIHibBVhyMHGCPXg96c3ykEH5zyCDyPw/rXnPwR8UDXPDA029k3ajpmIif78P/ACzbnqR90/QV6MpB+8rLg9ewPruP5UAIckEEsD3DHOfakY/JlyW2+o4X8adGQRlFLZ4yMcZPemGQxkEqAij0yf8AP0oAdgMw+YD+E7cj0/X9KCDt4HXsSRkeg9OKQ7m3KWUEDkk4A56gYyaQMzMc4DDAOBtAx6/p+dAEig/IFj44K89vcfUUwYYEB+pzjZ79ST09PWhBypCkEjIbPOB0wv60HadhIVQBncoJ/Pv+P5UAO2lSFVZCRwP4See/+fem5JYHIyv8KnJH5Hn6UdSW7dQcZC49PegdMBmzj5jtAA47nv8AjQAc8vyeflbbjHv0oBJBGHHTPBLc++MUBucqQg/2WwPTp9PWnF8j7+F6n+HP4DufU0AGASMD5RkjHc+9LsC4wqr656N9QKYPmcFYzgc5PU/QfpTowu4BVy35A/5FACjJHO0nq3OBWLqOWunJAKAcvwwwf8961pCu3gKRjkE8n8ewrn9Q2rcSs7YCgsTjau0DOQPTA60AeIfGLSNQfxVd3yMg0wWqZkUj90emCOrEn+dcSJtukXGn3MQu4lUpbwmQo0Zf5nxjkscA7TwK7nx5qGmjVjqNjNsku7Xz0muYyybiML5eM4OR1PrXKT63bXNjHZ6vplvqWo2jvK14JChmB+8h2Y3f75+lAH1X8ONai134d+HdXs2mhWOFbd0ch2+T5SCf+A9fetrUIkSeVNgMbYdQSRw3X9a5X4ZTz2HgrSxPaWUKSwhntIiEREblcf7QHWuomdJ2jMIby1iVAXOW4J60AZZ+ZTb7ismMCQH+Ie30rE+IKTRfDjxWJn8xk0m7Acj1gcf1revoVcsxf5iAwCr3+tcr8RrkH4e+JgUYMdIuhkj1iegD2aiiigDg/inE8134Mjjbax1l8H/twu6e8TRW7COEMSM4Q8kge9O+JfGoeCuM/wDE5f8A9ILypx97Axng4IxigDOsDtfaGLSMMPGR8wx/Orz8hizYU/eVlwPfP40hiVrlJVCqwBDY4AB6Eqav6XaRyW8klyjeWMRqinoe5oA4f4mXt1YeBdVuNPHkXvkBYnjbaVLsF47g89RXiF/8Q9en8F2uhamsbztuW4uCAXaLoqH0Yckk+tfQHjzw5HrNqdIu7p1jmHnwTBhnK9Nw7jJ5r5e8WeH59A8QXWl300DXNuF3SQn5WDDI/SgDFZMKSryAYwxxgde9CmVSRGfLz8p6EH+lW4FiiEc0n7zdhTGHxu9Qe+fcU0zCK4PlAmPqFZufofcUAQRxtJIVTCyDK8nAP4+v14oEOCVlPlgA7vY/h/SldFkVy+4S5GFXJ3Z6knqP1pZbR4vmkUrkbt5UkE9s0AdXD4Hvf+EQ/wCEqguLW8sEbCwxqxkyDgk9uOprjWI6Mw2ddrHj6jNfSHwg1vRpvh5ZWNxd2cUllFIl3FKVT5cklivdSD1FeTyeJvDOla5fPoPhPTb3TZG/cy3sjv8AL6qD90Z7UAcOgDsTHlivI4yw/qRUkkTxKrSQkKmAGGR+X+FdpefEbUZohb2GmaHpttwTHBZLkHPJDGuTklvLu4uHklcs5LMw5Ujr+FABHc2Ud68ywNcorARJcMRj3YLywHp0qxr2u6jr1zE+pyQmOIbIre3jEccI/wBlRxz3zzVGJRMYw4BCDJ4+9zn8famfMxUIGKM3CMuf5UATGNI3ZIispDYKrk4HUEGvVfh1rOkab4YTw/r1wy2GueeZGeQLFbAYUDcecnqew4zXmWk+ZHqECwQrO24gRf31/ugnjmrN6h3S6Y9k/wBoJCxpE5LKxP3OMhs9Dj0oA7fVvgJqL7bjw3runXunS/PGZyUfb2+ZQQ31FeifCr4cw+CLK8mmuBfa1eqI5ZkBVIol52Lnkgnknviur8DeF5NG8M6bpVu8pitYl8xnkyGkbl8H2JPArpZ9ImghJiYSKAAQudxA6f1oA5nw9rGmeIbGS70G5S8tI5Whd0yq7lHOOlacYbhlAAI69c/SqyQWthBtt4ILSGMF9scYRFHViQBgGvPYfiroNvfSW9nJLeQISDNECid+FJ5Oe30oA9PUIQSpYADg4/mK8B+Olo9z4pilkkW2t1iwkpYMvbnjkj6frXod58Q7B9Fe8gsL6IsVVfMVRgsOpAPHTofwr5+8Uao+sajNdXMbB92xSrhlxz68/rigDLk06SO3a4+02U0ecbonLNx224H61SwWI8oK4PQKeR9e9WsCJCUZ1BHBOdrD/PSo1EXmS4MhlVS21V5Hu3tQB6D8H/iAng1L+01K0861nBlimhQF1kA4Vj/dPbriuCurmO7vrm4k+Rp5GlKA92OcZ/HpUTOSgVstsX/lpwQPQYr6B+Dt14b1DwxZWWpW+ix63tIeCVVE0kWflbnuR7570AeBAlF2lACSd2Bz/wDWFEOUO9N6HoHDnHvn/Ct/x9Y2eleKtTt9MuYJ9PZ98LwYIAPVCegweKwJZIXjKpFHG4PJJJOMUANbO5g0e7aOMvgr71Z026azuG2AvG6+XJGxwGUjvT5ktDYRmKVDcIf3gZdvmAjtn06YqO2uLWK2mSewEtw7hopd5AjXHI298/0oAhVM5KkAAAAMOSM471ZmNuzO4XDHhfmxhvUjuPpV6x03T9QgmeN7qK5jjLeRs3IxB6ByQBkc4NZwXD8FcZwFwABQB9D/ALO+qTr4Flt4ZF32t08S7jxtYBhkZ6gk1285kg8yaAAB+GUDIPviuG+BFtaW/hrUHtIL2BpZ1aQ3BG1mC/w9OP8AGvQblQlszlQSCCAMjBxQByvjwxj4d+LN8qtKNKvAM8DmJjxz1rqfiv8A8fHgz/sNN/6Q3dct8Qo5Ln4e+KZnKhE0m52+p/cvyK6/4lf8hHwTwD/xOn4P/XheUAU4YCbkRSjOPmcEnPPr7Vo9+d3OcccYH/1qhtx8xlAALDkY68nmp2ZhFwNvy8c4+nvQBs6bp8MlkGnTdJKMgt1UD7uPTsa+OPGVtv8AEmsXRkieGS9lKyKfvEHqf8819rXBaHTpSjBXjiJBboCB3r4xn0281iaGOxgVYnbY0kY+V8sSzHPuTQBn+Iry8n8LaG9xExtLSSRvMVMLJMx4V+wbaMg1N4e1az06DStfisIRqaTSxmN8NHKFUDce/c1q2ng+81HVNbsPEuoDSNGt0VYJZZA8aSK3yH8QTz71neItKttLU6XaXLXI075BJs2pJuOS69z26nFAGXqV3Nq+oyzzHYpzgBQwQDooA6L9K7rwSNE8PQfaNcmuJbS9tjBcmGLzI7dmI2Bm5O7OCAK5FNOtU06C5a9e2SeYwIsiZO/IHyjo2efpXoM+j621ysOma5o9rLbtBdi0mQxmd1O3axb5cegoAztZsLAau/hs67o0rTXMcMF6sv75UI+aKQYAGCcjHXoabonw4m1m4R9HjEmiea6i/kkBZgvGCo5Dbh0PT3rQvfCy+D5zfxWeltqVzHcwxi5Pmu1zI2coCOFjB6jmuUj8QaidOsNH02aYCzO5ri2kZPPck7nkA4I5oAyvFemT6Vq1xaTSW8jwExtJGuFJB6c9SPWszEIgZInck4BJORn6jp9KlvZTEZYHCyOsxcux3Mf+Bdx7VVjfcB5kgBJLZxjr2oA9L+H3izw/oslms1vcNe3sP2TU7+RsFYuQoUegGOTyQB6Vz3jbwunhi9u7e/mPnPKDYJERsniPImZ+g44Cjqa5gpL9nEwR1tRJ5fmY4DEZ2gnPOKkmuLi5KGeeSaWBFjj85t2Ix0H05oA2Ph/4jPhPxVaahPkWj5hugqnDRN1J9wcGvqz5cB0bKPghlI5z3/H1618eBlMN1FLb28k9yqqkxYnyuewHGT0Oele+fAzxA+q+FX0m7Yve6QwhDSHl4jnbnPUjBXPpigD0Yg4AZTnOCMj8MmgHB+U4BbbznJA7f/rpNxCkB9xUYyR/U9O3SkYFchlPP3s+oHGP896AAh2yhQcr90ndzQSeQykjcDwdvPpx/XimDYF8sfuyFAUZIwfQcZpcKpQ7SVIA3AdfqO5zQA4BgjEZbkDcFBU89Pw/Sg4PBOcDHXaG9/w/nSHqQ3D9yME59T2x+XSnBjuxjdkjHcn6+3TAoAEY+m05646jPXjk/WgZCkkkDsucAj6DrSkHO4KJH6Z6L/j64+nvSE5fK/MTj5cc/j7/ANKAFZuQzOZFBH3uMn19gOKaVwFyse/JGQODj/PfinKdpyTuyp9tvPOT2NAZesW4gjJI6+mc9x2x1oAMdMcqT0zx+nH40BgytuJcnqpOPx544/zzSqCOVdsn2/P2/rTXdI0JbYSo5YDH6/5NAGH441N9J8O3V3BGZbhI8xpGpOT03HuAPWvErfVNd1f7F/aWoPNai4wLdflaZJBhy5x8qgevXNd18UNduLuzn03RJ/IngdWvbhSM28RGU2/3mJ7ehrn/AADLEfDNtLNtaymuytxtz5lwVcYZR1CdMjoDQBi6taW8HhV1kS2UQyGO2neQFUg8wkfu+uzjAbHtWJZ6f/wjN3P4gvJLabUZN0mlW0igISVy0zg9NueFPU11mkm11vxtfatqMNnaWskhgcMwWMxjISBD0J3DJPY1n+KrDSrKBpr63jlS4gkuZoQpCiXdhDzz2wcHnuKAOt+Al7qV1Jrs2qTSzeYkMrSAghnLH5gf4QR29O1euwjZHyQvPcA/l3rzD9nCCWXStalvkcaXG0UsSOFT5gDnAH8PSvXL9If3FzCFWKZSGVMjJ9qAMvUciNNjsGXnIPQ9q434jNj4eeJS3OdNuwWYZOfKbjNdtdD/AEdwFO5SDtOOfX/J964f4jD/AIt74iKcH+y7vIHYeU1AHt9FFFAHE/EgZ1LwUDnH9sv0/wCvC8qUlWAAbbvzkOOPUH+lRfEgZ1LwUOf+QzJ0/wCwfeelWTvbA+YNk8nk4P8AU0ARBSyqxI2557jp6fStPT42k0iaONv3iSscITn261ncFSY1AfJPyvtJx1q5p98tlMxuJH+zyHqy8qffjn60AUfEEJgj0iK4Yu6oySHGeoH+fwr5a+IUOo6feQ2Gu2UK6sq7Hukb/XxgnY3X+7ivpXVXkuJHuJZWBLlfMGDsGDgj2FfKnjGe5vNaluL++TUnfCC6A2hgOAMetAGTbxtLKqxopYnaFAzv9uKVQS7oWALHC7OgPoT1qONmjdWiwswzgqSCPpSx5YrAV+Z2GC4JI+lADZIwgjKldrZ+793IOCCeuQal86cQPCrSNGWDmPsW7Hn0ruPhhDpmu+OrC28SBZ7dIWFu7fu1Mg5Bbpnvyetcx4rtUtvFWr2tuzNCl04i3N82M8E+tAGZcKoVlmjUzNtAlDEFeeRgcGlgt57p5BFE0hRd8m1SQi5ALnHpmrM1iIdJ8+d1F35+w24wSI9v3zn34xVSOV0U+WZYgwIbYxGeemRx+FAEgjxcSQwTiSNWI3L90rn730NMbIilADNuPzMMkYHfjt3q1aWt1fWkqQRJIwkVPvKHIP8ACAcZrU0DwzPqml6ldrrGkWDWcoiNvdTeW02epB7qP1oAwZRGZT5cm8EfeKkHPr61Pp96bNri4Qr9sMZjRyudisMM3s2OB9a6TxJ4Um8OaQH1K+sJ2usfYPsUwlEg3fM3T7uM/Q1ydwuwK+dsTMVDDHHqcd6ALaadLFpcV5JAIbEMUjkbOZmPO1M9QPyHrXp/7PfhldY8VHUni8vTdKXzNxAG6ZuAB6YGT+VeT3Ezsx3TSXQT5YWfIwM8bV/hz6V9e/DLQj4V+HFlB5avd3H768YkDLt1B+nAoA6+V9+Y4QAcYVSdo68n3HQU+KTAwCSA23KjkY7kfpQm2NZA3Cgbgw4I7cDtSvHvO2NkEaDLK6kdR3NAHBfFzRr7UvDur2mib1v7m2DRopwJfm+dAScAkZx65r5OWJ7K6Mc0DRlG2yR9GUg4IHoR719u3audPguHaUT2z7GJOAQTjjsecYr4suUQa5f22sF7eQXUqySICxVtx+Yr/d74FAE8eoC3mk8qQ7GTZIJWyGHY+3b8apywsYJp3dI9rrtjZfmftkAcADrk0RXJjgfT40t5lwVjlMHzsxbIYE8r0Ix6GqsZcFSAylc/MuOo7UASmVtqYjUovPzLwB3GK63U/EulyeBYNC8P6ULRpnEl/dSDMshXou/0/piuRWIIXiuEZCv91eR34JNXtJuo7PVLKW48y6sEuUmmtSciQA/MM9OnbvQBQl0+RQhminVZAfJ3ArvHrz1HvUJWa8vgUAnnJEa7eDxx972r1/4xeO/D3iaws9MsrTUZJIJRMt0ipGIk7xgH73HGOleWag8UwtlWSRmVSDJ5YjUJn5UwOSVHBPegCC6ikiklUlAyNtBhO6MEdfr+Fa+vanb61NazLZ2umS2sK2729qm1ZsfxZ/vH3JrHTcqlAWMZILIv3Wx05P8AhVnSryPT9Vt7ye282KJg4iyQWIOcZ9+/tQBDG0QjidCzOWJMeAEAHqe5pgR0YSIgPBYc8DHvU2ryW82rXclpCY7eWUyIhbATdztwOoGcVteDbNpNUnuWlgijs7SS82z4YPsHygA8Mc44IoAxI55/IMGX8pyG8vqCccHA61Jcx+Tcql2pjmVQzIFOV9sfrTbSa7urwvauTdXDFvkwvzHngdB9KSW5nvna4uHy6IBJI7kl+2c9zQB7z+zXp95e6LrkrS5tnuljXcSVQKuTgepJFeq6hbtEssDjHIyQeD6HmuR+Cmmz2fwg0ZrFCWvZ5LqUIOu5yBnP0Fdvrbr/AGiwOD8ioRnGT1P6UAch8SAU+GnigP8AIw0e6GN3byW7Vv8AxN/4/vBffOsuP/JC8rD+Jox8OfFaKqqBpF0fkTt5Ld63/iOgk1LwUrdP7ZkOPXGn3hoAemI0WMucAcjPensQGOCACfXt9aXBIO8gEgA454/yKaWJRiF3HnIHBoAv+K9RjsNJvFcu5kiZiIhllTHJHv6V5HrmiTaQDeaWHl0yKyFtDpkUe1p2cZLM/sMknHWvQ5AZrvbM7OWVQCQMDAIxXkPxN8QXFpri/wBn+ZGQxQ7UZwyYwZcdFAPGD160AcHq2pXU+jtCLh302U741IX7gOAjjuc9KTwcYZtctrfU7J7+Bl8ryw3zKndwx6beuKm0+1ufEmqNItnJeLbRebKLchOnAz2AJra0rSL3+zrnWLi0eG00+ea1vEBy67V4weBtJIGRzQBleLvE+leGvGcUGlaXFqVlpqgQm5kO3LDl1GMBueD7VpwW+m+ItP0bw9BHNLDeIupTT3U7MyxgksWfGSR2GcAc1z9jpaeKNZjMyQwztuE01y4YIAvDHJyQMAYr0i0svD2uXGjx3UqRC3sFtZbaCMxRznd8hXb91sjO0ZyMZoA878Va7fXGr29xcyC4FsjRQI+QqoCQDnrnHfv3qj4e1q00m+S7ltf7QjJAkgLGFHGCD06nngcjNdd4+/srXL7ToNKsWtnU+TLGBtctnqB0z7E81y2oaBdaPOZr6K4tozzb+bHy5zwx7D1wecUAYRginu2USGKAsxWSZ87BnjcQD7CpLyJLDUN9pNb3scTBlk8s/N9UPUUkwkCukoPmFg2/lgMj+vrx2qxoWjahr12LSxhURw/62ZvuxKepY/xewHWgClHNGWy+4xFsmAvhd3bPXI9MfjVi7FxJ80qBWYl1YgJjI56c444rsUtPD+iwzR28N1NeKpV7+5wFIxzsTGBz9faqWkeHG8RX0TWVzaxvJ85S4l8vzAg6qT3GOlAHPfYoYY43mvbW3kkUFF3FvlPf5c811HgbUtO8PeK/7RvNdS2gS2KXCtFIfPZsfJnGCBw3Y4rk5IIkguGuM+Yx+VBnO7JG0/hyOgrW0S0s9Qu9Ktbi0luorh9nku5yxJwu0DBA9z6UAfTOn339padbXtjPHNBNGHicDKsnqD6fyqXdPjasaEg8HPA7cDv6VX0e0h0zTbPTLCERwW0axII8lAB1wevJrTCSBsSqCmPvLx8voaAKbIwQr5bhMg8LggduM5JNTxZ3FVGCCP8AP/16lbAiJWVgQu/kDC+pHpTMrKx8onHQFT+dAAWyi/NtycBOvOOT9Pf8KfuVVC8oP4iF+96/SmK4SMLlpQwyCx454H+HNKYWBLbmZiOi8BR/+vv+VACTkpH2Rf7uPuj0Pf0705Cxh3Ljy25BCjkdufr2qFTIJo1zuAb7+cBfQU+VPLOY/lkbsPmGT6g8H8OaAJf4eW+U84H8R9QO+KCfkDAqAOm47yfcgfzzioxK3z7gGY8HkDJ6cn19ugqpquq2OjQCbVLkWsbNgYH6beuT3PSgC1NMI0PzKEA5z8qrnpya86+KPjufw7e6dplnGr3d4vmsZQMBSflGTwA2DzXlfxU8dajqXie8gt3dbC3kIt8D93swMS47k+prlpNavLW4t4NWJ1KeNw032jkxo2MKjDkYB3Y9cUAep6Y1v4q1LUNViiFxd5awNnkql1PtyJmY/d29MDr14rfudP0zRbLQbzXLmH+07O0njs7aFQsczA7ir4JGV9+TisLxBJb2+tpY6H5AttNO6F5mKuZgqksxHJJ6d81m60iavDp9nZ2lvbm4utlzaQzkxlGO4zbvU5I20ATapZWWtNb31nGRds7TNYtjy4ZuDvUdArdcH9as2dvaT2U9jq2l28ssK7pTPdHa6kqxkjPTpnisLw/eWmn63rMmo3r2to532duo2vPIDtUFR02jqRVrww0+h2CXNpJHc+XMVubPC3CC2JIaRH9ORkDkGgD039ny0ijg8TwWt01xZM6rBvXGRtJBPvhgPoK9FbcdORCo4mcAKePu9vavO/g2iaJp+pT2uJbU6lJtYdWTAGP1GPpXo2q3EDeUsL+bGpaRiT0JxxQBWBymCw29OvHTHWuP+I0Mf/CtvFKqW3R6Zd4O7PAhauxXGVUn6nPFcr8SBj4d+LgBsJ0q6YjrkeS+KAPWqKKKAOJ+I/8AyFPBH/Yaf/0gvKsFSqncr/d3Bge3sDTfHtxDba54EkuXVIzrjR5bplrC8UD8SQPxq/q8Bs50khBET5AVSBg46c8YOKAKblXDEuDzn50yOnJ4/nUZCsqgFQGHRHAx6YB+tHmfKV2FXAOOCD+B6e1BkXcMJn269B0waAMzXLF9S0TU7KF1Wa5tmRHVcHdjg8delfNHw8utGVdZ0rxQ729teQCNbgRZ+zTI2d2D0J6cV9TxfNOsUJPmE/KIwODj07V8+/HLwZLoGvtrdsjDTtQlJkjdTi3mPUj/AGW6g+vFAHnl1B9muhHHNDMFbKSRZCsD/ECP6iksI0a72gALnjKgcd+fpmnByEhS4QCFSW3RqMndyeT1HFaGiwL5c9/f2tw+kgGMuhKbmPRVboTQBnX0kU99KEAjt2kOxmJGOPr0/OmSiKaEZZzMq7cAcMBxnr1/nTBEiRMMRvGRhDjB/LOA1OtLV7yciJD5YG6TcmAoHXk8UAQXCXAijZy33RhmfjFSpLO9kYHutsKOGSCQ4DFu6/TuaJJGYOEBS1J+SPcCABUZhRdiwTqpYHcr5XB/3vSgDV8MGzbU3XWLlIbIQs8jbRIXKDKBR2YtgZ96xFjBYblVW6qfTPNad1Zz2axvKYJUmXajQuJAPUHpgg1TeMAENGkjryzoxUj/ABoAVn3wxBlJVAUTnAUZycHoDn2pI4kVpXfaWVRhCMb+e5FTGSG3aPylE83llnJztDnquB1GO/rTNI0+51nV7bTdLjdr25bagXLbfVj6ADJNAHefBjwn/bWuS6vfBW0/TGBWM5/fTn7o57L949ecV9TaDAX023JI2HcWzyD8x5Hv7muF8MaPZ6B4fs9HsCGjtlBkYABp5SfmbjuTk810tlLdW7sLV5o0Y5KsgYZ9fagDc1No0w084Q7flABY9+oHao7CeCREgjuvO+XbsY5b349O9Yb5aRmkZ5Sw5Y5Yk/8A6s+1IDkgg5dfmG04YHPGPf8AzigDW14Lb6VNCXbzWjDMfXBUZx+NfN3x68Jz6fqEXiK0EgtrsrDeDH3Jv4XwOgYDH1HvX0Hd3NzN8s5VkPDCPCMfTPqfYVz+sWMWsWV7pF9Mfsl7EUkO0fLnofqCAaAPkYfKcSB0ONyLGAzZq1L/AGbJpJumuLuPU/NCm0eIFHTHLhx0+hFTa1odzoGsXekavFtuYGAEinh1P3ZF/vA1BcQpHcRyCaGWCZsiWBCfYgqeRQBCPIEAcXPmTBseWYTwvqrdPauo+HfhZfF+tz6fDcm1uFt3lilKhlOCPlZep69ua5eNYmhmWPe0hCkIRnvgjjvXSeC0utK1I6jLJNZpHEygROI5XLKQoVeuD69qAKXifQ59A16/0i+MctzasAREdwbIBB6Zzj6VmxI43keUfL+ZkPOR3GK2rxV12TVdRxKLx5BIVklIPlnguCfvFTjPsaxwJrdRKiJGrjYp4OSOuCaAGN5kMp8mWbZ2MK8DPOCaiDvuLpjrlnJ259j60oGIyrORGhyAW+8f8aaePvJEyjPByf54waAJpwctKjAIXCKEbAHGe/NSQy+VBdLGhWadQjStg/LnkZ9TTLeKIswkmZcLlTGODTAEHBUlT/C7EZ9uev0oAWCZrK7jmjkiLRNlSMEDjuPxqB0Q2hnGWJYxqAPb/wDVVlYXEUMgjdI5Syo5U4YjqMjpj0rrvhd4VPibxhbZBNhYEXN2SCRwcqn1JH5UAfTPw60+LTPAOmafels2EEbsQ2MMRuI49zjFWZJHmlkeUffJJGcHHpSASK77w2CRleMZ9x605Dl2JLsN24AKOnqKAOb+JT7/AIbeKyxAYaRdnHJyDC3etb4qXkdjf+BZpmVUbxAsOW9ZLO6QfqwrI+Ju0fDnxYBkudJu8jd/0xY5PSsf9q2+k0vwd4Zv4mZXtfEFvMCpwflhnPXt0oA79uGZSR6e+PXmoiQXYED5eRnjHpTYbhLuBLiIKUlRZFIH8LAEdfrSBWRj87JnAPUg8egoAYWQSxZ6t07k9iK8H8e39/pesXcLzXSxRb1VGjCIRuOMdz16mvo3SreCa1uXutjozhARwU4GcHqOTXkXxo0S4m1nTo7qZltXYRRyov3GPB3fUY5PpQB5Fp+u3NvEUTakLRnzRvx5vscf1q34j8T6hrtzJcSTMkRjjtvLhyqlR0DJnBHv1pviLw/Z6HbyW7XZuNYEu1reJd6RIByS/dvYdqzrOxm1K8t9P05HnmwQSo+UKcEknqMe9AEtrpt5ftELIEvJmJVLKFk9VHY/Su28OaQdJ1OKC+urqO5ijjvlkiXdGvzbcZ6bhnkdvSs3WNKktL/QNNtYo4760BlVS43yOvzluuVYD+E9a1bMRP4M0S/srk6c+pa0zpLfx427s70j7AE9GPegCr4k0O8imn1KeHy5omaQ2yuPP65DgD8Dxzg0678WQmwm0vV9JuWhhLst0LXeXTAXMY7ld2dxqpDDdnWL6whvnBhsv9DtXlHn7mbDOrDkkHOcdR6UscV1egWOrYjwyyLJI3nPcthg0KqvKjAyCTgEmgDIm0iximlWK4W5kt0ikuRcb4hHGwzkqo5OOcfzrUtfFNpZ6Po6NYG4jmZprS+QGBFLfuwQijLEEEgtnHNTW2t2+raDei4MmdMhDQSCZklXzDjyiGHzKq8bs/L1xV7Utf067WabWtE1GSx8lY/M007GjMZxHGEbBbJIJPAOc0AY1lpcF5pUusa0Emt4ZQoNo7SG5cg4G77oGQT7dKw7O63ajaymGHYgKs4O3IAOQo7HHGOhFdpLouvaRfwaVbTNHFIP7RfTblPKj27cLGr8o0hAO4duvauDS4lTWcwrGzkkYU/KrN1A7cdPegBxtpdSkVLa3kmKrhURegJ4A+vauz8BfDrUD4qSK7uIYp7KRZ7hopPNkhHZOP4mPBz05qj4b0/U116TUHRdL+Rvs0zN5aySYwEj5yx6sQPSvfPBVlFa6BazpCFmmiVpZSuxp255bPJPselAG0IVTzODgtn5eT7DP9KnRYmKiWNS5wRz97HbNQvIpIKbvLA468/QdvrTctuLFtm44yvU456fn0oAXVtPaGNpbbDxn5uRnB64NZ8Q/cxiNdsfDDnI59v6Vu2M21hHIuIiCGDHcp/Hv9azdSjSO8eFRkAkpvbA55P4dqAIVVsnLDcCcuRz9PpjFN+Uhg4AZsFi3IXj07mlJJJYtsTnORkgdunQn3qtqN9b6Xpt3f3ZCwWsTTvk5baoz19f64oArwmXcnmSR/PkkZ25UfX+Y9aj8Q38WkeHr7VTE8wgjLRxxfM0jHoP5V8k+IfGGp+JNS1G/uZHjN5jakTH91GOkY9Bjr6mux0jxtJeXehJFcz2lnpFkyy2u/CXGeXfB4JGcYPbnjFAHqfw78ZalqNzM3iWx+w2IjJikkKpvk6bQB296858c6Ze+LfEGsnR9XcTmUXLafdKInRcY+V84wBjj0qTUNWt/EPji5tYBO4s0cBY1HlNAgDPbq3bOAd/Xg1i+MPE9tqwu7Z1gjmbEi/Zs5uHX7ilu2OePagDGn8P6npehv8AbM2t9K2yGK4bi4hB+Y8+/TpkVZbwhe22iwa/rkPk6ZGQ8sZk/fOc/KFXrg469hVMn/hK1mm1XUGtJ7eNWkZ2Z1EQAUsB2bOBgdc120sqzanqVy9rdTaUsdvZwuBv80RoOi/xSAjcf9nNAEMfjppppdcstB0yAm2llQ3MZc+cCF3AnoAelGgXcuuaW9xc3FhpYgMV4L2BCiSIW2vG4GfnyeO4zWjNp2l6pa3ckt0LTQ4kaRr63+XDr1QcY5zgg88g81e1SLTrvwoXtXs9G0RLZFtpZSHVmjIJ3KOXbPTHU9aAKfiD4calFL50OpaXNI96Ls7Rh7W1xj5c9s8EDrXJatBeeGIU1C2kbTYrp2fTY7NmkiOTzu4zk8fKe/ar1+LbVbXUPEWm3fiD+y9OVYJTtCyyXD9TwchR12ntXp/gyeOC78PaVb2l3c3skbXc/wBswRAu0Zdx08w8bR+dAHdaXEi6RpkccEdtI1vHLJGsfl7WKjcSvY+1aiZ2ArkEnJYHjP8Ah7Vrywpb2N3b4AKwmVnYYy59/bFYxDGIqVwdgypIODjPSgCYEnHQnBBKrx+PFcr8Syg8B+KSQUzo16DgZAPkvj6ZJ/WumQq8Z5PPU9uPauA/aA1UaZ8JtcfJD3arZphsHLn5hx22g8UAe40UUUAeJ/tX38ul+DPDWoW5YS2viCCddpwcrDO2M/hXoOh6pBr+kW8sDiW0vYVuLZnGcAjIzzz3H4V5r+2F/wAk60b/ALDUf/pPcVk/s1+JI9S8EvosshF3pEhwxGT5LnKHPscj8qAPV0RFjKeWVfJB2MU79CDwaJosK2/cCDwwfJ/UYq3djzY45tgcSPiRVIOHHf8AHriobckD5Y5FAOMKv6UAS6U3lahBM8iMrfJkKAeR3IJ7ipNf0mHXbG/0bWm82zusqjIpEkZPKkN7evrVRUGBhgUYYxsIII+hFaVnO17Gscjul5DkZ248wevPcUAfGviTQ7zwn4jvtH1ZfNlt2Jj83lZEP3ZB069frVG6vb+8jjR5ZJba1HyRLkxxjoSFxgfWvqH46eC4fE+kWEkDRprduWW3ncYDrjLRsR2OPwNfLU1nLaXtxa3kElpPHlJYnYqVx1ByRkHtQBCy8RqWBVmyAAM/iP5UMZWVUw6r1Cx5GD67RT/Ic5SCOYk5YqwLMijnPQgjGaekUhuYJVeQSyfdDxfMfTHQsKAGIFEPPltuBPCEFCD+tV2b7xwCD1G4gfy4pzkmVtzu0hXOeCFx1HNXbHNw0dsDCqkkrJJhQvHdueOOlAFYeakbRxSFYs5KhvkP4VLDCr2Ny7NicOgjCkhSpznJ5x2xSZkMSKEUqBjPl8fia2fBfhHWPF+qiz0W0cQlx5t1Im2OP1Occ/SgDMs7e71jUBZabAl1dTsCscRHy47k4+VR74r3v4d+EbfwrYu7n7TqlwAJ7vG3H+xHnnaP1x+FdloHhTRfAWinTNMRJL+Zf3924G9vbPYegFMb51xDFtI4BjyevH4d6ALOlqr6lBaKYY/OyDIEKsD1+90Yn6V139lWyKYo442XOSGYhlJ7g1yUEUYLhQWkAHG7gDsOn8609Mvru3l2XsW+3bG4McsvPYnqB6UALfQXFqTugkbn78Sk8epAHzfiRRp1ob3YxjlWF/mDmPapH4/p3rZS7kiuHg3BiVMgy2T+HtjmmS3xlkljYxC1VN7TEZCegPYmgB0Gmx42i2RAODJI29z9PSuQvzmeaFih8mQqrOB8wB4PStC91WTUWkjgM9tFzhUUgt7swz78cVUlVfLMMbFGVeCq5U+2COfzoA43x54Rt/GtkkbK1rrVomLa4YfLnrsYgcof0r551TRLnTNUn0/U7eSG9RgsgZGIX0we49xX1nb3Fxpk6tHG37riSNI2IkQ9eB0qj8TfhtaeN9Ihv9IdIdTiTdbu/Adf+ebcdD+hoA+UhFL8yo8jYbbuB2Bv8in2/mvMtw6iYqNpZ2DY9FJ7e2auavpl3p14+n6rYNZXkLYeOZSpz2YHuPTFSafpF3eC0gt2+0PeiRo4IRvdth5yvb2oAbcWks/h651NwoitLhLd0Z8SMWGQFX+IAfzrSHhDUZvDcmv2tqV0hHCuzOPMReAWK9wM5/CsjUnWSQAhopEQRmMrjGODknvVrQfEOqeHppJ9Ou2QzARyRzEOkiZzgqeP/wBdAG/8UNN0TRJtNstAmMxt4BHezocrJJ1yW7nB/AYrhsCRQWl3DPAKgj+ddR4vvrK61OaSC1ngublRLKzfd3EDawUdMjjHtWPp/kXMVzbzTRQOsWUmdtpJBztA6nI6UAZ+0hQSjk5+9yQPpx/Wr2lmQy+QIFbzSFZnXDKM/wALdqj+zrNNDDbJPLNKwVN7lQzHgV0XhbwpqOt6nc6VZC2XV7VzIY3UlQBgfK4Pr2oA0LXwnfaiscnhtLqWJ5VSGGfIezY8MZVxx6gjqK948IeG7bwzoVvptr5sj/enn8o/v5D1Y57Z6Dtir3gTwvN4P0j/AEyc6hrt3hpp34ROwAOOg9+a6HxBudbOKQeZMOX25GOPT86AMsKibVEY3NnknuaezjIHyELwMEnI9M8UiAKWbKAezDA/L+tPR0XOAzMvTkkfyoA5j4lbj8N/FQOzJ0m6yExxiF/esD9sQBvhxo4PQ6zGP/Je4rpPiRGZPh34sVY8Kuj3jlnXsIH5BPPXiuc/bC/5J1o3/YZj/wDSe4oAf8GNYk1v4daLcg+ZNaodPuFOT80fCk/VcGu8YkPu8vg4PDYIIH+eK+ef2YNdK6vqvhqZ8R3Uf2y3HfzF+VwP+AnP4V9CFIkkUsVO7gYIwf50AaWkyRzSXls67gVWSNSQc49B+Vc38X7qXTtDtNUgkkhbf5MgYfLyDjcPXqBWwk32OaC4+6Y22nkYYHrVzxXotvrPhbVNMupHaC4Tcj8EoScgj6EUAfKOjaNcav4khtECl5xJcO5OCsS/MzY4J47etbfjbzvDHhN7fQbGS5t9UCR/2nA3zSr1KMV+4T93AxzXbyeHofCWkMqauq30hj+03MluFeWEtt8pOvBzyBzXJ2mk6X4Iub2OXU5NR0FnKXGlWWZWswwIPmd1y20g9iKAL9np/h22srLV1F1dX011bhbrZvVJREdgk5wQDkM3Xjmua8Q2uuavrmlT21xb2VneFYXMvyLGyN0ETdOOQO+a6VfDMXhTQtftrK+m1W2vBEzW7DyI4oW+6uezjdk//XrI8QTQafp9nA15PJq4cPLYoA8gKDKoehOQQMjJoAsahrMet6lPe2QVJ3WUXMsigNAigCNXx/q1cjt1ziqOhT65cSQiyg08+IgIYJNXlGfJQbm8tAcAnHGVBPNR2N5dyKmrTWdhpF9i5jvrcZEd2wQtHHIvUKAeSTwcd6sLoNtrKaFHb6b5FvZaeWaf7UYorZjhw6Sk5mJI24HTpQBa8RpceJtJu9cfwzJca1Ekts91cyGGKO3Rxt+QkESMeASOg6GpLPTLuH4lWMFnfx2+ru8DyQzxZiRFQMVJ6MwXK+verfjzW5tZaCwudOVIGXzZbkf6RdSu0flrJHEhw+w4Bz657VhaNZXPhG11ixN02sXsRC30kS58lCoLRqD+8f5eGwOCw9DQAmlW194n8ZHM9w80epPI/mytM4VGDBIy2F+YDt7YrU/su4l1qZNd0E2H21mNnaRokVyyhsmIcnfx8xPUAHrxR4V1LTtN06wlttMka5vZWbTYJPNC2jRKdqEEHnPA5561Q8OaPcafrsWoXV7etq2pRs0GnSTidPNY4bzZc5XAJyqgEDgmgDa8EaVd65qlzquqeUAMWENrZ4nt7KNSGYsxOUfACAdSea9w09gbdQMknO7I+7z78elYXwx0yGKwjvLjSl0iaVy0tq0gcqwJCLkcHgbvxGc11mqyRb4HSRA025dx+6Md/wClAFUbm+8SODnP8I9Se56dfwxTWDGIPtHPUn0Genr9OlO3RBEwRnbzu6fp1+lMSVCcBlZgQvJ4+gx16E0ASg8qepJH3z39fc4/IVDqBmmZmjiaaQj7idQMVpWcEdyJNjkSjhuc45z/APrp2kSRvbvJEVGZPKDKM5A9PxzQByUUty+wQlmZsgkpjJ6ckenavLfij8RbnRPETaNpM1jPHbQk38U8e83JI5gJ/h+U9ucmvbNZtBa6i08aKIpTkY4/eY6E9s8c/WvlrWgsvjLU/tXh0nU5b13+SQM8cpx8pHTC/eJ44oA5DxXafZNWhtIUu0tDGk8KSw4MayDcAWUfPj1rp4PC0Ph2XRtW1TTNTma3VJtQtVVtrKx+UsSoIDAhdgz0yap6/F4hn1e3tNKuNVfTo4R9kmdyqso5Z/8Avonp2xXZeNNJ8YeHo9I1rSdTu9WvHRIbu6iLYQRqCEkViQVzuJfgdAelAE97o40O7g1p7JWMt/NbW1tqDfZYI4wpLCUA5clDhfpyO1cF4y0rS/7bvrzRoLmztkdJGhEe63ijKg5jkHXJJxnpitmy1WKfxXeWGiXMVzFqr+YY5o5ZluLjYQqLuHQMWO8H9K09c0hIvEOg2pvLYS6vawW50EpmO2QHDM+1sKGIJDcnrmgDJ0G6S21PWUGgSz6eyjK+VuyuchgewxnLV0Gn6TbXfhSM28txpCSRSSR6e5ZpnYAsZY93JLjjHoDVPU7ltIu7u1TFxqdkzWEqpct5cELEh3bkEEj5R2q7o7/b9HupY1Yyu8loYhMI5rNGHyMcnsmce1AHPaZfSw6fpC2WkSroMoNqLS4cI89ySA8gPTnjH5dq6u28Fp4pgu7J9MvbOGxaR2lERj2tjIgQHqSedw79a4mTSjp1gb/Qb6TUjYB0inimMhSUMPn29CBnj3r0zwHd62qz3XiGea51K5sxLdR3V5gWa5wrFRyu8EcAZoA5S3jmtL2CG4l0vRvC0EMpgtzcDz2mVNrO5XJZwx5zwO1ev/Bu3glS4l8lpJIJsveTNumlIQZJ64XOMD8a8y0ZNKsdb0zTrrQ2a9gEy29vZkO7xsxOZg2chm5HXGOa9y8CadbaAkOmWMHkRNG7FSd2HJ3MS2BkZOKANjULhns5cSq4uHCIGUggDlh+VZTAEEdehKscEYNXNQuRc3ZkXHkxnYjKfpkj6n+VV9jgbvKco5G19pBI/GgAX5FI4BX/AGh+gr54/as14Sx6VoMLE7EkvpjyMkjamfX+I173NNmVLaNd+5vXgHvwO35Yr40+K+v/APCS+L9b1BSDbqWt7fb08uMFQR9cE/jQB+hNFFFAHhX7YX/JOtG/7DUf/pPcV8//AAZ8T/8ACK/EDT7meby9Ouz9jvAc42N91j/utg5+tfQH7YX/ACTrRv8AsNR/+k9xXyOyhlKnoRigD9AYJoodyPtkt5PlkXqfr07VHPCLchZJIcMMqckBh6jp/wDWrz/4G+MD4q8E28dzLGdV01RaXWZCGZR/q5cehXAJ9Qa9GjmkjTyZU3QOcsFY7l91Of0oAb1DIJCOegm6n15NRS+YG8yOeNXX5t2wE5/A5qe7hZUaWMrJblhiTzCcf73HFRBjnDHBwcHjj/61AEkuoW97ai31ExrMvzpLH93PZsdR7iuM8Y+GdM8VWnk63CILxV/c3ttIivGR9fvD2NdTKoIXDQsTxnyMk49x3qINNBlJUjZMZV1iKZHv70AfPWsfD7xLoV87wadJqcJU+VPZKGR1x8ytzlD7Yrltd1KNb+K10+KS3S1GUaVmEok4yBkdAelfV5hCjcQqsehBUAj9apX+l2WpF/tljDdhhg+aASPxwKAPke4vICHQDzAW35DfMrVoWGi6jqjQQaXpl4zOvzu0OxCT7nAA/GvqC30KysstaaZaRFsZYRICR6lua3NJkSO5ae5X7QV4RUkLhT67T0oA8l8C/AaaV4rrxTcCOAjmztmxn/ebv+Fe1Wy6b4d09LDRbaGKGNcKEYbV+p60txqc8zEICkZ4C46j3Oaz98auo8uEEn5doAIP0H9aAK7xM7MxMJkfJJ8zeffJzz+lQpbwF0ZZEEwGOMDj1BzV7C9VQL77TnP4d6QFiMGW4IznDL8uPy/rQBDJCSS+Jy3Tlsg+/B4/+tR5TgR/IseSF3Mynr6gjvUjRyYXySqjPOeDjv3p/lSHaQcrjtHn6dKAJIDO1gLWB8PbXASPa2cKfuk5HOORiq90plYQJ5zwwlnPlxHy3k9T22g5AHtmktZjZXN1LJLHEJLYoqjKt5mflxn6mkggEEcaIANgySSWOcdeuOaAGToj8PmRTkf6wKMfrUYtxtKKFxk/8tSOPcD/APVVsK8YwJtmOMMNwx370iRllyQo38g+SWU/TJoArPYhQuyUqykHcW6fiD71t6LqC2wFtNLGyZwpGRt+ue1ZyIig7JORjiJF/nz+lSli4YO1weMfvD2/LpQBa8WeFNF8ZWDQalDHJgYSePAljPs3UfSuO0TwNZeELC4s7aORpJ3P76aTJdfQFcFa6SK7lt7vZbyu0gAZ1wMe2eQDW5HqVrcxCK9VUduCrjIPv7UAfMHxJ8CX2na5cXmm7LjSmBnOwKJLYd0IzkjPf3rg/wCyLiOxSWa0dInJETKrbnPUjGMcCvsbV/C8V1ayxxpBdwSDDw3KhsjrgMBn8688n8C6SqJBEL62tzem7mtC7SpKcYKYbkL9KAPDbDTk1aytrO1jkl11XfEZJQTQ44TJz84P6GmSeHr97m3to4lOpSSGE2scm5lI7HGBmvdl+H+iQ4m0+DUbKQy+ZuR2aSPttTd91R9Km07wJ4dsbyO9g08zagrmRbm6uZGJYnktg9eKAPINP+Gvir7fJZ3Vi1rbu2ZJlddmR0O7Jr2r4Q+DdM8NagHt0a4vmgYS3UnJHI4XsB2963xCZH3NJJ1ztRWHPckkirVtqDQQmK0CGY8NO7ZfGeABjmgDcu2isZjcFnadySsIcfOT3x6AVjTMZi0lwyNIfvEjGPpTNwMu6W5kd8EkPIMn3OOg9qcHjUALL82OpdhzQA0LGP8AV9R02KPlH4iiMHgBGIf3znPYc0rFZTiOR5O+BIGz6Hk1Y3DT8OoJuWA2qy5EQPGWxyW9qAOd+KC/Zvhj4sg2uJH0m6aVwARxC+Ez3x3rlf2wv+SdaN/2Go//AEnuK3viX/yTjxUrZZv7Ju2OC3Xyn5wawf2wv+SdaN/2Go//AEnuKAPl3wrrlx4Z8SadrVozCWzmEhC/xJ0dfxXIr7etbqDULK2urWVHtrmNZomRwdyMMg5xx2r4Mr6V/Zw8Yrf+G5PDt/LmfS+YNxA3W7Hgevytx9CKAPX5HkPm28ibWwCpA5bHcAVo6Fcfb7G4sJCVljUqhJwSP/rGqM0PmR9WiAHD8Zz7cZNZkLzWN2ZEPluGBzgfKT/Q0AY3xH8O3Wu+GrxdJvDZasuwrJL0GwklM/wZz94V4P4XuxpBmv8AxLFcXE+oCSxgjeNhHcSAcGZuPMTOOnOe9fVE80l1KLlUjAkAEg2nqBjINeY/Etdb0XZqsEljq2hRyDGjX8G4ISOSjhSQcjj096AOH8N+Mzf2Ju1tW0vVoZYrC5EEe+1QE/u5plbqmQVYc4wDUa6JBqnjGyGoaLqUl8mpeX9v83yopEJLeanByo6j611+l2t3a3DJ4R0G3tdNv3jbWV1SQGV43B3KC3OQTxx2FVdWvNJ+GOtjUb281DxLNMrWdugZQtmoOQrAfxdOTj2oAWw0jRdQ8Q63I+izmWFJLC8t5b4CE27HicLjh3PQZ681Q8NtoelQSX8kOkrBY2ch09Zy/mQW5bayvuJXdvJzx34rHufEfii60O3HhnV5hO9w7SW91GkVy+RkIN3DKOw4zXQHS7HxNomjJr9zYi8trdri+htIMtfwj5tilTwwbqUBxgk0Ac14utpLwaWnm3skEhmb/iUDCbFIwrH72ecZHUdq67RLrQtS1+BrQvJNM3l2+o3DBXdhGS8CbgGcZXH49ax/hzrM2r+L7NPD1tpun21srTajAitNFFABgCJzg7j375+launaVZeJoPFEFl58dnFctcaJd7W81ZNv7xYGPVSFxwOM9c80AReCdLVrWy1C8WaKSxLGzs5bkQxXU7bv3cZY5JA5J5ySRniu58O+F7SR9I8uws7V9PmllWEF8xblBwXP+sAJyT06AV5X8MbPVfiXrjaT4m06S58N2gaZFm3xG0nGAAr8Ek87lr6N06ygsZI9GsIXW1SIRlt7ZRV6BQf4O3vmgCwtxZWNm0nztbxgKhVv9a55OB6nv6VW0hE1W8N3In7uEKY41JwOoAx6dTWbro+0apHY27eXDbDYGznnqx+vbNOspvsE0Zjhd4mXa4JO9T6lh0NAGn4giJmjuYSFtnUxucYw2e/8qzd25dqqzZHfrjPOP610Jli1K0aK3lZsYOCfmHX73fB9eazG0S43JuwIyxDKSCAMcNnOeT2oAsaN5tuDdPbu4nKRxH+IjnLEfwiq+oSvo2pSTxRBllAch27ckgD1B6VoyXdvpdpHDI7yShT8nTOe5/uj61zsk01xL9o2oQGU7BwHwfu89sUAa+oXSSeVP5Zk065hBYYLE9+B6jP6Vi3Wh2r3DG7t7d5ZI2iF4IgsjI4xkEc5x1+lbmjtaPDLbPKE3SmSBC4+UHBwPxzxT5kAiW2nhJKHevlLzGSSeOeeM59aAPCrO+gnmudL1nS7jSdNErWdldCb7QsiRgqx4+6RwfTJqve21lb61pY8L3epXFp9omiuZJWZ1ubjytv2dl/hhIXluRnIq58QfAvirT9WvNR8OXsFzpt9MLjystELYEfMyAcepz19jWV44n0fT/CNjq2l63qV9cW8T2pvViJjLswOJgu3Dc/KT2oA43w1YXtjBbai088ryrJDc2aNv+yQtlXlJUn5cZULwcmunuLnSPEni3QtGsvD7w6GlirwTwvukKICSkuOUzjHUYzXQfDvUbibS28V2Mcn2SWOWTUZri2RBIFG0W0e3oC+HLe9Y+j6/aReD7HUtAsNP8PvHPK2oQWbpN5ih9q7gzBthJJ3Doe2KAHax4estRhvtQs9G0/UNI1OWKG8v7W9AexWMfNK/O3hscY7c9atWOneBdV/s6bRtXvp7/Q2LPZSKiXF0M7A7qQA3JyOTxWHonhOxGg2i2WvW1zbSzyT31rCjMt9E7DYGUcFlPBUH3qHWPBCw+JFgjttNv8AwkJVe6ujdFp7JEHzRyMCCuDwBjJ4FAFzTNf8R/bZ7WxbUYtMt5Wmt5ZlhtnuFXhllwAAi44A6k471t6TqGp6nbal4h0DTU07WpWWPU7SdFSO4iYkNO2fmG1RwARz2NYll4e0nX9Xvr2DUbppL+ZFhgniYva2qn5fvZUqdozn0rpPCvhXWPE/iTVl8QmSONGxMYoTEbkHG1F5wygAbiR34oAu/CHwbpulWbaxHbpOssjy6fNcBvtKAkqdxPQEdsepr0m13xO4hZyxTYSG5I64APYmpLy3kslQ3kccMe3bHHG4HC8BfT8Kis1Zi8skjqGORtOfpzjtQBu6dpK24je4WOWbP3QMKvfOO5qfX51j094mXfLL8sajhifUfSqUWrXSoEMaGQdXYdffj+dVJGMtwZJPnlYcls5HsPbrQB5/8WdePg/wJqN9HIkep3imzsymfld+pGfRdxJ9cV8d3ChbOVRnAQ9fpXrf7RPisa/4yXSrORG07RgYQY/uyXB/1jfhwv4GvJbr/j1m/wBw/wAqAP0xooooA8K/bC/5J1o3/Yaj/wDSe4r5Ir63/bC/5J1o3/Yaj/8ASe4r5IoA634WeL38E+MbbUzzYzD7NepngwsRlvqp+YfSvs2NopIYpYnMsEkfmRyiQ7JFPKsp9xzXwLX0B+zp47Rol8I6uUMiAtpkjkAsOphz6jkr7ZHagD3yK5MErbCzA5BG8MHHoRjkVPttbsBrdIo5/wDnkcEEexxx9DVVbkFyBsRuxwTz+AxT3kMiDL7uhIC4B/wNAEcjGNysoVT3Xa2R7kCmhTkKY1GRwShIP4Z/Sr8MwfFvcyM8bsBHIrDfGfr1IpbjTZIVcKslwoOco5yD9O1AGYY5Yc+XHcNEQM7FKAfXjkVJJAZR85yD1+6xx6den601GMbcxL6ldp3D3I/zmn+WF3CNIIwDkAll/D60AReRGqj+7/sooHX6H/P51ahBADBflB4ZnPH+fpTI25yPvdCI42IH5/59KUAqGdlEJJ6tjn+dAD1KkYHmORxiOPcB+lJ5cY+9byjB/j2rj8jkUhkZ8HLN6EIAPwA7fWjcGOCrZ+hx79zQAuIlPI2kes7dPUDGDSMMEMjSEH1Ix9etAxzs37cdl3YH40jfNyS6MTgEnH8s0AMZEbK4JP3euw4PoaPLxGN0MgXgDILZH1OM1IzfKczkr7MQAPxFMDozEDcACP4Tj8PWgCMxR7SxQSHIA8z5iB7AnH4U8LyMMAQfuMoTI/Dn9aZNOoABm2r6YGSfSoI7oBuJAoPP3QfyoAuNGzq4ZTIDyRtJJGfUUqIQpXDfQtz+Wc1XS7iJwXJZugAH9KnDIzcKOec55/8ArUAO5CBjuRAOjHIOe2TyKVVBJ/ftkdx82PY0Bipz93jhjg08u5OfNUr2zHkfj3oAiS2iDhlZlY/xoBy348ZNTK4U4ExBGeGQDP4D+n5Uzk8hYwcdjjNEjzfKVXep4YhgQPoMfjmgB7u0QxFNLn0EhUY78dKzma53ksvnKT945JPsasvcBDteeEYGMSKP5nrSku/I/wC+oyCCPUCgCqJHHHlzKV4x5nH4VLKJQn78SEdvmX8DnOSacqgKcMVHTHb8vWoVY3EjKsimOMDKDIYn0PbFAEbxzT/Kd4QDnJA/mxFXFhEcYjQSR4PCqwPH5frQ7xxRbnVAB/AGzj2HFOiRmiU+ScMM45BA9zk8UAPBZflE0vPJyhP4grjj8KEMkuEEru5OVjBYn8mANSRW6mLzpFkjhOADjcXPoo/qaWSV2QRxxvbx9T82Wce56/gKACRhbkE5kn7FtpEXuOOT79qrksW3L87E5ZsAlj6kgjNPCMvHlSq2edrEfhWfret2Gh6Xdahq0zQ2lonmyu4Y4HIAyM5JJwPc0AcD+0J4vg8N+ALuyjEUmo6zBLawxupysJUiWTr2BwPc1P8Athf8k60b/sNR/wDpPcV8x/EXxTeeMtd1DWb9fL8xCkEGciCEA7UH9T3NfTn7YX/JOtG/7DUf/pPcUAfJFbPhDxBceF/Ednq9pkmFtsqdfMiPDr+I/XFY1FAH3BpWrQXVpa31hMJrS5jWeBxzuU9MZ/X6VqFYbuP7sfqCFJx6ivmX4P8AxQj8Nae2g69bSXel7y9q8bfPblvvLg9VPUDsc+te56L4j0HX2P8AYmrRNOcEw3BEUg9sGgDfgilsW2kKYG5Vhk4+vXFTvDM7qkFp5+77679wI9/aqQuZ7WTZcRtgcfMQCR6jnn8a2dGuxaStImPs7ffTjI9x60AeZeLfBN1cX97q1rdXt3qu1zFFd3AjSEkHG5ccqo6HNeX6F4bl08i2tNVN1rVyoW6xcoYGcHKpG5++W5BPbHFfW1ysd0FaZIri1b7j4+ZSeuT2GK89134P+F9QmGo6daJZams32iGSNjHsl6hyg4J4z0FAHiXje58K+H9NtNFu9BTVvEESA3R+2ui2+MlEdlOXcAngdKp23iy21i/h1PT7UaBd6Tp4t7cQMDGIx/eZhkDPBx2bmuj8ZfBbUr/xBdXllqsETXjmV4r9WWUyHqQRndk5PHSr3hb4O3OkxY1LU7XzZMi48u28xWT/AJ55fgDue+aAOStbzUNAOm6d4YhWx1jxMqXzyWL+dEw3nZGrH7qdd3Wu98M+FvGa2GlL4i1Q20kV013cKQHkWIcLCu3AXoST05FekWul2lhJDLaWdpbCGERJJGm0onoo/h/nWT4wu9TtLC0vtHuorKKK6j+0PPB5qNG52byCVJCsysTkYAPWpnNQi5y2WoJXO10aWNrS4e7uDbzzNtVY+DGnUAe/cn3+lT3N/J5IgsSdw+XzWA3H2Ari59dutGhdvFGnTQ2iDc9/ZubmEDrllwHT1JKlR3biukhmWaOOVJGZJAGjK91I4xge9YYXGUMZD2mHmpLy/rQcouLsyCO1CEufNDZIZt2N/PQ1IQqxsWVVXjhs5x2A9zUkkYc4ZpDtAIJyTx0I7U0oC+4Lg52iQHv6c10iFjws4aE7Zwch84I9jn+H2qys0My+bKhMbRuXTcSBtOGT88YqrncSELDBI+hHp704SmNJbcE7LhgzOeikY4/HHX2oAriJ3klnut7XEp3swOFGMYUA9h0zTmYA4+VWPLDO3B9z/SpAuSScDB44Gc+oOPSlDEBgHyFHQsOPyH6UAUrqASEiMujIQylVBAPcj371r6ZqMmCl+FuEK7TIF+Yex9RUAdw42s6lhtODjr1oyWyctjPA3gn/AOt3oA34VhuLRY7d0kgJwwcknHp6g151418Ji1a9uNMjhF1eQLb5uU8y1eMNlhJEP4scB8flXUKVHUyDjHp/KsPXtc02zukhvbzzr4rlLWNWmnYe0SgsR05xgd6mUlFc0nZIDx+/0zxnPd6DZWUEemSwRyGzIyIgytuMcgX5TGRjBYfnWX4n8IHw9aY/sLTRd3VobvUL55C1lCQ/7yNe6/w4XnOeK9YGratJr+mWC6PHp9rdiSWU3E+ZxEgAJ8uPKqCzIBlyfmPy8Guh1LTotQ06exu4PtVnMgEsEnSQenHfgGs6GIpYiHtKMlKPdbaDaa0Z4p4WvtL1+/mNltl0pZENjpnlizW3kiG4tG2T5jZ5x6Hn0rMt/CfiHSrnVtJ0fRJ7y01xR9skutsiQ4O7JkGAGzyPbGa9vt7DSLQ2rQabYQyW7HYBECyFupXjOTgdPSup0/TTcIkl4jRW5bcYiuDIfVh2H15rYRwPw/8AhsdOhsLy78u2ls4wplgZm+0Lg8OGyG68EfrXqEUUUdqRHIbe0Qbncttb6kmo7+7t7N/Mubh4wCNkI64xjgDt9awJ9QuNRbcImjthzHCi5Gc/eY+v6UAWNRmfU71Z2ylqnEaMfvf7R9KaAi7fkZiTgDPWoUjkZtz7QnTAJY/iBgf/AK6GlgiPT5uy5+YfnQBIVC4zvLk5Jzx+nauO+LPjKPwX4Rnu7WRF1W5JhsEOW/eHq/PUKOfyro7rUlhiadpIoYIkaSSQt8qoByT7DmvkP4meMZ/GniR7wsw0+DMVlF0Cx5+/j+83U+2B2oA5MlmZmdmd2JZmY5LEnJJ+pqG6/wCPWb/cP8qlqK6/49Zv9w/yoA/TGiiigDwr9sL/AJJ1o3/Yaj/9J7ivkivrf9sL/knWjf8AYaj/APSe4r5IoAKfDLLBNHNbyvDNGweOSNtrIw5BB7GmUUAfWnwm8Zf8JxoO7zVGtWahb62HAOTxKo7qe/ociu0zMgBaEjBH3e2e4wOa+JdF1fUdC1GO/wBHu5rS7TgSROVJXupx1Br3vRvjBZzQx7vFV3aNjDW+r2HmqD6CWHnGfWgD2SO5kwu7leM70AyB+ua6CDXo5HZZYdmR9+Nw2eOOK8v03x4L/DW6aDqxyOdP1NIm/wC/c2DWsfEdmFY3nh/XLXjJKW3nr+DISPpQB6L/AGraybWS42qMZJU4PtVDW5bZxFLC6yXIIVio6r/Q+lecz/EfwnasRPNqkT4wVktXTj3BGM/yoT4k+Dps41i5iPfzIGC/n2oA64vPJLlplSIckEZJHoeamiiiiHyf8CDtyP8ACuMn8d+CIUDya8kpzkJGjMfbj/IpB488FMuW1cp2ZWgZiR6dKAO4DZPyGH0yjBv/ANVBlTJxIVI6qWAz74/pXFr418FSFSNbUMemY3XI+gHNPXxf4LPLa/EoIxu2OMn2OM0AdZLdwJ96UkZyTvbPHt0NV21CLpCJMngYAGT+JrlZ/HvgWzXJ1VJHHVYLaRyf0rndS+OHhq1VzpGm397sHV1ESgjp1yetAHpIuLpz+5icLn7zYH5c81IlveXA+cKTjjywc/U4rwLUPj9rLwbtO0fSbUBtoMyNKR3z1rkdW+IXinxCCmueJ7qztG/5d7MGNT7YXn86APpfVdX8P6IduravZQyg48tpfMf8VGawz8TPh0s4jfXUjcDBL28gH8q+XtTuo1uF2mTAXhA5Ur7k9yetQ3tyJoIyqK8O0DcQMq3fPpQB9g6brnhjWVA0nX9MlLdEjughJ/3Tg1rSabcxgMhGw9GkcHjHoeK+GY4RJIojjV3xwAvJ+ldb4f8AFHinw1bedpeuXtq24bLUt5qN65RsgUAfWQuLmH5zE3HV0xj/AAqaK/iZlLjaScjPyg+oz2NeGeHPjtq0JEfiXRbS/wAdZbNxDJ/3z92vSdE+JPg/XlAW9l0yZzzDfRbOfZx8p/OgDtFmR1XDBueMqvP0xT8o3HG7oQjbfzzVCKzgu1WWwvIJ1OcGCQSZHbof/r1YbTtQT7rEDP3emPxoAmbEiFZMSr14YDH4Z/lVdreNM+Uz2/f95nAP0PP50fZ9TJGcZzjO3GPrkdaUx6jHg+WjHsTwAP6CgBImLuyzqFZenGVIPQg/1qeFFMO22jdzk42EkZ98jn8armW4BPmxfMpwSg7fzrTsNWhtLVIhExIO7Ic5OfUUAQrpdxLIJpYQGAwGm2rj8Rg/mK0tP02ItHI+2fk7trEIp7YU9apy675g2wwIyZ6yZzn1wf5VSnvdSuXA826QHhfLUBT+XNAEuoXStcySXLOkpYqq5B2rnAAwapNefKxWMjuHkTp+RpPsFxy8cEUI673QjJ9TVKS70uCZkuL+Cab/AJ42+ZXP0Cg/yoAnaR5WVfOTGMjZlffrXzH8aPH3/CUaiulaTNnQ7Jz86H/j5m6Fj6oOi/ia6D4u/Fue9guvD3hy2l0uLcYryfzMyyL0MYx9zP8AF37eteJgADAGAOgoAiuv+PWb/cb+VfXn7YX/ACTrRv8AsNR/+k9xXyHdf8es3+4f5V9efthf8k60b/sNR/8ApPcUAfJFFFFAAOMYJB7Edq7HRtQXUIG82NPtUIBZ8kE+jD0rjqvaLqt7ompw6hpcwhu4shWKB1IIwVZTwQR1BoA9i8OfEnVtKMdtLcxXluRj7NeqX3f7r5yK9R0DxzoOr3EMXnPpeoPjZFcA+UWPYSdOfevBbTxhoOpxBfEGhCzlPLXOj8DPq8L/ACn/AICRWnHpWmanbyJ4a8SaVdO4+S2vpjaMp7Da/GffNAH0zbalcWMrBx5Mn8YWMlG9+v61swatZ3ARpEaNs7gy8pnpnjnNfPGi+MPHHhbTY7fxTp0l3aQqFjkuYSybf9mVMggccmtqx+M2jvN5cuhXkbKd0rQSqUx3Iz/KgD3l3t5EWNmt5YefmkkBI/PmsvUbGwtl/wBHWdpx93bIWC+p5PX9a5XR/EGk65bR3OiavaThxkJNIEdD6FTzn0rZAughby/NUYOQ2/P4jpQA8qjsNy7nHRSM5/PA96bf2qahZXNpeJvjuI2jkVuUKMMHOPUGqkt5g4ntth9Sn3cfXvUqXqKFUq+7kkZ5A9/c0AcHqVj4lGm2V7fSs82mN5ahEEkg8vKC52D/AFgf5i8XUqVKbXXB7Dwp4gg1y2I2QxXiKjSxLIXUhvuyI38cbAHaw9CDgggaCaihUbTuJ5HQ89yK4jxNob6dc/2x4eaSERs0skcSF3t2Y/M6J/Gjf8tIf4sb1xIPm8yGFWXq+Gj7nWK/Nefddemu9uXP8R6BiIooZDsJyM5Ib3z6ZpHbd2+UDOQfvfhWJ4X1+PX7c7fKt72NE3wo/mJtYZWSM9HjbBIYdcEHBBA22bqTKpznqoA49a9GE41IqcHdMhqwMpYjepwM47c0srvFEwVFdNxAUnHJ5xxUMtxGhbBDN3KjJ+tV57lpsJFFMFzkYXqfxqgLmCy788HsRjvQsrbzEJGDEbtpHOB29qz4bp7dgoimHI3BiP61OuoxNgOCAcDDDpQBc25z82Gz2NOHPJyN394AgZ9x1qiuoWvVQ6kNzgnn8qJNTgVGbbvXltxyuPWgC47quWbCqOSWUAcdetecXWrXGteKIW8LxpHIwDi5CkfaEAZRLKRgm3X5ti/ekYfLtQFjW1/X7nxNONP0tQ+nSqHCMDtuEzjzZec+RkHavBmIxxGGJ6nRLVNItnghDzSykyTTvzLNJgZdjjGcAAAYAAAAAAFedWisfejb931ffyXl3fyWt2rXu69R3hX7TqN/qOt39vJazzstpDE65MUUWQ35yGU57rs9BW+FjQudrpvPzDkZHrntWd9punZSqSAtySM/5NSeTfSlhHBLnqHyxx+HvXVhcNTwtGNCkrRirImTcndmzZXkECDfBG8w48wKFf8APufpRdanIwPlSi3zjcV+Z27AZPQ/hWLLFPGcXdxb20jA/JLIqsB6HPaq0l5p1qSbnV7RcKQyxt5hHqcLk1uIvtNbo5IUsxJ3sw3Mf1pj3xc5gj+Yf7Pzflmuft/FGnSvMsPh3XBaxni7uYBbwyD13SMuP61ha78S9KsYXista0HS5f8AnorvfTL/ALqxjbn6tQB34hup1JDssX95jgD9f51yPiHxz4Y0B5IZ7251K8GF8ixG/n3J4ryfxB8SdI1B2W7n8R+ICBhUdksbYfQLlvzrk7r4iXlqkkegaNoujmQEGZITcTgEY/1kmcH3AoA6X4zfE618Q2Eeh+G4bi2sid1/JOAHkIPyxqR0UHlvU4rx+j8yepJ70UAFRXX/AB6zf7h/lUtRXX/HrN/uH+VAH6Y0UUUAeFfthf8AJOtG/wCw1H/6T3FfJFfob4z8IaH400yHT/Etkby0hmFwiCaSLbIFZQcoyno7DGcc1x3/AAoX4b/9C/J/4Mrv/wCO0AfEdFfbn/Chfhv/ANC/J/4Mrv8A+O0f8KF+G/8A0L8n/gyu/wD47QB8R05HZGyp68H3r7a/4UL8N/8AoX5P/Bld/wDx2j/hQvw3/wChfk/8GV3/APHaAPi9RHJ8/ko4xyWGdv4Vdsr+6szusby5ts8gwzOhU/QGvsQfAb4cA5Hh+UH21K7/APjtL/wof4c/9ACX/wAGV3/8doA+V7fx94rtlxD4i1Fo/wC5LIJB+G4GrP8AwsrxXkb9StpCvKl7KE4x/wABr6f/AOFEfDn/AKAM3/gzu/8A47QPgR8OgMDQZgPT+07v/wCO0AfLw+JHiTr5mltjtJpsJx7fd6U7/hZWvnBaLRD2IOlxc/XjkV9Pj4EfDkHI0GYH1/tO7/8AjtH/AAoj4df9AGb/AMGd3/8AHaAPmA/ETVMES6P4bkUnLeZpidfwNKvji3YD7b4R0CXJ58sSx5P0V+K+nv8AhRHw6xj+wZsf9hO7/wDjtH/CiPh1/wBAGb/wZ3f/AMdoA+Z28XaDIP3/AIPVAeSbfVJUGOnQg02XxB4PuUK3PhvWcZyNmoowHp1QcV9Nf8KH+HPI/sCbB5/5CV3/APHaX/hRPw7z/wAgKf8A8Gd3/wDHaAPmFNQ8EJj/AIlniSAHg4eCQH6ggVGJPBBfMf8Awk0L85byIH7+u6vqH/hQ/wAOSMHQZsen9p3f/wAdoPwI+HR66DN/4M7v/wCO0AfLB/4RPJ2anrsI5/5hkT59878mnIvhDfmTU9b3nqF0uMbv/ImK+pv+FEfDr/oAzf8Agzu//jtA+BPw7AwNCnx6f2nd/wDx2gD5hgj8DRTJP/aXiKOVD/FpqEg/TfSXZ8GXEhd9a8TNu5bZpka4/wDH8n6V9P8A/CiPh1nP9gzZ/wCwnd//AB2g/Aj4dHroMx/7id3/APHaAPlhj4JhA8i98SOwGcjT4VP6vQbvwcDgzeMJCRnGLdc/zr6nPwJ+HZOToU5/7id3/wDHaP8AhRPw6/6AM3/gzu//AI7QB8wwa74Qth+60/xM7nqRfRQ89uUWr8HjrRbd98Fl4mY4483xA4A+oC19HD4EfDodNBmHOf8AkJ3f/wAdo/4UR8Osk/2DNk/9RO7/APjtAHz7/wALWCjCabqTjOSX12cke3Srlr8XxA4K22swseCY9ZZ/z3qa92/4UP8ADn/oAS/+DK7/APjtJ/wob4cf9C/L/wCDK7/+O0AeS2PxriynnX3iKJAPuvb21wP02n2rWX41aTgB9YvN56ltGB/9n616KfgP8OT10CU/XUrv/wCO0H4D/Dk9dAmP11K7/wDjtAHmtx8atPCD7PqesOo7R6TEB+buax7v42xSD90niOckc4ngtQR/wBSRXsX/AAof4c5z/YEuf+wld/8Ax2hvgP8ADlvvaDMceupXf/x2gD551P4qX16SbfRbZuwkvbua6IHqQSFP5Vy2r/EPxRfQvb/2zJbQNw0WnIttHt9PkAP5mvq//hRHw6xj+wZsdP8AkJ3f/wAdpv8AwoX4b/8AQvyf+DK7/wDjtAHxHRX25/woX4b/APQvyf8Agyu//jtH/Chfhv8A9C/J/wCDK7/+O0AfD11/x6zf7h/lX15+2F/yTrRv+w1H/wCk9xXSn4CfDYgg+HpCDwQdRuv/AI7XY+M/CGh+NNMh0/xLZG8tIZhcIgmki2yBWUHKMp6OwxnHNAH55UV9uf8AChfhv/0L8n/gyu//AI7R/wAKF+G//Qvyf+DK7/8AjtAHxHRX25/woX4b/wDQvyf+DK7/APjtH/Chfhv/ANC/J/4Mrv8A+O0AfEsbtGwZetXQ0Uqbti+mCMmvs3/hQvw3/wChfk/8GV3/APHaUfAb4cDp4flH/cSu/wD47QB8j6Lr+taA+dG1a9scnG2GYhD9UOVb8q6KL4gT3Lsde0DRdWfBDTrCbSbHuY8A/lX0uPgR8OQcjQZs+v8Aad3/APHaT/hQ3w4PXQJf/Bld/wDx2gD5ri1/wXMwaTw9q+nkH71lfJL+auo/nWvYa94et38zRfGeraROPufbLFwF/GNiP05r33/hQ/w5/wCgBL/4Mrv/AOO0v/Ch/hz/ANACX/wZXf8A8doA8ysPG3iGW2C6b4z8J6pNwEaciGQn+8RIFyfrWzaeKPG4i/0jRNN1L5uWgKkN7ko5/LFdmfgL8OD18Pyn/uJXf/x2iP4DfDiNt0egSq3qupXYP/o2gDlk8Y+Id4Nz4GkfPOYlkBH6cVdh8STSrvuvA2trL/dVl2H8SQf0rpk+C/gZAAmmXygdhq94P/atRt8EPAD/AH9Hum+uq3h/9q0AeYa6byK5+2aNoN1pUys0iRXV5AixyMclwd/COQPMjPB++u1x83XP420e2TE8dmsm0bvO1WADPtgnitxvgP8ADliS2gSknqTqV3/8dpB8BvhwOmgS/wDgyu//AI7WdOlGm246X1+f/B6/eNu5yGq/ES2+y+Xol94Wsrk4zNc3/mAL3wAmCfrXM33j3X5Y5M+P/Ctruzgwxlyv/jnWvVv+FD/Dn/oATf8Agyu//jtH/CiPhyOmgzf+DO7/APjtaCOC074t2SWcaarrvhm5vUADTRx3SK5/vEBOOfSi2+LMIuZjeeIPCM9q2NkMcd1EU567vLOfxrvf+FEfDrP/ACAZv/Bnd/8Ax2j/AIUR8Of+gDN/4M7v/wCO0AcPefFK2eMLpeq+EIccsZprhvyHliuV8Q/E06gzabq+oaHNbsA6yWMUvkTE5yJsjdsXAJjUfvCygkLvr2M/An4dnroU5/7id3/8do/4UT8OsY/sKbH/AGE7v/47WdWmqsHBuyfb+uo07Hlml/E7QdFtDFa6pFNO58ye4/sqWSSeTHLMzMozgAAAAAAAAAAUlx8cLMZMVzqbtxjydMhjA98s5r1T/hRPw6x/yApv/Bnd/wDx2k/4UR8Ov+gDN/4M7v8A+O1cYqCUYqyQjxu4+OE8nEEeuvkdGuoIDn/gMZ4rGufjBqEoO3TZnB73Oq3Df+gba9+PwJ+HZ66FP/4M7v8A+O0n/Ch/hz/0AZv/AAZXf/x2mB8xT/EC9mnM8OjeHo7hjkTS2rXD/gZGaqN5498VTrtOv3UEX/POyC24H0EYFfVn/CiPh0c/8SGbnr/xM7v/AOO00fAf4cg5GgSg+2pXf/x2gD43vLu91Ah7+6uLr/auZmk/RiagSFQ3zZbtjGPpX2gPgR8Oh00GYf8AcTu//jtH/CiPh1/0AZvT/kJ3f/x2gD4smmMeVU4b0HaqpJJJJyT1Nfbn/Chfhv8A9C/J/wCDK7/+O0n/AAoX4b/9C/J/4Mrv/wCO0AfEdFfbn/Chfhv/ANC/J/4Mrv8A+O0f8KF+G/8A0L8n/gyu/wD47QB8R1Fdf8es3+4f5V9w/wDChfhv/wBC/J/4Mrv/AOO0H4CfDYgg+HpCDwQdRuv/AI7QB6hRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A:&nbsp;A small segmental region of honeycombing is demonstrated in this 39-year-old female with systemic lupus erythematosus&nbsp;in the anterior segment of the right upper lobe (arrow). Panel B: Extensive end-stage fibrosis and honeycombing&nbsp;are demonstrated in the lower lobes (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Farnam, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1062=[""].join("\n");
var outline_f1_2_1062=null;
var title_f1_2_1063="Clinical features and diagnosis of infantile spasms";
var content_f1_2_1063=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of infantile spasms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/2/1063/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/2/1063/contributors\">",
"     Daniel G Glaze, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/2/1063/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/2/1063/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/2/1063/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/2/1063/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/2/1063/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile spasms (IS) is an age-specific convulsive disorder of infancy and early childhood. Children with IS typically exhibit the electroencephalographic pattern known as hypsarhythmia. Infantile spasms were described first by West in 1841 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/1\">",
"     1",
"    </a>",
"    ]. The triad of spasms, arrest of psychomotor development, and hypsarhythmia is known as West syndrome.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of IS are reviewed here. The etiology and pathogenesis, and management and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/15/1273?source=see_link\">",
"     \"Etiology and pathogenesis of infantile spasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/28/30154?source=see_link\">",
"     \"Management and prognosis of infantile spasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;IS is characterized by epileptic spasms with onset in infancy or early childhood that are usually associated with the electroencephalographic (EEG) pattern of hypsarhythmia, and also developmental regression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Age of onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority (90 percent) of affected children present at less than one year of age, with a range from one day to 4.5 years of age (",
"    <a class=\"graphic graphic_figure graphicRef82370 \" href=\"UTD.htm?33/25/34205\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The peak incidence of onset (50 to 77 percent) is between three and seven months; onset after 18 months is rare. The true age of onset may be uncertain because IS may be initially mistaken for other conditions, such as hyperirritability, exaggerated startle responses,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4943774\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Spasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spasms can involve the muscles of the neck, trunk, and extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/2\">",
"     2",
"    </a>",
"    ]. They are usually symmetric and synchronous, but there can be variant clinical patterns. Two phases of muscle activity typically occur. The first phase consists of sudden, brief contractions of one or more muscle groups. This is followed by a longer tonic phase. The initial phasic contraction lasts less than two seconds. The less intense tonic contraction that follows usually is two to ten seconds in duration. Less often, phasic contraction lasts less than 0.5 second and occurs without a tonic phase [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three clinical types of spasms have been characterized using time-synchronized video and polygraphic recording [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In one report, 5042 seizures in 24 infants were classified as flexor, extensor, and mixed flexor-extensor in 33.9, 22.5, and 42.0 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/6\">",
"     6",
"    </a>",
"    ]. Most infants have more than one type of spasm.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flexor spasms consist of sudden flexion of the neck, trunk, arms, and legs, and contraction of the abdominal muscles. The latter may be severe enough to cause the torso to jackknife at the waist. The intensity of the contraction and the number of muscle groups involved vary in different attacks and from infant to infant.",
"     </li>",
"     <li>",
"      Extensor spasms consist of abrupt extension of the neck and trunk, with abduction or adduction of the arms or legs.",
"     </li>",
"     <li>",
"      Mixed flexor-extensor spasms usually consist of flexion of the neck, trunk, and arms, and extension of the legs. Less commonly, they involve flexion of the legs and extension of the arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The extent and intensity of seizures varies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/2\">",
"     2",
"    </a>",
"    ]. The ictal event can range from a precipitous, massive contraction of flexor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extensor muscles of the neck, trunk, and extremities to an evanescent contraction confined to the rectus abdominis muscles or a brief head nod. Body position can affect the type of spasm.",
"   </p>",
"   <p>",
"    Motor arrest, or episodes of attenuated responsiveness, sometimes occurs after the spasm and can last as long as 90 seconds. These episodes also can occur independently as a seizure without a preceding motor spasm. Deviation of the eyes or rhythmic nystagmoid eye movements occurs in approximately 55 percent of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/6\">",
"     6",
"    </a>",
"    ]. Asymmetric spasms occur almost exclusively in patients with focal brain lesions.",
"   </p>",
"   <p>",
"    Changes in respiratory pattern occur frequently during spasms. Changes in heart rate are rare. A cry or scream frequently occurs after an attack, but it is not considered to be part of the seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most infantile spasms (80 percent) occur in clusters consisting of 2 to 125 spasms at a rate of as many as 13 per minute [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/8\">",
"     8",
"    </a>",
"    ]. The intensity and frequency of the spasms in each cluster often increase progressively to a peak, then decline until they stop (a crescendo-decrescendo pattern). Although the average duration of an individual spasm is four to ten seconds, a cluster may last for several minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/2\">",
"     2",
"    </a>",
"    ]. Different seizure types may occur within a cluster. Parents may observe a behavioral change at the onset of clusters.",
"   </p>",
"   <p>",
"    Spasms occur more frequently in the waking state and in the daytime [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/9\">",
"     9",
"    </a>",
"    ]. Clusters tend to occur following arousal, rather than during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/8\">",
"     8",
"    </a>",
"    ]. One video-EEG monitoring study noted that spasms in younger patients (&lt; 3 years) were more frequent between 9 am to noon and between 3 pm to 6 pm, while older children have spasms mostly between 6 am and 9 am [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/9\">",
"     9",
"    </a>",
"    ]. The sleep pattern in affected infants is characterized by frequent arousals during the night. Photic stimulation, handling, feeding, or loud sounds do not precipitate spasms although they may appear to do so [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recognition and accurate reporting of spasms can be difficult for both parents and medical personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Although massive muscular contractions are easy to recognize, brief contractions confined to the abdominal muscles may be detectable only with video EEG monitoring. Single spasms and even some clusters may be short-lived and can occur on arousal from sleep when the infant is not observed. When parental reports of seizure activity have been compared to video EEG monitoring, most parents underestimated seizure frequency by five- to tenfold [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143069252\">",
"    <span class=\"h2\">",
"     Other clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurodevelopmental delay",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regression with motor and cognitive manifestations is evident in most patients.",
"   </p>",
"   <p>",
"    Seizure types other than spasms occur in one-third to one-half of patients with IS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. These include partial, myoclonic, tonic, and tonic clonic seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2763158\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;IS typically progresses through several stages [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/13\">",
"     13",
"    </a>",
"    ]. During the initial stage, spasms may occur infrequently and be isolated and relatively mild. Abrupt developmental regression may begin in infants who previously were normal.",
"   </p>",
"   <p>",
"    In the next stage, which is the most severe, spasms increase in frequency and appear in series or clusters. As peak activity is reached, hundreds of spasms may occur in a 24-hour period. Developmental regression or arrest is most pronounced during this stage.",
"   </p>",
"   <p>",
"    The third stage is characterized by a progressive and sustained decrease in the frequency and severity of spasms, which may be rapid or gradual. Resolution of spasms may be followed by the appearance of other types of seizures.",
"   </p>",
"   <p>",
"    In a retrospective review of 44 children with untreated IS the cumulative spontaneous remission rate of spasms was 2 percent at one month, 5 percent at three months, and 25 percent at twelve months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/14\">",
"     14",
"    </a>",
"    ]. In most patients, spasms disappear by age three to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/12\">",
"     12",
"    </a>",
"    ]. Other seizure types frequently emerge and persist, and permanent neurodevelopmental disability is common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/28/30154?source=see_link\">",
"     \"Management and prognosis of infantile spasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4943774\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of infantile spasms includes colic, gastroesophageal reflux, excessive startles, exaggerated Moro reflexes, repetitive body arching, spasticity, benign myoclonus of early infancy, benign neonatal sleep myoclonus, tonic reflex seizures of early infancy, and benign and severe myoclonic epilepsies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/6,7,10\">",
"     6,7,10",
"    </a>",
"    ]. These conditions also may occur in patients who previously had or currently have IS.",
"   </p>",
"   <p>",
"    Visual observation alone often cannot distinguish IS from other normal and abnormal infant behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The random, often abrupt, uncoordinated movements of infants with brain damage may be especially difficult to differentiate from IS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Video EEG monitoring is usually necessary to differentiate these conditions from IS, evaluate the persistence or recurrence of IS, or identify other seizures (eg, myoclonic) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/6,10\">",
"     6,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IS should be distinguished from benign myoclonus of early infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], benign neonatal sleep myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/17\">",
"     17",
"    </a>",
"    ], and tonic reflex seizures of early infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/18\">",
"     18",
"    </a>",
"    ]. Similar to IS, these disorders occur in infants and are characterized by sudden jerky movements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2763032\">",
"    <span class=\"h2\">",
"     Benign myoclonus of early infancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign myoclonus of early infancy is a rare condition characterized by brief series of nonepileptic spasms that occur during wakefulness [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The episodes are characterized by tonic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myoclonic activity of the truncal or limb musculature. Spasms typically result in flexion, extension, or abduction of the arms and rarely involve the legs. The neck musculature often is involved with flexor or extensor components",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aversive jerking movements of the head. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link&amp;anchor=H13#H13\">",
"     \"Nonepileptic paroxysmal disorders in infancy\", section on 'Benign myoclonus of infancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to IS, infants with benign myoclonus of early infancy have normal neurologic examinations, EEGs, and development. The myoclonic episodes typically resolve before the child reaches two years of age and no other seizures develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2763039\">",
"    <span class=\"h2\">",
"     Sleep myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign neonatal sleep myoclonus is characterized by abnormal jerky movements that occur only during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/17\">",
"     17",
"    </a>",
"    ]. The myoclonus is bilateral, synchronous, and repetitive and affects the distal parts of the upper extremities causing flexion of the fingers, wrists, and elbows, with occasional dorsiflexion of the ankle. In contrast to IS, infants with sleep myoclonus present within the first week of life and have a normal neurologic examination and EEG. The disorder resolves spontaneously during the child's first year, often within the first three months, with no sequelae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link&amp;anchor=H5#H5\">",
"     \"Nonepileptic paroxysmal disorders in infancy\", section on 'Benign neonatal sleep myoclonus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2763046\">",
"    <span class=\"h2\">",
"     Tonic reflex seizures of early infancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tonic reflex seizures of early infancy is a nonepileptic movement disorder that presents at one to three months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/18\">",
"     18",
"    </a>",
"    ]. Affected infants have episodes of generalized tonic contraction with extension of all limbs, accompanied by apnea and cyanosis and lasting three to ten seconds. In the initial description, the episodes occurred only when the infants were awake and held in a vertical position [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/18\">",
"     18",
"    </a>",
"    ]. They were provoked by shaking or tactile stimulation. This disorder is distinguished from IS by the normal ictal and interictal EEGs. The prognosis is benign, with spontaneous resolution within one to two months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of IS in a patient with clinical features is confirmed by EEG [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/2\">",
"     2",
"    </a>",
"    ]. A full EEG evaluation should capture an ictal event and include a full sleep-wake cycle. The recommended approach is an overnight inpatient 24-hour video EEG; a two or four-hour EEG study may be sufficient in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/19\">",
"     19",
"    </a>",
"    ]. Prolonged or repeated monitoring may be required if the initial evaluation is not diagnostic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4943541\">",
"    <span class=\"h3\">",
"     Hypsarhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most affected patients have an interictal EEG pattern known as hypsarhythmia. In the 2010 consensus report, this EEG pattern was identified as a defining feature of IS. The classic pattern of hypsarhythmia consists of very high voltage, random, slow waves and spikes in all cortical areas [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. The spikes vary in duration and location. They appear to originate from one part of the cortex at one moment, then from another or from multiple foci a few seconds later. The spike discharges occasionally are generalized but never are rhythmically repetitive or highly organized, as is the pattern in childhood absence epilepsy, for example. The chaotic appearance of hypsarrhythmia suggests significant cortical dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypsarrhythmia is usually seen in the early stages of IS and can precede the onset of spasms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/21\">",
"     21",
"    </a>",
"    ]. In some cases, clinical spasms may precede the onset of hypsarhythmia. Longitudinal studies using prolonged monitoring show a highly variable and dynamic EEG pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/22\">",
"     22",
"    </a>",
"    ]. The initial multifocal and chaotic pattern evolves into a more organized pattern known as &lsquo;modified&rsquo; or &lsquo;atypical&rsquo; hypsarrhythmia, which is characterized by features such as greater hemispheric synchronization and symmetry. Variations of this EEG pattern include hypsarhythmia with increased interhemispheric synchronization, an asymmetrical pattern, a consistent focus of abnormal discharge, episodes of attenuation (electrodecremental response), and hypsarhythmia comprised primarily of high-voltage slow activity with little sharp-wave or spike activity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The hypsarrhythmic pattern may disappear with hormonal therapy while the infantile spasms persist [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/10,22\">",
"     10,22",
"    </a>",
"    ]. Hypsarhythmia tends to disappear later in childhood, sometimes evolving into other abnormal EEG patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypsarrhythmic pattern changes with the state of the patient, and varies if the infant is awake or in slow-wave quiet (non-REM) or active (REM) sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/7,10,22\">",
"     7,10,22",
"    </a>",
"    ]. The classic pattern is most pronounced in quiet sleep and often is markedly reduced or absent during REM sleep. Patients with hypsarhythmia often have very reduced amounts of non-REM sleep, and as a result, long-term monitoring studies may be required in some cases to capture hypsarhythmia.",
"   </p>",
"   <p>",
"    Other interictal patterns in patients with IS include focal or multifocal spikes and sharp waves, diffuse or focal slowing, paroxysmal slow or fast bursts, and slow spike and wave [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/8\">",
"     8",
"    </a>",
"    ]. These may occur singly or in combination; the latter EEG features suggest evolution towards Lennox-Gastaut syndrome. It is rare for the interictal EEG to appear normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ictal EEG",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ictal EEG typically shows a high-voltage, slow-wave transient followed by attenuation of activity. Variations in these EEG events do not predict the type of spasm (flexor, extensor, or mixed). Episodes of generalized attenuation (electrodecremental response) also may occur in both waking and sleeping states without clinical evidence of a seizure.",
"   </p>",
"   <p>",
"    Immediately after either a clinical or electrographic seizure, the EEG sometimes shows a marked decrease of abnormal activity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/6,22\">",
"     6,22",
"    </a>",
"    ]. It may transiently appear normal for age. No consistent clinical changes are seen during these periods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Lateralized findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal or lateralized EEG findings may indicate the presence of a structural brain lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In one report of 77 patients with IS, 38 percent had focal or lateralized features on video EEG [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/23\">",
"     23",
"    </a>",
"    ]. Unilateral hypsarhythmia and asymmetric ictal EEG changes often occurred together. Both of these features consistently indicated the side of a focal or asymmetric structural cerebral lesion that was visible on computed tomography (CT) or magnetic resonance imaging (MRI) of the brain.",
"   </p>",
"   <p>",
"    Asymmetric EEG changes occur with asymmetric IS, which is uncommon. Lateralized hypsarhythmia also occurs with bilateral structural lesions that are more severe on one side.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging studies should be performed in all patients with IS to identify lesions associated with the disorder, as this may influence treatment decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/2,25-27\">",
"     2,25-27",
"    </a>",
"    ]. Approximately 70 percent of patients will have an established etiology after clinical evaluation, EEG, and MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/28/30154?source=see_link\">",
"     \"Management and prognosis of infantile spasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CT may demonstrate cerebral atrophy, ventricular enlargement, calcium deposits, tubers, or encephalomalacia. However, CT has a limited role in patients with IS due to the higher sensitivity of MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI is recommended for all patients with IS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/2\">",
"     2",
"    </a>",
"    ]. Children younger than one year require special MRI sequences due to immature myelination patterns; these should included high-resolution coronal and axial T2-weighted sequences, along with sagittal, axial, and coronal T1-weighted sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/28\">",
"     28",
"    </a>",
"    ]. Ideally, MRI should be obtained prior to the initiation of therapy, which can sometimes cause imaging changes. If MRI is normal and no other etiology is identified, then repeat imaging at six month intervals is recommended, particularly if there is not an expected treatment response or if there is clinical deterioration.",
"   </p>",
"   <p>",
"    MRI may detect cerebral malformations, cerebral atrophy, delayed myelination, and other focal lesions not visible on CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/26\">",
"     26",
"    </a>",
"    ]. MRI also may provide information regarding prognosis, especially with regard to motor development. Patients with normal findings on MRI have better outcomes compared to those with lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with IS and symmetric hypsarhythmia have diffuse structural brain diseases that are not lateralized. They rarely have focal or lateralizing features visible on imaging studies. Positron emission computed tomography (PET) may help identify an etiology in these cases, as illustrated by a study of 140 affected patients referred for evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/30\">",
"     30",
"    </a>",
"    ]. A specific disease or syndrome was diagnosed at presentation in 9.3 percent. CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI detected lesions in 20.7 percent of cases without a clinical diagnosis. Among the 97 patients whose underlying condition remained uncertain, PET scanning detected unifocal or multifocal abnormalities in 92 (65.7 percent). As a result, an etiology was identified in 96 percent of cases. Specialized MRI studies, including magnetization transfer imaging and magnetic resonance spectroscopy may also identify lesions not visible on a standard MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2763109\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 30 percent of patients whose etiology is not established after clinical evaluation, EEG, and MRI, a metabolic etiology will be established in less than half; the remainder will be labeled &lsquo;idiopathic&rsquo; or &lsquo;cryptogenic&rsquo;, or by the more inclusive term &lsquo;non-symptomatic&rsquo;.",
"   </p>",
"   <p>",
"    Studies that can establish a metabolic etiology include, among others [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1063/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pyridoxine challenge",
"     </li>",
"     <li>",
"      Urine for organic acids",
"     </li>",
"     <li>",
"      Serum for amino acids",
"     </li>",
"     <li>",
"      Biotinidase determination",
"     </li>",
"     <li>",
"      Cerebrospinal fluid analysis of neurotransmitters, lactic acid, amino acids, folate metabolites, glucose, glycine",
"     </li>",
"     <li>",
"      Chromosomal studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2763118\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile spasms (IS) is an age-specific convulsive disorder of infancy and early childhood.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most children with IS present between three and seven months of age; onset after 18 months is rare. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Age of onset'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spasms are symmetric contractions of flexor or extensor axial or limb muscles. They vary in pattern, intensity, duration and extent. Most spasms occur in clusters of two to more than 100 over one to several minutes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Spasms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When spasm or spasm clusters are brief and involve limited musculature they may be unrecognized. Parents typically underestimate seizure frequency by a factor of 5 to 10 (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Spasms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EEG is essential for the diagnosis of IS and should capture an ictus as well as the characteristic interictal pattern of hypsarhythmia. A 24-hour inpatient video EEG monitoring study is ideal. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Electroencephalography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypsarhythmia on interictal EEG is an essential feature of West syndrome. Hypsarhythmia varies with the sleep-wake cycle. The classic pattern is most pronounced in quiet sleep and may be reduced or absent when the patient is awake or in REM sleep. NonREM sleep may be reduced in patients with IS. (See",
"      <a class=\"local\" href=\"#H4943541\">",
"       'Hypsarhythmia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other diagnostic studies in IS focus on etiology. Etiology is critical to determining treatment and prognosis. An MRI is essential in this regard. If an etiology is not identified after clinical evaluation, EEG, and MRI, further studies to assess a metabolic origin should be obtained. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Neuroimaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2763109\">",
"       'Other studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/1\">",
"      West, WJ. On a peculiar form of infantile convulsions. Lancet 1841; 1:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/2\">",
"      Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S. consensus report. Epilepsia 2010; 51:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/3\">",
"      Trevathan E, Murphy CC, Yeargin-Allsopp M. The descriptive epidemiology of infantile spasms among Atlanta children. Epilepsia 1999; 40:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/4\">",
"      Vigevano F, Fusco L, Cusmai R, et al. The idiopathic form of West syndrome. Epilepsia 1993; 34:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/5\">",
"      L&uacute;thv&iacute;gsson P, Olafsson E, Sigurthard&oacute;ttir S, Hauser WA. Epidemiologic features of infantile spasms in Iceland. Epilepsia 1994; 35:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/6\">",
"      Kellaway P, Hrachovy RA, Frost JD Jr, Zion T. Precise characterization and quantification of infantile spasms. Ann Neurol 1979; 6:214.",
"     </a>",
"    </li>",
"    <li>",
"     Kellaway P, Frost JD Jr, Hrachovy RA. Infantile spasms. In: Antiepileptic Drug Therapy in Pediatrics, Morselli PL, Pippenger CE, Penry JK (Eds), Raven Press, New York 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/8\">",
"      Hrachovy RA, Frost JD Jr. Infantile epileptic encephalopathy with hypsarrhythmia (infantile spasms/West syndrome). J Clin Neurophysiol 2003; 20:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/9\">",
"      Ramgopal S, Shah A, Zarowski M, et al. Diurnal and sleep/wake patterns of epileptic spasms in different age groups. Epilepsia 2012; 53:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/10\">",
"      Glaze DG, Zion TE. Infantile spasms. Curr Probl Pediatr 1985; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/11\">",
"      Koo B, Hwang PA, Logan WJ. Infantile spasms: outcome and prognostic factors of cryptogenic and symptomatic groups. Neurology 1993; 43:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/12\">",
"      Wong M, Trevathan E. Infantile spasms. Pediatr Neurol 2001; 24:89.",
"     </a>",
"    </li>",
"    <li>",
"     Lacy JR, Penry JK. Infantile spasms, Raven Press, New York 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/14\">",
"      Hrachovy RA, Glaze DG, Frost JD Jr. A retrospective study of spontaneous remission and long-term outcome in patients with infantile spasms. Epilepsia 1991; 32:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/15\">",
"      Maydell BV, Berenson F, Rothner AD, et al. Benign myoclonus of early infancy: an imitator of West's syndrome. J Child Neurol 2001; 16:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/16\">",
"      Lombroso CT, Fejerman N. Benign myoclonus of early infancy. Ann Neurol 1977; 1:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/17\">",
"      Coulter DL, Allen RJ. Benign neonatal sleep myoclonus. Arch Neurol 1982; 39:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/18\">",
"      Vigevano F, Lispi ML. Tonic reflex seizures of early infancy: an age-related non-epileptic paroxysmal disorder. Epileptic Disord 2001; 3:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/19\">",
"      Gaily E, Liukkonen E, Paetau R, et al. Infantile spasms: diagnosis and assessment of treatment response by video-EEG. Dev Med Child Neurol 2001; 43:658.",
"     </a>",
"    </li>",
"    <li>",
"     Gibbs, FA, Gibbs, EL. Atlas of Electroencephalography, Addison-Wesley, Reading, MA 1952.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/21\">",
"      Philippi H, Wohlrab G, Bettendorf U, et al. Electroencephalographic evolution of hypsarrhythmia: toward an early treatment option. Epilepsia 2008; 49:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/22\">",
"      Hrachovy RA, Frost JD Jr, Kellaway P. Hypsarrhythmia: variations on the theme. Epilepsia 1984; 25:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/23\">",
"      Donat JF, Lo WD. Asymmetric hypsarrhythmia and infantile spasms in west syndrome. J Child Neurol 1994; 9:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/24\">",
"      Drury I, Beydoun A, Garofalo EA, Henry TR. Asymmetric hypsarrhythmia: clinical electroencephalographic and radiological findings. Epilepsia 1995; 36:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/25\">",
"      Haginoya K, Kon K, Takayanagi M, et al. Heterogeneity of ictal SPECT findings in nine cases of West syndrome. Epilepsia 1998; 39 Suppl 5:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/26\">",
"      van Bogaert P, Chiron C, Adamsbaum C, et al. Value of magnetic resonance imaging in West syndrome of unknown etiology. Epilepsia 1993; 34:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/27\">",
"      Aydinli N, Cali��kan M, Ozmen M, Tongu&ccedil; E. Neuroradiologic aspects of West syndrome. Pediatr Neurol 1998; 19:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/28\">",
"      Gaillard WD, Chiron C, Cross JH, et al. Guidelines for imaging infants and children with recent-onset epilepsy. Epilepsia 2009; 50:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/29\">",
"      Saltik S, Kocer N, Dervent A. Informative value of magnetic resonance imaging and EEG in the prognosis of infantile spasms. Epilepsia 2002; 43:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1063/abstract/30\">",
"      Chugani HT, Conti JR. Etiologic classification of infantile spasms in 140 cases: role of positron emission tomography. J Child Neurol 1996; 11:44.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6145 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-DF7F161079-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1063=[""].join("\n");
var outline_f1_2_1063=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2763118\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Age of onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Spasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H143069252\">",
"      Other clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2763158\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4943774\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2763032\">",
"      Benign myoclonus of early infancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2763039\">",
"      Sleep myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2763046\">",
"      Tonic reflex seizures of early infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4943541\">",
"      - Hypsarhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ictal EEG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Lateralized findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2763109\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2763118\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6145\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6145|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/25/34205\" title=\"figure 1\">",
"      Age of onset of infantile spasms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/15/1273?source=related_link\">",
"      Etiology and pathogenesis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/28/30154?source=related_link\">",
"      Management and prognosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=related_link\">",
"      Nonepileptic paroxysmal disorders in infancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_2_1064="Pazopanib: Drug information";
var content_f1_2_1064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pazopanib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/5/20566?source=see_link\">",
"    see \"Pazopanib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9524345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9511644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Votrient&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13108831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Votrient&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9524350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor;",
"     </li>",
"     <li>",
"      Vascular Endothelial Growth Factor (VEGF) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9524485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Renal cell cancer (RCC):",
"     </b>",
"     Oral: 800 mg once daily (Sternberg, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Soft tissue sarcoma (STS), advanced refractory:",
"     </b>",
"     Oral: 800 mg once daily (Van Der Graaf, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Thyroid cancer, advanced differentiated (unlabeled use):",
"     </b>",
"     Oral: 800 mg once daily until disease progression or unacceptable toxicity (Bible, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Concomitant CYP3A4 inhibitors/inducers:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CYP3A4 inhibitors: Avoid concomitant strong CYP3A4 inhibitors (may increase pazopanib concentrations). If pazopanib must be administered concomitantly with a potent enzyme inhibitor, reduce pazopanib to 400 mg once daily with careful monitoring; further dosage reductions may be needed if adverse events occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CYP3A4 inducers: Avoid concomitant strong CYP3A4 inducers (may decrease pazopanib concentrations); use of pazopanib is not recommended in situations where the use of a strong CYP3A4 inducer is required.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9524486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9524487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary (renal impairment is not likely to significantly influence pazopanib pharmacokinetics).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9524488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Pre-existing impairment:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Mild (bilirubin &le;1.5 times ULN or ALT &gt;ULN): No adjustment required (Shibata, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Moderate (bilirubin &gt;1.5-3 times ULN): Consider alternative therapy or reduce to 200 mg once daily (maximum tolerated dose in moderate hepatic impairment) (Shibata, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Severe (bilirubin &gt;3 times ULN with any ALT level): Use is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      During treatment:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Isolated ALT elevations 3-8 times ULN: Continue treatment, monitor liver function weekly until ALT returns to grade 1 or baseline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Isolated ALT elevations &gt;8 times ULN: Interrupt treatment until ALT returns to grade 1 or baseline. If therapy benefit is greater than the risk of hepatotoxicity, may reinitiate treatment at &le;400 mg once daily (with liver function monitored weekly for 8 weeks); permanently discontinue if ALT &gt;3 times ULN occurs with reinitiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     ALT &gt;3 times ULN concurrently with bilirubin &gt;2 times ULN: Permanently discontinue; monitor until resolution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gilbert&rsquo;s syndrome with mild indirect bilirubin elevation and ALT &gt;3 times ULN: Refer to isolated ALT elevations dosage recommendations above.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F9524489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Initial dosage reduction:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Prior to dose reduction, temporarily discontinue therapy if 24-hour urine protein &ge;3 g or for other toxicities when clinically indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      RCC:",
"     </i>",
"     Reduce to 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      STS:",
"     </i>",
"     Reduce to 600 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Further modification:",
"     </b>",
"     <i>",
"      RCC, STS:",
"     </i>",
"     Adjust dose in 200 mg increments or decrements based on individual tolerance; maximum dose: 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Proteinuria (recurrent 24-hour urine protein &ge;3 g refractory to dose reduction), hypertension (severe, persistent, and refractory to antihypertensives and dose reduction), wound dehiscence, reversible posterior leukoencephalopathy syndrome (RPLS):",
"     </b>",
"     Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Infection, serious:",
"     </b>",
"     Consider treatment interruption or discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9524496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Votrient&trade;: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9524348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9524347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM188476.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM188476.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9524490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer on an empty stomach, 1 hour before or 2 hours after a meal. Do not crush tablet. If a dose is missed, do not take if &lt;12 hours until the next dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9524351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of advanced renal cell cancer (RCC); treatment of advanced soft tissue sarcoma (STS) (in patients previously treated with chemotherapy)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13108832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of advanced, differentiated thyroid cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9524346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pazopanib may be confused with axitinib, regorafenib, SUNItinib, vandetanib",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Votrient&trade; may be confused with vorinostat",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9524404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (40% to 42%; grade 3: 4% to 7%), peripheral edema (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (19% to 65%), headache (10% to 23%), dizziness (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hair color change (38% to 39%), rash (8% to 18%), alopecia (8% to 12%), palmar-plantar erythrodysesthesia (6% to 11%), skin depigmentation (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (41% to 45%), hypophosphatemia (34%), hyponatremia (31%), thyroid-stimulating hormone (TSH) increased (27%), hypomagnesemia (26%), hypoglycemia (17%), hyperkalemia (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (52% to 59%; grade 3: 3% to 5%; grade 4: &lt;1%), nausea (26% to 56%), weight loss (9% to 48%), anorexia (22% to 40%), vomiting (21% to 33%), taste alteration (8% to 28%), lipase increased (4% to 27%),  abdominal pain (11% to 23%), mucositis (12%), stomatitis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Leukopenia (37% to 44%; grade 3: &le;1%), lymphocytopenia (31% to 43%; grade 3: 4% to 10%; grade 4: &lt;1%), thrombocytopenia (32% to 36%; grade 3: &le;3%; grade 4: &le;1%), neutropenia (33% to 34%; grade 3: 1% to 4%; grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (51% to 53%; grade 3: 5% to 7%; grade 4: &lt;3%), ALT increased (46% to 53%; grade 3: 8% to 10%; grade 4: 2%), bilirubin increased (29% to 36%; grade 3: &le;3%; grade 4: &lt;1%), albumin decreased (34%), alkaline phosphatase increased (32%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain (23%), myalgia (23%), weakness (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (20%), cough (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Tumor pain (29%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Chest pain (5% to 10%), left ventricular dysfunction (&le;8%), venous thrombosis (&le;5%), MI/ischemia (2%), QT prolongation (1% to 2%), facial edema (1%), transient ischemic event (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (9%), dysphonia (4% to 8%), chills (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Dry skin (6%), nail disorder (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypothyroidism (4% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Dyspepsia (5% to 7%), mouth hemorrhage (3%), rectal hemorrhage (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Proteinuria (1% to 9%), hematuria (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Epistaxis (2% to 8%), pneumothorax (&le;3%), hemoptysis (2%), PE (fatal; 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Cardiac dysfunction, cerebral hemorrhage, cerebrovascular event, extrapyramidal symptoms, gastrointestinal fistula, gastrointestinal perforation, HF, hepatotoxicity, hypertensive crisis, intracranial hemorrhage, ischemic stroke,  nephrotic syndrome, pancreatitis, reversible posterior leukoencephalopathy syndrome (RPLS), torsade de pointes, tumor hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9524357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9524358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal perforation/fistula: Perforation and fistula (including fatal) have been reported; monitor for symptoms of gastrointestinal perforation and fistula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: May cause new-onset or worsening of existing heart failure; baseline and periodic LVEF monitoring is recommended in patients at increased risk of heart failure (eg, prior anthracycline treatment). Concurrent hypertension may increase the risk for cardiac dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhage: Hemorrhagic events (including fatal) have been reported. Use is not recommended in patients with a history of hemoptysis, cerebral hemorrhage or clinically significant gastrointestinal hemorrhage within 6 months; these populations were excluded from clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Severe and fatal hepatotoxicity (transaminase and bilirubin elevations) has been reported with use. Monitor hepatic function. May require dosage interruption, reduction, or discontinuation.",
"     </b>",
"     Transaminase elevations usually occur early in the treatment course. Use is not recommended in patients with pre-existing severe hepatic impairment (bilirubin &gt;3 times ULN with any ALT level); dosage reduction is recommended for pre-existing moderate hepatic impairment (bilirubin &gt;1.5-3 times ULN). Mild indirect (unconjugated) hyperbilirubinemia may occur in patients with Gilbert's syndrome; for patients with known Gilbert's syndrome (only a mild indirect bilirubin elevation) and ALT &gt;3 times ULN, follow the dosage modification recommendations for isolated ALT elevations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: May cause and/or worsen hypertension; hypertensive crisis has been observed. Blood pressure should be controlled prior to treatment initiation. Monitor for hypertension; antihypertensive therapy should be used if needed.  Hypertension usually occurs early in the treatment course. Dosage reduction may be necessary for persistent hypertension (despite antihypertensive therapy); discontinue for hypertensive crisis, or for severe and persistent hypertension which is refractory to dose reduction and antihypertensive therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections: Serious, including fatal, infections have been reported; monitor for signs and symptoms of infection. Temporarily or permanently discontinue therapy for serious infections as clinically indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proteinuria: Has been reported with use.  Obtain baseline and periodic urinalysis and 24-hour urine protein when clinically indicated. Dosage reduction may be necessary for significant proteinuria (&ge;3 g/24 hours); discontinue for recurrent proteinuria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation: QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, including torsade de pointes, has been observed; use caution in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, with medications known to prolong the QT interval, or with pre-existing cardiac disease. Obtain baseline and periodic ECGs; correct electrolyte (potassium, calcium, and magnesium) abnormalities prior to and during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reversible posterior leukoencephalopathy syndrome (RPLS): Has been reported (rarely); may be fatal.  Monitor for neurological changes or symptoms (blindness, confusion, headache, lethargy, seizure, visual or neurologic disturbances); discontinue pazopanib in patients who develop RPLS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events: Venous and arterial thromboembolism have been reported. DVT, pulmonary embolism, angina, transient ischemic attack, MI, and ischemic stroke were observed more frequently in the pazopanib group (versus placebo) in clinical trials. Fatalities were observed. Use with caution in patients with a history of or an increased risk for these events. Use in patients with recent arteriothrombotic event (within 6 months) has not been studied and is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disorders: Hypothyroidism has been reported with use; monitor thyroid function tests.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Wound healing complications: Vascular endothelial growth factor (VEGF) receptor inhibitors are associated with impaired wound healing.  Discontinue treatment at least 7 days prior to scheduled surgery; treatment reinitiation should be guided by clinical judgment. Discontinue if wound dehiscence occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Patients with mild-to-moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute) were included in trials. There are no pharmacokinetic data in patients with severe renal impairment undergoing dialysis (peritoneal and hemodialysis); however, renal impairment is not expected to significantly influence pazopanib pharmacokinetics or exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chemotherapy: Increased toxicity and mortality has been observed in trials evaluating concurrent use of pazopanib with other chemotherapeutic agents (pemetrexed, lapatinib). Pazopanib is not approved for use in combination with other chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Avoid use with strong CYP3A4 inhibitors or inducers. If pazopanib must be administered concomitantly with a potent enzyme inhibitor, dose reductions are recommended.  Use is not recommended in situations where the use of a strong CYP3A4 inducer is required. Pazopanib inhibits UGT1A1 and OATP1B1; pazopanib may increase concentration of drugs eliminated by UGT1A1 and OATP1B1.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging agents: Concurrent use with other drugs which may prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval may increase the risk of potentially-fatal arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Patients &gt;60 years of age may be at higher risk for ALT &gt;3 times ULN. Additionally, patients &ge;65 years of age may be at higher risk of fatigue (grade 3 or 4), hypertension, and decreased appetite.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9628714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C8 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2D6 (weak), CYP3A4 (weak), SLCO1B1, UGT1A1",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9613151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Pazopanib. Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: May enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased. Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: May enhance the QTc-prolonging effect of Pazopanib. Lapatinib may increase the serum concentration of Pazopanib. Management: Avoid this combination if possible. Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm as well as for other evidence of pazopanib toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9524444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Systemic exposure of pazopanib is increased when administered with food (AUC twofold higher with a meal). Grapefruit juice may increase the levels/effects of pazopanib. Management: Maintain adequate nutrition and hydration, unless instructed to restrict fluid intake. Take on an empty stomach 1 hour before or 2 hours after a meal. Avoid grapefruit/grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may increase metabolism and decrease pazopanib concentrations. Echinacea may diminish the therapeutic effect. Management: Avoid St John's wort. Consider avoiding echinacea.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9524352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9524353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal reproduction studies. Based on its mechanism of action, pazopanib would be expected to cause fetal harm if administered to a pregnant woman. Women of childbearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9524355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9524356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9524455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take on an empty stomach, 1 hour before or 2 hours after a meal. Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Votrient Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (120): $8556.42",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9524494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor liver function tests at baseline and at least every 4 weeks for the first 4 months (more frequently if clinically indicated) and periodically thereafter; serum electrolytes (eg, calcium, magnesium, potassium); urinalysis (for proteinuria; baseline and periodic), 24-hour urine protein (if clinically indicated); thyroid function (TSH and T",
"     <sub>",
"      4",
"     </sub>",
"     at baseline and TSH every 6-8 weeks during treatment [Appleby, 2011]); blood pressure; ECG (baseline and periodic); LVEF (if at risk for cardiac dysfunction; baseline and periodic); signs/symptoms of gastrointestinal perforation or fistula, infection, heart failure, or neurological changes.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Votrient (AR, AT, AU, BE, BR, CH, CN, CZ, DK, EE, FR, GB, HK, ID, IE, IL, IN, MY, NL, NO, NZ, PH, PL, PT, SE, SG, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9524491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tyrosine kinase (multikinase) inhibitor; limits tumor growth via inhibition of angiogenesis  angiogenesis by inhibiting cell surface vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-alpha and -beta), fibroblast growth factor receptor (FGFR-1 and -3), cytokine receptor (cKIT), interleukin-2 receptor inducible T-cell kinase, leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9524447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; primarily via CYP3A4, minor metabolism via CYP1A2 and CYP2C8",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Rate and extent of bioavailability are increased with food and increased if tablets are crushed (do not crush tablets)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~31 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (primarily); urine (&lt;4%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Appleby L, Morrissey S, Bellmunt J, et al, &ldquo;Management of Treatment-Related Toxicity With Targeted Therapies for Renal Cell Carcinoma: Evidence-Based Practice and Best Practices,&rdquo;",
"      <i>",
"       Hematol Oncol Clin North Am",
"      </i>",
"      , 2011, 25(4):893-915.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/2/1064/abstract-text/21763973/pubmed\" id=\"21763973\" target=\"_blank\">",
"        21763973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bible KC, Suman VJ, Molina JR, et al, &ldquo;Efficacy of Pazopanib in Progressive, Radioiodine-Refractory, Metastatic Differentiated Thyroid Cancers: Results of a Phase 2 Consortium Study,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(10):962-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/2/1064/abstract-text/20851682/pubmed\" id=\"20851682\" target=\"_blank\">",
"        20851682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cella D, Pickard AS, Duh MS, et al, &ldquo;Health-Related Quality of Life in Patients With Advanced Renal Cell Carcinoma Receiving Pazopanib or Placebo in a Randomised Phase III Trial,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2012, 48(3):311-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/2/1064/abstract-text/21689927/pubmed\" id=\"21689927\" target=\"_blank\">",
"        21689927",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hawkins RE, Hong SJ, Ulys A, et al, &ldquo;An Open-Label Extension Study to Evaluate Safety and Efficacy of Pazopanib in Patients With Advanced Renal Cell Carcinoma (RCC),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15s):5110 [abstract 5110 from 2009 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heath EI, Chiorean EG, Sweeney CJ, et al, &ldquo;A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2010, 88(6):818-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/2/1064/abstract-text/20980999/pubmed\" id=\"20980999\" target=\"_blank\">",
"        20980999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hurwitz HI, Dowlati A, Saini S, et al, &ldquo;Phase I Trial of Pazopanib in Patients With Advanced Cancer,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2009, 15(12):4220-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/2/1064/abstract-text/19509175/pubmed\" id=\"19509175\" target=\"_blank\">",
"        19509175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hutson TE, Davis ID, Machiels JP, et al, &ldquo;Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(3):475-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/2/1064/abstract-text/20008644/pubmed\" id=\"20008644\" target=\"_blank\">",
"        20008644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schutz FA, Je Y, Richards CJ, et al, \"Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(8):871-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/2/1064/abstract-text/22312105/pubmed\" id=\"22312105\" target=\"_blank\">",
"        22312105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shibata S, Longmate J, Chung VM, et al, &ldquo;A Phase I and Pharmacokinetic Single Agent Study of Pazopanib (P) in Patients (Pts) With Advanced Malignancies and Varying Degrees of Liver Dysfunction (LD),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(Suppl 15):2571 [abstract 2571 from 2010 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sleijfer S, Ray-Coquard I, Papai Z, et al, &ldquo;Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(19):3126-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/2/1064/abstract-text/19451427/pubmed\" id=\"19451427\" target=\"_blank\">",
"        19451427",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sternberg CN, Davis ID, Mardiak J, et al, &ldquo;Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(6):1061-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/2/1064/abstract-text/20100962/pubmed\" id=\"20100962\" target=\"_blank\">",
"        20100962",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sternberg CN, Szczylik C, Lee E, et al, &ldquo;A Randomized, Double-Blind Phase III Study of Pazopanib in Treatment-Naive and Cytokine-Pretreated Patients With Advanced Renal Cell Carcinoma (RCC),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15s):5021 [abstract 5021 from 2009 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Der Graaf WT, Blay J, Chawla SP, et al, &ldquo;PALETTE: A Randomized, Double-Blind, Phase III Trial of Pazopanib Versus Placebo in Patients (pts) With Soft-Tissue Sarcoma (STS) Whose Disease has Progressed During or Following Prior Chemotherapy -- An EORTC STBSG Global Network Study (EORTC 62072),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(Suppl 18):LBA10002 [abstract LBA10002 from 2011 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Xu CF, Reck BH, Xue Z, et al, &ldquo;Pazopanib-Induced Hyperbilirubinemia is Associated With Gilbert's Syndrome UGT1A1 Polymorphism,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2010, 102(9):1371-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/2/1064/abstract-text/20389299/pubmed\" id=\"20389299\" target=\"_blank\">",
"        20389299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9524 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1064=[""].join("\n");
var outline_f1_2_1064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524345\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9511644\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13108831\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524350\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524485\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524486\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524487\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524488\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524489\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524496\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524348\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524347\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524490\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524351\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13108832\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524346\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524404\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524357\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524358\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9628714\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9613151\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524444\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524352\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524353\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524355\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524356\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524455\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322744\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524494\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962017\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524491\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524447\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9524\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9524|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/5/20566?source=related_link\">",
"      Pazopanib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_2_1065="Treatment of relapsed or refractory mantle cell lymphoma";
var content_f1_2_1065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of relapsed or refractory mantle cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/2/1065/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/2/1065/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/2/1065/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/2/1065/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/2/1065/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/2/1065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/2/1065/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/2/1065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mantle cell lymphoma (MCL), one of the B cell non-Hodgkin lymphomas (NHL), has a variable course. A minority of patients with this disorder may survive untreated for many years. However, more frequently, MCL assumes a more virulent character, akin to that of an aggressive NHL variant.",
"   </p>",
"   <p>",
"    There is great variability in the initial treatment of MCL used in clinical practice. While some advocate intensive chemotherapy with autologous transplantation, others prefer combination chemotherapy regimens used for aggressive NHL subtypes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17402?source=see_link\">",
"     \"Initial treatment of mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite all efforts to the contrary, therapy for MCL is not curative and virtually all patients will have refractory or recurrent disease. Treatment of recurrent MCL is difficult, due to the rapid development of chemotherapy resistance. There are multiple chemotherapy regimens that may be tried and clinical practice varies greatly by center. Given the limited efficacy of these agents and paucity of data comparing these various treatment options, participation in a clinical trial is encouraged whenever possible.",
"   </p>",
"   <p>",
"    The treatment of relapsed or refractory mantle cell lymphoma will be discussed here. The initial treatment of mantle cell lymphoma and the clinical and pathologic features of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17402?source=see_link\">",
"     \"Initial treatment of mantle cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of chemotherapy regimens have been evaluated in patients with recurrent or refractory MCL, with variable success. Some of these agents are undergoing further investigation for use in combination therapies. All patients should be encouraged to participate in clinical trials whenever available.",
"   </p>",
"   <p>",
"    For those young patients without significant comorbid diseases who do not have access to clinical trials or who choose not to participate in a clinical trial, we offer treatment with a salvage regimen. If chemosensitivity is shown, these patients may benefit from high dose therapy with autologous stem cell support or allogeneic hematopoietic cell transplantation (HCT).",
"   </p>",
"   <p>",
"    The salvage regimen used for a particular patient depends upon patient comorbidities, side effect profiles, prior therapies, and the clinical situation of the patient in question. The sequential use of standard chemotherapy regimens can portend long survival in a select group of patients with MCL [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/1\">",
"     1",
"    </a>",
"    ]. Aggressive combination chemotherapy salvage regimens such as R-ICE (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ), R-DHAP (rituximab,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ), or R-HyperCVAD (rituximab, hyperfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and dexamethasone, alternating with high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and cytarabine) may also be a reasonable option for some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bortezomib",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been several prospective phase II trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    in patients with relapsed or refractory MCL demonstrating overall response rates from 29 to 50 percent and complete response rates from 4 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. The median duration of response is approximately 10 months. Adverse events are similar to those previously reported for bortezomib in patients with multiple myeloma and most commonly include anorexia, nausea and vomiting, peripheral neuropathy, cutaneous reactions, neutropenia, and thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Bortezomib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a survey of the studies that have evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    in patients with recurrent MCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter prospective phase II study included 155 patients with recurrent MCL treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      1.3",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      given on days 1, 4, 8, and 11 of a 21-day cycle for up to 17 cycles [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/5\">",
"       5",
"      </a>",
"      ]. The overall response rate was 33 percent (8 percent complete or unconfirmed complete response). Median duration of response was 9.2 months. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      adverse effects were peripheral neuropathy (13 percent), fatigue (12 percent), and thrombocytopenia (11 percent). Treatment related deaths were reported for 3 percent of patients.",
"     </li>",
"     <li>",
"      Another phase II prospective trial evaluated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      , given at the same dose and schedule as above, in 29 patients with MCL, 13 of whom had received no prior therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/6\">",
"       6",
"      </a>",
"      ]. The overall response rate was 46 percent with a median response duration of 10 months. Response rates were similar in previously untreated and recurrent disease. Two deaths due to fluid retention were noted in the first 12 patients enrolled therefore subsequent enrollment excluded patients with baseline effusions, dyspnea, or edema.",
"     </li>",
"     <li>",
"      A prospective trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      that included 24 patients with relapsed or refractory lymphoma reported responses in 7, including one complete response [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/4\">",
"       4",
"      </a>",
"      ]. Another phase II trial of bortezomib in 40 patients reported similar overall response rates (50 versus 43 percent) and progression-free survival (5.6 versus 3.9 months) for patients with relapsed or refractory disease, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based partly on these studies, the United States FDA granted approval to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    for the treatment of patients with MCL who have received at least one prior therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caution should be used when combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in patients with recurrent MCL, as several studies have demonstrated high rates of toxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 42 patients with",
"      <span class=\"nowrap\">",
"       recurrent/refractory",
"      </span>",
"      MCL, follicular lymphoma, or Waldenstr&ouml;m macroglobulinemia demonstrated responses in 11 of 19 patients with MCL [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/10\">",
"       10",
"      </a>",
"      ]. Toxicity was significant with 16 of 42 patients requiring discontinuation of treatment due to side effects.",
"     </li>",
"     <li>",
"      In another study, 25 patients with relapsed follicular lymphoma or mantle cell lymphoma (14 patients) were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/11\">",
"       11",
"      </a>",
"      ]. The overall response rate was 29 percent in patients with MCL, but toxicity was significant with 52 percent developing grade 3 neurologic toxicity.",
"     </li>",
"     <li>",
"      In another phase II study, 16 patients with relapsed or refractory MCL who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and pulsed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      demonstrated a response rate of 81 percent (44 percent complete) with a median overall survival of 39 months [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/12\">",
"       12",
"      </a>",
"      ]. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included thrombocytopenia (38 percent), fatigue (19 percent), and peripheral neuropathy (13 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bendamustine plus rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single arm prospective trials evaluating the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     bendamustine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in relapsed or refractory MCL have reported overall response rates of 75 to 92 percent. The most common severe side effects include infection, myelosuppression, and fatigue.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective, phase II trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      included 12 patients with recurrent MCL [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/13\">",
"       13",
"      </a>",
"      ]. The overall response rate was 92 percent with 59 percent complete or complete response unconfirmed. Median duration of response was 19 months. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      adverse events were infection (8 percent) and fatigue (5 percent).",
"     </li>",
"     <li>",
"      A prospective, phase II trial included 16 patients with relapsed MCL treated with up to four cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/14\">",
"       14",
"      </a>",
"      ]. Overall and complete response rates were 75 and 50 percent, respectively. Myelosuppression (16 percent) was the most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      adverse effect.",
"     </li>",
"     <li>",
"      A multicenter phase II trial including 18 patients with MCL treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      for four cycles reported an overall response rate of 78 percent with 33 percent complete responses [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/15\">",
"       15",
"      </a>",
"      ]. The median progression-free survival time and two-year survival rate were 21 months and 60 percent, respectively.",
"     </li>",
"     <li>",
"      A multicenter phase II trial investigated the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 30 patients with relapsed or refractory indolent NHL, seven of whom had MCL [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/16\">",
"       16",
"      </a>",
"      ]. The overall response rate was 83 percent (71 percent among those with MCL). Common toxicities included nausea (50 percent), neuropathy (47 percent), fatigue (47 percent), constipation (40 percent), and fever (40 percent). One patient died of sepsis. At a median follow-up of 24 months, the progression-free survival rate at two years was 47 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fludarabine, cyclophosphamide, mitoxantrone plus rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    (FCM) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    has been evaluated in a prospective German study resulting in overall response rates of 60 to 80 percent. The most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    side effects were neutropenia (40 percent), lymphopenia (51 percent), and thrombocytopenia (12 percent).",
"   </p>",
"   <p>",
"    In a cooperative German study, patients with MCL and a nonresponse or relapse following at least one course of chemotherapy as well as disease recurrence after autologous HCT were randomly assigned to receive four monthly cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    IV over 30 minutes days one through three),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    as a four-hour IV infusion days one through three), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    (8",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    over 30 minutes IV on day one) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (375",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day on the day before each of the respective FCM courses) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall and complete response rates were 58 versus 46 percent and 29 versus zero percent for those assigned to treatment with FCM-R or FCM, respectively. Further accrual to the first part of this study (ie, FCM-R versus FCM) was discontinued after 50 patients because of the superiority of FCM-R; 56 subsequent patients with MCL received FCM-R for induction, with overall and complete response rates of 79 and 20 percent, respectively.",
"   </p>",
"   <p>",
"    A second randomization tested the effect of two courses of maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (ie, rituximab 375",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    <span class=\"nowrap\">",
"     once/week",
"    </span>",
"    for four consecutive weeks versus observation) given three and nine months following completion of FCM-R in those achieving a complete or partial remission with FCM-R [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/18\">",
"     18",
"    </a>",
"    ]. After a median observation of 26 months, median response duration was slightly prolonged by rituximab maintenance (14 versus 12 months) but with a significantly higher proportion of patients with ongoing remission beyond two years (45 versus 9 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Single agent rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective phase II trials have investigated the use of single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in patients with MCL [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Overall response rates were approximately 28 percent and did not differ between patients with newly diagnosed or recurrent disease. Median duration of response was 14 months. Common side effects include infusional reactions and infections, neither of which is typically severe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H19#H19\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of these prospective trials included 28 patients with previously treated MCL [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/19\">",
"     19",
"    </a>",
"    ]. The overall response rate seen in this subgroup was 37 percent with 14 percent complete responses. At a median follow-up from treatment of 1.3 years, the projected median duration of response was 1.2 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Single agent fludarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    has limited efficacy in patients with relapsed or refractory MCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective multicenter phase II study included six patients with relapsed or refractory MCL after chemotherapy with or without radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/22\">",
"       22",
"      </a>",
"      ]. One of six patients with MCL achieved a partial response and the rest had stable disease. The median time to treatment failure was 6.1 months. The most frequent severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity was neutropenia seen in 70 percent of patients.",
"     </li>",
"     <li>",
"      A prospective phase II trial of single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      in 15 patients with newly diagnosed (2 patients), relapsed, or refractory MCL reported five partial responses and no complete responses [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cladribine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two non-randomized, prospective trials have evaluated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in patients with newly diagnosed or relapsed MCL. Additional trials have looked at cladribine in combination with other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Myelosuppression is the most common severe side effect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A non-randomized, single arm trial of single-agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      in patients with MCL included 26 patients with no prior therapy and 24 patients with relapsed disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/26\">",
"       26",
"      </a>",
"      ]. Patients with no prior therapy had an overall response rate of 81 percent (42 percent complete) with a median time to progression of 13.6 months. Patients with relapsed disease at the time of therapy had an overall response rate of 46 percent (25 percent complete), a median time to progression of 5.4 months and a median overall survival of 1.9 years. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia and thrombocytopenia were reported in 51 and 12 percent, respectively.",
"     </li>",
"     <li>",
"      A second non-randomized trial evaluated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 29 patients with newly diagnosed MCL [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/26\">",
"       26",
"      </a>",
"      ]. Overall response rate was 66 percent (52 percent complete) and median time to progression was 12.1 months. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia and thrombocytopenia occurred in 34 and 17 percent of patients, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Temsirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial trials suggest a benefit from the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    as a single agent in patients with relapsed or refractory MCL. Ongoing trials are also examining the use of temsirolimus in combination with standard chemotherapy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Two single arm phase II trials and one randomized controlled trial have evaluated single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    in patients with relapsed or refractory MCL [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Overall response rates have ranged from 22 to 41 percent with few complete responses. All three trials demonstrated a median duration of response of approximately six months.",
"   </p>",
"   <p>",
"    The largest of these trials was a randomized three-arm phase III trial that evaluated two doses of single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    (175 mg weekly for three weeks followed by either 75 mg or 25 mg weekly) versus investigator's choice of therapy in 162 patients with heavily pretreated relapsed or refractory MCL [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/29\">",
"     29",
"    </a>",
"    ]. More than half of the patients had received at least four prior chemotherapy regimens. The majority of patients assigned to investigator's choice were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (42 percent) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    (26 percent).",
"   </p>",
"   <p>",
"    When compared with those assigned to investigator's choice, patients assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    had the following significant benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher overall response rates (22 and 6 versus 2 percent for those receiving 75 mg, 25 mg, or investigator's choice, respectively)",
"     </li>",
"     <li>",
"      Longer median progression free survival (3.4 and 4.8 versus 1.9 months, respectively)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most frequent severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    side effects with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    treatment were thrombocytopenia (52 to 59 percent), anemia (11 to 20 percent), neutropenia (15 to 22 percent), and asthenia (13 to 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter phase II trial evaluated the combination of lower dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    (25 mg weekly) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in 69 patients with relapsed or refractory MCL [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/30\">",
"     30",
"    </a>",
"    ]. Rates of overall and complete response were 59 and 19 percent, respectively. Response rates were similar for those with previously demonstrated rituximab-sensitive and rituximab-refractory disease (63 and 52 percent, respectively). This trial was designed before the phase III trial reported superior responses with higher doses of temsirolimus. As such, the optimal dosing combination and efficacy of temsirolimus plus rituximab remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other regimens have been evaluated in phase I or II prospective studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective, phase II study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      plus hyper-CVAD (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ) alternating with rituximab plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      in 29 patients with relapsed or refractory MCL reported an overall response rate of 93 percent (45 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/31\">",
"       31",
"      </a>",
"      ]. Grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      toxicities included neutropenia (74 percent) and thrombocytopenia (63 percent). Eleven percent of patients had neutropenic fever. At a median follow-up of 40 months, the median failure-free survival time was 11 months.",
"     </li>",
"     <li>",
"      A trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 16 patients with recurrent MCL demonstrated overall response rates of 81 percent with 5 complete responses [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/32\">",
"       32",
"      </a>",
"      ]. Median progression-free survival was 20 months. Grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      toxicities included thromboembolic events and neutropenia.",
"     </li>",
"     <li>",
"      Several phase II trials have reported on the efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      in relapsed non-Hodgkin lymphoma, including MCL [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/33-36\">",
"       33-36",
"      </a>",
"      ]. An international phase II trial of single agent lenalidomide in 57 patients with relapsed MCL demonstrated an overall response rate of 42 percent (21 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/37\">",
"       37",
"      </a>",
"      ]. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included neutropenia (41 percent), thrombocytopenia (19 percent), anemia (9 percent), fatigue (5 percent), and febrile neutropenia (2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A phase II study of the radioimmunoconjugate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"       ibritumomab",
"      </a>",
"      tiuxetan (a murine anti-CD20 monoclonal antibody conjugated to Yttrium-90) in 34 patients with relapsed or refractory MCL who had received a median of three prior treatments reported an overall response rate of 31 percent and a median overall survival of 21 months [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/38\">",
"       38",
"      </a>",
"      ]. This response rate is lower than that seen with the use of this agent in relapsed indolent lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of relapsed or refractory follicular lymphoma\", section on 'Radioimmunotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A prospective trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (RT-PEPC) in 22 older adults (median age 68 years) with relapsed MCL reported an overall response rate of 73 percent (32 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/39\">",
"       39",
"      </a>",
"      ]. The median progression-free survival was 10 months. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included neutropenia (64 percent), infection (23 percent), thrombocytopenia (18 percent), and anemia (5 percent).",
"     </li>",
"     <li>",
"      A phase II trial in patients with previously untreated or relapsed MCL indicated modest activity for the cyclin-dependent kinase (CDK) inhibitor flavopiridol [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/40\">",
"       40",
"      </a>",
"      ]. Additional studies, using different administration schedules of flavopiridol or other CDK inhibitors, are in progress [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A phase I study that used a new technique involving chimeric antigen receptor T cells (CAR-T cells) directed at CD-20 in two patients with relapsed MCL with no evidence of residual disease after lymph node resection reported disease progression at one and two years after completing T cell infusions [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC CELL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies using high dose chemotherapy followed by hematopoietic cell transplantation (HCT) have had variable results in patients with relapsed MCL [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/43\">",
"     43",
"    </a>",
"    ]. Autologous HCT is not curative and not commonly employed in this setting. There is very limited data on the use of myeloablative allogeneic HCT in this patient population and this approach is likely too toxic. In contrast, studies evaluating nonmyeloablative allogeneic HCT demonstrate promise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Autologous HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians offer conventional chemotherapy followed by high dose chemotherapy and autologous hematopoietic cell transplantation (peripheral blood progenitor cell rescue) as part of the",
"    <strong>",
"     initial",
"    </strong>",
"    treatment of patients with MCL. Studies have also evaluated its use in the setting of relapsed and resistant disease. Although autologous HCT does not appear to be curative, some patients may experience a prolonged remission. Median event-free survival after autologous HCT is approximately three years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17402?source=see_link&amp;anchor=H1967069#H1967069\">",
"     \"Initial treatment of mantle cell lymphoma\", section on 'Autologous transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty out of 28 patients in the Dana-Farber series of purged autologous HCT for MCL had relapsed disease prior to transplant, with an estimated four-year DFS of 31 percent post-transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/44\">",
"       44",
"      </a>",
"      ]. In three reports, at least 50 percent of mantle cell lymphoma patients relapsed within two to five years following HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/45-47\">",
"       45-47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A report from the Seattle group has indicated success in patients with recurrent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      resistant MCL in phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trials utilizing a combination of high-dose Iodine-131-labeled anti-CD20 antibody (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"       tositumomab",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , followed by autologous HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/48\">",
"       48",
"      </a>",
"      ]. At a median follow-up of 19 months, 15 of the 16 patients were still alive, with estimated three-year overall and progression-free survivals of 93 and 61 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nonmyeloablative HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial results of nonmyeloablative allogeneic HCT for relapsed or refractory MCL are promising, but longer follow-up is necessary before this becomes a standard approach [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/49-53\">",
"     49-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 18 subjects with advanced recurrent mantle cell lymphoma, 16 of whom had chemosensitive disease, were treated with non-myeloablative allogeneic HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/49\">",
"       49",
"      </a>",
"      ]. Complete remission was obtained in 17 of the 18 patients with a day-100 mortality of zero. At a median follow-up of 26 months, estimated three-year event-free survival was 82 percent.",
"     </li>",
"     <li>",
"      A prospective, multicentered, phase II trial of reduced-intensity conditioning followed by allogeneic HCT included 14 patients with relapsed or refractory MCL [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/54\">",
"       54",
"      </a>",
"      ]. At a median follow-up of 33 months, three-year overall survival for patients with MCL was 45 percent. The rate of transplant-related mortality was 13 percent among all patients in the trial. Overall three-year cumulative incidence of graft-versus-host disease was 49 percent.",
"     </li>",
"     <li>",
"      A retrospective analysis of consecutive patients undergoing nonmyeloablative allogeneic HCT for lymphoma at a single institution included 15 patients with MCL [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/55\">",
"       55",
"      </a>",
"      ]. Approximately one-third had received a prior autologous HCT. At a median follow-up of 26 months, estimated one-year and three-year overall survival rates for patients with MCL were 60 and 40 percent, respectively. Progression-free survival at the same time points was 30 and 40 percent, respectively. Acute GVHD occurred in 20 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although MCL cells are extremely radiosensitive in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/56\">",
"     56",
"    </a>",
"    ], use of radiation therapy (RT) in MCL, even in patients with localized disease, is not curative [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/57\">",
"     57",
"    </a>",
"    ]. However, RT may be helpful on occasion for local disease control in patients with chemotherapy-refractory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1065/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma (NHL) with a variable course. These patients are best treated by physicians with specific expertise in this area.",
"     </li>",
"     <li>",
"      A number of chemotherapy regimens have been evaluated in patients with recurrent or refractory MCL, with variable success. Some of these agents are undergoing further investigation for use in combination therapies. All patients should be encouraged to participate in clinical trials whenever available. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those young patients without significant comorbid diseases who do not have access to clinical trials or who choose not to participate in a clinical trial, we offer treatment with one of the salvage regimens described above. If chemotherapy sensitivity is shown, high dose therapy with autologous stem cell support may be considered, but is not curative. The role of allogeneic hematopoietic cell transplantation is uncertain. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The salvage regimen used for a particular patient depends upon patient comorbidities, side effect profiles, prior therapies, and the clinical situation of the patient in question.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/1\">",
"      Martin P, Chadburn A, Christos P, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008; 19:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/2\">",
"      Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/3\">",
"      O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/4\">",
"      Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/5\">",
"      Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24:4867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/6\">",
"      Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007; 18:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/7\">",
"      Gerecitano J, Portlock C, Moskowitz C, et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 2009; 146:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/8\">",
"      O'Connor OA, Moskowitz C, Portlock C, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. Br J Haematol 2009; 145:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/9\">",
"      Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007; 13:5291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/10\">",
"      Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstr&ouml;m macroglobulinaemia. Br J Haematol 2010; 151:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/11\">",
"      Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/12\">",
"      Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011; 96:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/13\">",
"      Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:4473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/14\">",
"      Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/15\">",
"      Weide R, Hess G, K&ouml;ppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007; 48:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/16\">",
"      Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/17\">",
"      Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104:3064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/18\">",
"      Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108:4003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/19\">",
"      Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/20\">",
"      Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/21\">",
"      Andersen NS, Pedersen LB, Laurell A, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009; 27:4365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/22\">",
"      Tobinai K, Watanabe T, Ogura M, et al. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2006; 24:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/23\">",
"      Decaudin D, Bosq J, Tertian G, et al. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998; 16:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/24\">",
"      Rummel MJ, Chow KU, Karakas T, et al. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. Eur J Cancer 2002; 38:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/25\">",
"      Robak T, Smolewski P, Cebula B, et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006; 107:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/26\">",
"      Inwards DJ, Fishkin PA, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 2008; 113:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/27\">",
"      Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23:5347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/28\">",
"      Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/29\">",
"      Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27:3822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/30\">",
"      Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011; 12:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/31\">",
"      Wang M, Fayad L, Cabanillas F, et al. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 2008; 113:2734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/32\">",
"      Kaufmann H, Raderer M, W&ouml;hrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/33\">",
"      Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009; 145:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/34\">",
"      Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/35\">",
"      Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012; 97:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/36\">",
"      Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012; 159:154.",
"     </a>",
"    </li>",
"    <li>",
"     Zinzani PL, Witzig TE, Vose JM, et al. Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle cell lymphoma: results of an international study (NHL-003) (abstract). Blood 2008; 112:Abstract 262.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/38\">",
"      Wang M, Oki Y, Pro B, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27:5213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/39\">",
"      Ruan J, Martin P, Coleman M, et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 2010; 116:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/40\">",
"      Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/41\">",
"      Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119:4597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/42\">",
"      Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012; 119:3940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/43\">",
"      Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16:3803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/44\">",
"      Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998; 16:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/45\">",
"      Andersen NS, Donovan JW, Borus JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997; 90:4212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/46\">",
"      Laudi N, Arora M, Burns L, et al. Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma. Am J Hematol 2006; 81:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/47\">",
"      Dietrich S, Tielesch B, Rieger M, et al. Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer 2011; 117:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/48\">",
"      Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99:3158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/49\">",
"      Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21:4407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/50\">",
"      Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104:3535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/51\">",
"      Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104:3865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/52\">",
"      Baron F, Storb R, Storer BE, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006; 24:4150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/53\">",
"      Le Gouill S, Kr&ouml;ger N, Dhedin N, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012; 23:2695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/54\">",
"      Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/55\">",
"      Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/56\">",
"      M'kacher R, Bennaceur A, Farace F, et al. Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma. Oncogene 2003; 22:7905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/57\">",
"      Leitch HA, Gascoyne RD, Chhanabhai M, et al. Limited-stage mantle-cell lymphoma. Ann Oncol 2003; 14:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/58\">",
"      Rosenbluth BD, Yahalom J. Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT). Int J Radiat Oncol Biol Phys 2006; 65:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1065/abstract/59\">",
"      Rossier C, Schick U, Miralbell R, et al. Low-dose radiotherapy in indolent lymphoma. Int J Radiat Oncol Biol Phys 2011; 81:e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4735 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-189.41.172.26-C8F2277E62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1065=[""].join("\n");
var outline_f1_2_1065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bortezomib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bendamustine plus rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fludarabine, cyclophosphamide, mitoxantrone plus rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Single agent rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Single agent fludarabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cladribine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Temsirolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HEMATOPOIETIC CELL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nonmyeloablative HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17402?source=related_link\">",
"      Initial treatment of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=related_link\">",
"      Treatment of relapsed or refractory follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_2_1066="Hematopoietic cell transplantation for primary immunodeficiency";
var content_f1_2_1066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematopoietic cell transplantation for primary immunodeficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/2/1066/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/2/1066/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/2/1066/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/2/1066/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/2/1066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/2/1066/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/2/1066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant clinical consequence of primary immunodeficiency is an increased frequency and severity of infection. The molecular pathophysiologies of many of the disorders underlying primary immunodeficiency are defined. A number of medical therapies have provided dramatic improvements in life expectancy and quality of life for immunodeficient patients. Hematopoietic cell transplantation (HCT) is clearly indicated for severe immunodeficiencies (eg, severe combined immunodeficiency, or SCID) which are lethal in the first few years of life. However, improvements in techniques of HCT have led to better outcomes and should prompt serious consideration of HCT for patients even when life expectancy may be as long as 15 to 20 years with supportive therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HCT is the only potentially curative nonexperimental therapy available for many primary immunodeficiencies, including various forms of severe combined immunodeficiency (SCID), several severe X-linked immunodeficiencies (Wiskott-Aldrich syndrome, X-linked hyper IgM syndrome, chronic granulomatous disease, IPEX, and NEMO deficiency), and",
"    <span class=\"nowrap\">",
"     immune/inflammatory",
"    </span>",
"    disorders (Chediak-Higashi syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the use of HCT in the treatment of severe primary immune deficiency states. For several of these disorders, the role HCT is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15176?source=see_link&amp;anchor=H7#H7\">",
"     \"Severe combined immunodeficiency (SCID) with JAK3 deficiency\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=see_link&amp;anchor=H11#H11\">",
"     \"Chronic granulomatous disease: Treatment and prognosis\", section on 'Hematopoietic cell transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25850?source=see_link&amp;anchor=H43#H43\">",
"     \"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked\", section on 'Hematopoietic cell transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link&amp;anchor=H24194283#H24194283\">",
"     \"Wiskott-Aldrich syndrome\", section on 'Hematopoietic cell transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link&amp;anchor=H19#H19\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\", section on 'Treatment and prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=see_link&amp;anchor=H24#H24\">",
"     \"DiGeorge syndrome: Management and prognosis\", section on 'Hematopoietic cell transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general aspects of medical therapy for immune deficiency, including therapy with immune globulin and other biologics and vaccination recommendations, are discussed separately, as is gene therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=see_link\">",
"     \"Gene therapy for primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Information regarding therapeutic strategies specific to one or a few disorders are discussed in the appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=see_link\">",
"     \"DiGeorge syndrome: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42278?source=see_link\">",
"     \"Chediak-Higashi syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=see_link\">",
"     \"Chronic granulomatous disease: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"     \"Wiskott-Aldrich syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY IDENTIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing is available for a growing number of primary immunodeficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Knowing whether the mutation is new (ie, sporadic) or inherited allows accurate genetic counseling and prenatal testing in the case of future pregnancies. This information permits parents to choose to abort fetuses who have, or are at high risk of, a particular defect. For pregnancies that are continued, in utero testing permits preparation for HCT in the neonatal period, or possibly in utero. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'In utero transplantation'",
"    </a>",
"    below.) Banking cord blood is suggested, either for use in future gene therapy if the infant is affected, or for future transplant of an existing or potential affected sibling if the infant is unaffected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=see_link\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HLA typing to evaluate potential donors should be performed on family members as soon as a diagnosis of SCID, or other combined deficiency that could potentially be corrected by HCT, is established.",
"   </p>",
"   <p>",
"    Experience clearly indicates that a good outcome after HCT for SCID depends greatly upon the age of diagnosis and intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The risks of HCT are reduced in patients who have not yet developed infectious complications of immune deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. In one study, patients transplanted within the neonatal period (first 28 days of life) had improved survival (95 versus 76 percent) compared with those who were transplanted later [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/10\">",
"     10",
"    </a>",
"    ]. Children transplanted before 3.5 months of age also had better long-term survival rates than those transplanted after that age (94 percent versus 70 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/12\">",
"     12",
"    </a>",
"    ]. Infants receiving HCT within the first 3.5 months of age also had significantly improved T cell development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many immune deficiencies arise from mutations in genes exclusively expressed in hematopoietic cells or in subsets of these cells. Replacement of defective hematopoietic stem cells through HCT permits the development of a functional immune system and may provide a complete cure for a variety of immune deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/1,11\">",
"     1,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary immunodeficiency disorders that have been effectively treated with HCT are listed in a table (",
"    <a class=\"graphic graphic_table graphicRef79368 \" href=\"UTD.htm?20/33/21019\">",
"     table 1",
"    </a>",
"    ). Survival rates for some disorders are as high as 90 percent following HCT and rates have continued to improve with advances in the methods of preparing hosts and donor marrow and in supportive and adjuvant therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=see_link\">",
"     \"Evaluation for infection before hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DONOR SOURCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLA-matched related donors are preferred for HCT in patients with SCID and other primary immunodeficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/11\">",
"     11",
"    </a>",
"    ]. However, most patients do not have such a donor available.",
"   </p>",
"   <p>",
"    Most reports of HCT for primary immunodeficiency have described patients with SCID, although successful outcomes have also been described with other combined immunodeficiencies (eg Wiskott-Aldrich syndrome, X-linked hyper-IgM syndrome) and disorders of phagocytic cell function (eg, chronic granulomatous disease, leukocyte adhesion deficiency). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"     \"Wiskott-Aldrich syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=see_link\">",
"     \"Chronic granulomatous disease: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22953?source=see_link\">",
"     \"Leukocyte adhesion deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=see_link\">",
"     \"DiGeorge syndrome: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     HLA-identical donor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less than 20 percent of patients with SCID who are transplanted have an HLA-identical family donor (usually a full sibling, also called a genoidentical donor; nonsibling relatives are termed phenoidentical). This type of transplant carries the most favorable prognosis. The marrow or stem cells may be infused without any processing to remove mature cells. HLA-identical HCT results in the most rapid and complete reconstitution of immune function. The risk of histocompatibility-associated graft-versus-host disease (GVHD) is very low. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Graft-versus-host disease'",
"    </a>",
"    below.) Survival rates of 90 to 100 percent have been achieved in patients transplanted after 1983 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/9,10,13-17\">",
"     9,10,13-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Matched unrelated donor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Matched unrelated donors (URD) can be identified among registered individuals in the National Marrow Donor Program. Such matches are an increasingly available source of MHC identical hematopoietic cells in the United States, particularly for Caucasians. Molecular typing has led to better matches and a lower incidence of GVHD. Serologic typing alone does not ensure that individuals share the same HLA genes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Earlier surveys suggested that survival after URD HCT was lower than HLA-identical donor HCT. Newer data suggest that the survival rates are converging [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. As an example, one study reviewed 94 patients with SCID who underwent various types of HCT at two centers between 1990 and 2004. Survival rates of patients with URD HCT were slightly lower than those of patients with HLA-identical donors (81 and 92 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/15\">",
"     15",
"    </a>",
"    ]. Another series of 58 patients with severe T cell deficiencies treated with different types of transplants reported a five year survival rate of 90 percent",
"    <span class=\"nowrap\">",
"     (9/10)",
"    </span>",
"    for HLA-identical transplants and 83 percent",
"    <span class=\"nowrap\">",
"     (10/12)",
"    </span>",
"    for URD transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/16\">",
"     16",
"    </a>",
"    ]. Three-year survival rates were identical in non-SCID transplanted patients with a genoidentical or URD donor (79 percent for both) transplanted in the 2000 to 2005 period in a European series [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/17\">",
"     17",
"    </a>",
"    ]. However, ten-year survival was 69 percent in SCID patients with a URD donor compared with 90 percent in those with a genoidentical donor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mismatched related donor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another source of hematopoietic cells for transplantation in patients with SCID is HLA mismatched related donors (MMRD), usually parents [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/9,10,13,14,19-21\">",
"     9,10,13,14,19-21",
"    </a>",
"    ]. Both biologic parents have at least 50 percent identity (\"haploidentical\") with their offspring and may be suitable donors, although the mother is usually preferred over the father. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H9#H9\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Maternal versus paternal antigens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis following haploidentical HCT in SCID is less favorable than that with HLA-identical or URD transplants. Reported survival ranges from 50 to 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/9,10,13-17,19,22-25\">",
"     9,10,13-17,19,22-25",
"    </a>",
"    ]. T cell function and cellular immunity recover within three to six months after transplantation with the use of T-cell depleted marrow.",
"   </p>",
"   <p>",
"    There is limited published experience with families with multiple children affected by immunodeficiency, in which one child receives an MMRD transplant, and then serves as a bone marrow donor for another HLA-identical child [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Early reports suggest that there may be lower rates of GVHD and more rapid immune reconstitution in the second child using this approach. The primary recipient may tolerize and functionally HLA-match the original HLA-mismatched donor cells. Thus, the first sibling acts as a functionally HLA-matched donor for subsequent affected siblings.",
"   </p>",
"   <p>",
"    After transplantation from HLA non-identical donors, patients with forms of SCID lacking B cells as well as T cells may have a worse outcome than patients who have B cells, although this has not been observed in all series [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/15,23\">",
"     15,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SOURCES OF STEM CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three sources of stem cells for HCT (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bone marrow",
"     </li>",
"     <li>",
"      Peripheral blood",
"     </li>",
"     <li>",
"      Umbilical cord blood",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bone marrow is the most common source of stem cells for HCT in patients with primary immunodeficiency. Stem cells from peripheral blood appear to be inferior to bone marrow in children and adolescents with acute leukemia and severe aplastic anemia. Data on peripheral blood HCT in patients with primary immunodeficiency are limited. Success with peripheral blood stem cell transplantation is reported in a few patients with SCID, Wiskott-Aldrich syndrome, X-linked hyper-IgM syndrome, and chronic granulomatous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Addition of donor peripheral blood stem cells to enhance engraftment rate in haploidentical BMT has shown moderate success in patients with various congenital immune deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H8#H8\">",
"     \"Sources of hematopoietic stem cells\", section on 'Peripheral blood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Umbilical cord blood (UCB) has several perceived advantages including a low rate of graft-versus-host disease (GVHD) (because of the relative immaturity of umbilical cord lymphocytes), a potentially large donor pool, and a low rate of infection with viruses such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Possible, disadvantages include the limited number of cells (generally not an issue for children and smaller adults), the inability to perform a boost transplantation from the same donor, and slower engraftment. In addition, UCB does not contain memory T cells, a potential disadvantage when transplanting an infant with an active viral infection. However, one relatively large retrospective comparison showed a similar rate of T cell engraftment and somewhat more GVHD in recipients of cord blood in comparison with MMRD transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/25\">",
"     25",
"    </a>",
"    ]. Five-year survival rates were similar for both groups (57 and 62 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=see_link\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H63572418#H63572418\">",
"     \"Sources of hematopoietic stem cells\", section on 'Umbilical cord blood'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IN UTERO TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In utero HCT (IUHCT) has been performed in an attempt to reduce the possibility of graft rejection by taking advantage of the immunologic immaturity of the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/35-41\">",
"     35-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first IUHCT for X-linked SCID was performed in 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/35\">",
"     35",
"    </a>",
"    ]. Paternal bone marrow cells were enriched for hematopoietic stem cells and infused intraperitoneally in utero at 16, 17, and 18 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/35\">",
"     35",
"    </a>",
"    ]. The infant was born at term and appeared healthy with normal cellular and humoral immune function at 11 months of age. IUHCT has been performed for other forms of SCID, including T-B+NK+ SCID due to IL7R-alpha chain deficiency and T-B-NK+ SCID due to RAG mutations, and other primary immunodeficiencies, including Chediak-Higashi syndrome, chronic granulomatous disease, and bare lymphocyte syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/36\">",
"     36",
"    </a>",
"    ]. Donor engraftment was poor for all of the non-SCID primary immunodeficiencies except bare lymphocyte syndrome.",
"   </p>",
"   <p>",
"    Split chimerism is common with IUHCT for SCID, with generally only T cells engrafting. Findings in a mouse model of X-linked SCID suggest that more rapid and sustained B and T cell reconstitution is achieved with IUHCT using lymphoid-primed multipotent progenitors rather than hematopoietic stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IUHCT is controversial since fetal loss is possible. In addition, it is not clear that outcomes are superior to what may be achieved in the neonatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/10,37\">",
"     10,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AFTER HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications following HCT include infections, graft rejection, graft-versus-host disease, and posttransplant lymphoproliferative disease. The incidence of these adverse events varies with the type of HCT and underlying disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the deaths that occur relatively soon after HCT are caused by infection during this extremely vulnerable period, frequently with organisms present in the host prior to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/9,14,23\">",
"     9,14,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=see_link\">",
"     \"Evaluation for infection before hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common pathogens are Epstein-Barr virus (EBV) and cytomegalovirus (CMV). Additional viruses include adenoviruses, parainfluenza, enteroviruses, hepatitis viruses, and herpes simplex viruses. Disseminated infection with Bacille Calmette-Guerin is prominent in areas where this vaccine is routinely administered.",
"   </p>",
"   <p>",
"    Active monitoring for viral",
"    <span class=\"nowrap\">",
"     infection/reactivation",
"    </span>",
"    by PCR and antigenemia is key to initiating preemptive treatment, particularly in patients with CMV or EBV infection prior to transplantation. One option for treatment of viral infections post-HCT is adoptive transfer of virus-reactive T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/43\">",
"     43",
"    </a>",
"    ]. This approach is used to reconstitute antiviral immunity without inducing alloreactivity. Adoptive immunotherapy is effective for both treatment and prophylaxis of EBV, CMV, and adenovirus infections in pediatric patients post-HCT.",
"   </p>",
"   <p>",
"    The various types of infections that commonly occur post-HCT, including viral, bacterial, and fungal infections, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Graft rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graft rejection arises when sufficient immune function remains for the recipient to mount a cellular immune response against donor major and minor histocompatibility molecules. This is prevented by \"conditioning\" the host (myeloablation) with radiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy to destroy immunocompetent cells, and by major histocompatibility matching between donor and recipient. Chemoablation is preferred in patients with primary immunodeficiency because many of these disorders are genetically 'radiosensitive', although patients with radiosensitive SCID may also have increased sensitivity to certain chemotherapy, such as alkylator-based regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/1,44\">",
"     1,44",
"    </a>",
"    ]. In addition, chemotherapy is preferred to irradiation for conditioning in infants and young children, because of the greater potential negative impact of radiation on neurocognitive development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pretransplant conditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The requirement for pretransplant conditioning depends partly upon the type of immunodeficiency. Initial restoration of T cell function is successful for virtually all forms of SCID without myeloablation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/9,10,23\">",
"     9,10,23",
"    </a>",
"    ]. However, long-term outcome is influenced by the form of SCID and by conditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/45\">",
"     45",
"    </a>",
"    ]. Prior ablation does not affect the rate of T cell engraftment in patients with SCID with B cells (T-B+ SCID) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/14,23\">",
"     14,23",
"    </a>",
"    ]. On the other hand, patients with SCID lacking B cells (T-B- SCID) have higher rates of T cell engraftment and long-term survival after myeloablation. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Reconstitution of immune function'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Long-term prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Pretransplant myeloablation is required for HCT for combined immune deficiencies (eg, Wiskott-Aldrich syndrome) and phagocytic deficiencies (eg, chronic granulomatous disease), where patients retain cellular immune function sufficient for vigorous graft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/19,46\">",
"     19,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"     \"Wiskott-Aldrich syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of myeloablation is also influenced by the type of donor available. Pretransplant conditioning is not indicated for patients with SCID receiving HLA-identical HCT from a sibling donor. The best approach for HCT from haploidentical donors has not been determined.",
"   </p>",
"   <p>",
"    Significant morbidity and mortality may result from the pretransplant chemoablation procedure itself. Drug regimens that do not completely ablate the bone marrow (nonmyeloablative stem cell transplantation) may still permit sufficient donor stem cell engraftment to reconstitute immune function [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. In one series, survival four years after HCT was 94 percent in the reduced conditioning group compared with 58 percent in the myeloablative conditioning group [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/50\">",
"     50",
"    </a>",
"    ]. An alternative approach is monoclonal antibody-based conditioning that suppresses host hematopoietic cells and immune cells (using anti-CD45 and anti-CD52-expressing, respectively) with reduced doses of chemotherapeutic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/51\">",
"     51",
"    </a>",
"    ]. This regimen was used successfully in children with primary immunodeficiencies who were under one year of age, had preexisting organ toxicity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    had DNA repair defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Graft-versus-host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;GVHD occurs when mature T cells are not entirely removed from the donor source and \"contaminate\" the graft. These cells may be activated by histocompatibility differences and mount a cellular immune attack against host tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/52\">",
"     52",
"    </a>",
"    ]. GVHD is minimized or prevented by processing the grafting cells before infusion to remove mature T cells and by prophylactic immunosuppression following HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Methods to deplete mature T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The requirement for removing mature T cells from the graft is a major distinction between stem cell transplantation for immunodeficiency and transplantation for malignancy. The anti-tumor effect of transferred histoincompatible mature T cells is therapeutic in the setting of malignancy, while it has no benefit for patients with immunodeficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9400?source=see_link\">",
"     \"General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of methods for removing mature lymphocytes, but not stem cells, from hematopoietic cell grafts was a major breakthrough. It permits the use of MHC nonidentical donors, primarily haploidentical parents, with a drastically reduced rate of GVHD. One of the most common methods uses soybean lectin agglutination followed by rosetting with sheep red blood cells to remove mature B and T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/9,10,53\">",
"     9,10,53",
"    </a>",
"    ]. This method results in a 3.5 to 4 log depletion of mature T cells. Similar results may be achieved by treatment of bone marrow cells with the monoclonal antibody Campath-1 (anti-CD52) and complement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/14,23\">",
"     14,23",
"    </a>",
"    ]. Mature lymphocyte numbers are also decreased by selecting for CD34+ stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Posttransplant lymphoproliferative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epstein Barr virus-mediated posttransplant lymphoproliferative disease is a potential and serious complication of HCT. The risk is greatest in patients receiving an unrelated or HLA-mismatched related donor and with T cell depletion of donor hematopoietic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Immune hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune hemolysis is another potential complication of HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/56\">",
"     56",
"    </a>",
"    ]. It occurs more frequently after nonmyeloablative than myeloablative conditioning. The most common cause is the passenger lymphocyte syndrome, in which the donor B lymphocytes (passenger lymphocytes) produce antibodies against the recipient's red blood cell antigens due to minor ABO blood group incompatibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RECONSTITUTION OF IMMUNE FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following HCT, T cell precursors develop from donor stem cells and repopulate the native thymus, a previously vestigial organ in these patients. Thymic T cell development can be monitored by measuring T cell receptor excision circles (TRECs) in the blood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few mature donor T cells generally begin to appear in the circulation after approximately three to six weeks, with larger numbers developing between six to 12 weeks after BMT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/57\">",
"     57",
"    </a>",
"    ]. Mature T cells may appear even earlier, expanding two weeks after transplant, in infants with SCID who have an HLA-identical family donor and who receive unmanipulated and unconditioned HCT that contains mature T cells in the graft. These expanding mature T cells provide some immediate immune reconstitution, even before de novo generation of T cells from donor-derived stem cells occurs. Thymic T cell output peaks one to two years after BMT, and begins to decline thereafter. T cell reconstitution (including thymic output, clonal diversity, and T cell function) is maintained long-term at levels similar or equal to normal healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some degree of hematopoietic chimerism is common after bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/9,13,14,19,23,47,59\">",
"     9,13,14,19,23,47,59",
"    </a>",
"    ]. T cells are 90 to 100 percent donor-derived in almost all cases of successful HCT for SCID. Myeloablation increases the rate of T cell engraftment in T-B- SCID, but has less effect in T-B+ SCID [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Graft rejection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Recovery of B cell function is less consistent after BMT, and does not occur in a substantial fraction of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/9,14,23,60\">",
"     9,14,23,60",
"    </a>",
"    ]. Pretransplant conditioning increases, but does not assure, the posttransplant development of B cell function. There is no B cell function without engraftment of donor B cells in patients with T-B- SCID. Host B cells may not function properly in patients with T-B+ SCID (eg, gamma-c or JAK-3 deficiency), even after donor T cell reconstruction, although exceptions occur (eg, IL-7R chain deficiency, or CD3 delta, epsilon, or zeta chain deficiencies). Finally, in some cases B cell function is not normal even with the presence of a significant fraction of donor B cells in the circulation.",
"   </p>",
"   <p>",
"    In general, patients with T-B+ SCID have a higher rate of B cell reconstitution after transplant in comparison to T-B- SCID [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/14\">",
"     14",
"    </a>",
"    ]. After HLA-identical BMT, the rate of reconstitution of B cell function is approximately 60 percent for T-B- SCID and 90 percent for T-B+ SCID. After haploidentical BMT, the rate of reconstitution of B cell function is about 40 percent for T-B- SCID and 70 percent for T-B+ SCID. B cell function may arise only after a few years. In those in whom it does not, lifelong therapy with immune globulin replacement is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    T cell-depleted haploidentical transplantations are successful in long-term reconstitution of immune function in patients with SCID. One study compared the quality of immune reconstitution after depletion of viable T cells from the bone marrow by either treating with anti-CD52 or selecting for CD34+ stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/54\">",
"     54",
"    </a>",
"    ]. Relatively high T cell numbers may remain in anti-CD52 treated bone marrow. However, these T cells are destroyed by complement-mediated lysis in the recipient because they are still coated with anti-CD52 when they are infused. In comparison, fewer T cells remain after CD34+ stem cell selection, but these cells are still viable and may cause GVHD in the recipient. This study found that both methods of T cell depletion lead to good long-term T cell function. The results suggest that patients in the anti-CD52 treated group have more complete B cell donor chimerism and better B cell function than the CD34+ selected group, although higher mortality was seen in the group treated with CD52-depleted grafts.",
"   </p>",
"   <p>",
"    Another study had similar findings in patients with SCID who were transplanted with megadoses of haplocompatible CD34+ stem cells without myeloablative preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/61\">",
"     61",
"    </a>",
"    ]. Over 70 percent of patients had T cell engraftment, but only one-third had recovery of B cell function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     LONG-TERM PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term prognosis of HCT for primary immunodeficiency has improved with advances in high resolution tissue typing, preconditioning regimens (especially for T-B- SCID), depletion of donor lymphoid cells using monoclonal antibodies and CD34+ selection, supportive care, early detection of viral infections, and GVHD treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/1,11,23,62-64\">",
"     1,11,23,62-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detailed information was reported on the general medical and immunologic health of 40 children who were alive at least five years after HCT for severe T cell immunodeficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients attained normal height and weight",
"      <span class=\"nowrap\">",
"       (35/40",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       33/40,",
"      </span>",
"      respectively).",
"     </li>",
"     <li>",
"      Endocrine abnormalities, most commonly autoimmune thyroid disease, occurred in 18 percent.",
"     </li>",
"     <li>",
"      Significant infections occurred in 13 percent of patients after the first year post-transplant.",
"     </li>",
"     <li>",
"      The majority had normal T cell numbers and function and required no ongoing therapy to prevent infections.",
"     </li>",
"     <li>",
"      Recovery of B cell function was seen more consistently in patients who had received conditioning regimens prior to transplant, a finding which requires further study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Longer term follow-up in a larger cohort was reported in another study that retrospectively analyzed outcome after HCT in 90 patients with SCID followed for a median of 14 years (range 2 to 34 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the time of the report, 71 percent of the 82 living patients did not require any form of treatment. However, nearly half of the 90 patients had experienced clinically significant issues at least two years after HCT. These issues included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Late mortality (9 percent)",
"     </li>",
"     <li>",
"      Poor T or B cell reconstitution requiring boost transplantation (12 percent)",
"     </li>",
"     <li>",
"      Growth failure (15 percent)",
"     </li>",
"     <li>",
"      Chronic GVHD (11 percent)",
"     </li>",
"     <li>",
"      Autoimmune and inflammatory complications (13 percent)",
"     </li>",
"     <li>",
"      Prolonged requirement for nutritional support (20 percent)",
"     </li>",
"     <li>",
"      Chronic human papilloma virus infection (26 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for late complications included nongenoidentical donors and Artemis deficiency.",
"   </p>",
"   <p>",
"    Few studies have assessed the durability of T cell function in SCID patients post-HCT. One such study of 83 patients from a single center who received identical or haploidentical transplants showed a peak in thymic T cell output at one to two years post transplant and then a rapid decline within 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/57\">",
"     57",
"    </a>",
"    ]. However, the same group following the same cohort with additional patients reported nine years later that the decline in thymic T cell output seen initially was not observed in the 115 patients followed longer-term [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/57\">",
"     57",
"    </a>",
"    ]. In another of the long-term follow-up studies previously discussed, T cell counts and function were stable over a median 14-year follow-up period [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/65\">",
"     65",
"    </a>",
"    ]. It is notable that these two cohorts differed in the predominant modes of transplantation. In the former group, 91 percent of patients received haploidentical marrow without myeloablative therapy and only nine percent had HLA-identical related donors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/57\">",
"     57",
"    </a>",
"    ]. In the latter group, 44 percent of transplants were preceded by myeloablation and 25 percent had identical sibling donors.",
"   </p>",
"   <p>",
"    In normal humans, a decline in T cell function occurs slowly from birth up to age 80 years. Thus far, T cell decline in transplanted patients has not been associated with clinical deterioration or increased occurrence of infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Consequences of underlying disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As long-term data become available, one emerging issue is that HCT in children with severe congenital immunodeficiencies is associated with behavioral abnormalities and decreased neurocognitive function [",
"    <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/16,62,66-68\">",
"     16,62,66-68",
"    </a>",
"    ]. This is attributed to two main factors: prolonged illness and genetic effect of the underlying disease. Children with severe primary immunodeficiencies have extended periods of illness and prolonged hospitalizations with secondary social isolation.",
"   </p>",
"   <p>",
"    The second main factor is that decreased cognitive function is a direct consequence of the genetic defect in some congenital immune deficiencies. HCT does not correct associated nonhematopoietic abnormalities in primary immunodeficiencies in which expression of the defective gene is not restricted to the immune system. Thus, continued and progressive symptoms are observed post-transplant.",
"   </p>",
"   <p>",
"    As examples, this is seen with cognitive function in patients with adenosine deaminase (ADA) or purine nucleoside phosphorylase (PNP) deficiencies, colitis with nuclear factor-kappaB essential modulator (NEMO) deficiency, and motor neurologic function with Chediak-Higashi syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, patients with severe congenital immunodeficiencies who have undergone HCT have lower IQ scores (85, 95% CI 81-90) than the population average (100) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/66\">",
"       66",
"      </a>",
"      ]. They also have lower IQ scores compared with matched siblings (90 versus 118). However, the IQ deficits are much greater in patients with ADA deficiency and Chediak-Higashi syndrome, diseases in which cognitive defects are an intrinsic part of the underlying pathogenesis. In these subgroups, the mean IQ score is approximately 65. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2488?source=see_link\">",
"       \"Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A boy with X-linked hypohidrotic ectodermal dysplasia with immunodeficiency underwent HCT from a matched unaffected sister, who is a carrier of the defect [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/69\">",
"       69",
"      </a>",
"      ]. Hematopoietic and immune reconstitution were successful. However, the child continued to have flares of colitis associated with bacterial infection because of the uncorrected NEMO defect in the intestinal epithelium. HCT also did not ameliorate the associated ectodermal dysplasia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H18#H18\">",
"       \"Combined immunodeficiencies\", section on 'Defects of NF-kappa-B regulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with Chediak-Higashi syndrome continue to have progressive motor neurologic decline after HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?1/2/1066/abstract/70\">",
"       70",
"      </a>",
"      ]. In addition, the oculocutaneous albinism is not corrected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42278?source=see_link\">",
"       \"Chediak-Higashi syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematopoietic cell transplantation (HCT) is the only potentially curative nonexperimental therapy available for many primary immunodeficiencies. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early diagnosis, including prenatally, and early transplantation improve HCT outcomes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Early identification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survival rates have continued to improve with advances in the methods of preparing hosts and donor cells, and in supportive and adjuvant therapies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview of HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three sources of stem cells for HCT are bone marrow, peripheral blood, and umbilical cord blood. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Sources of stem cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In utero HCT has been performed, but may not be indicated since neonatal HCT outcomes have improved, and unintended loss of pregnancy is possible. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'In utero transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications following HCT include infections, graft rejection, graft-vs-host disease, and posttransplant lymphoproliferative disease. The incidence of these adverse events varies with the type of HCT and underlying disease. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Complications after HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thymic T cell output peaks one to two years after HCT, and begins to decline thereafter. Recovery of B cell function is less consistent after BMT, and does not occur in a substantial fraction of patients. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Reconstitution of immune function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The long-term prognosis of HCT for primary immunodeficiency has improved, but challenges remain. HCT in children with severe congenital immunodeficiencies is associated with decreased neurocognitive function and behavioral abnormalities. In addition, HCT does not correct associated nonhematopoietic abnormalities in primary immunodeficiencies in which expression of the defective gene is not restricted to the immune system. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Long-term prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/1\">",
"      Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeficiencies. Bone Marrow Transplant 2008; 42 Suppl 1:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/2\">",
"      Cuvelier GD, Schultz KR, Davis J, et al. Optimizing outcomes of hematopoietic stem cell transplantation for severe combined immunodeficiency. Clin Immunol 2009; 131:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/3\">",
"      Szabolcs P, Cavazzana-Calvo M, Fischer A, Veys P. Bone marrow transplantation for primary immunodeficiency diseases. Pediatr Clin North Am 2010; 57:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/4\">",
"      Rappeport JM, O'Reilly RJ, Kapoor N, Parkman R. Hematopoietic stem cell transplantation for severe combined immune deficiency or what the children have taught us. Immunol Allergy Clin North Am 2010; 30:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/5\">",
"      Roifman CM, Fischer A, Notarangelo LD, et al. Indications for hemopoietic stem cell transplantation. Immunol Allergy Clin North Am 2010; 30:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/6\">",
"      Griffith LM, Cowan MJ, Notarangelo LD, et al. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol 2009; 124:1152.",
"     </a>",
"    </li>",
"    <li>",
"     A world database of laboratories performing genetic testing for immunodeficiencies. bioinf.uta.fi/IDdiagnostics/index_IDs.php?page=index/service (Accessed on December 17, 2008).",
"    </li>",
"    <li>",
"     Contact information for laboratories that provide genetic testing services is also available through the GeneTests website. ww.geneclinics.org (Accessed on December 17, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/9\">",
"      Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/10\">",
"      Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 2002; 99:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/11\">",
"      Griffith LM, Cowan MJ, Kohn DB, et al. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol 2008; 122:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/12\">",
"      Railey MD, Lokhnygina Y, Buckley RH. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatr 2009; 155:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/13\">",
"      Buckley RH. A historical review of bone marrow transplantation for immunodeficiencies. J Allergy Clin Immunol 2004; 113:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/14\">",
"      Antoine C, M&uuml;ller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003; 361:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/15\">",
"      Grunebaum E, Mazzolari E, Porta F, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006; 295:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/16\">",
"      Mazzolari E, Forino C, Guerci S, et al. Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. J Allergy Clin Immunol 2007; 120:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/17\">",
"      Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010; 126:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/18\">",
"      Grunebaum E, Roifman CM. Bone marrow transplantation using HLA-matched unrelated donors for patients suffering from severe combined immunodeficiency. Immunol Allergy Clin North Am 2010; 30:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/19\">",
"      Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 2001; 97:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/20\">",
"      Friedrich W, H&ouml;nig M. HLA-haploidentical donor transplantation in severe combined immunodeficiency. Immunol Allergy Clin North Am 2010; 30:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/21\">",
"      Hagin D, Reisner Y. Haploidentical bone marrow transplantation in primary immune deficiency: stem cell selection and manipulation. Immunol Allergy Clin North Am 2010; 30:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/22\">",
"      Speiser DE, Tiercy JM, Rufer N, et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996; 87:4455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/23\">",
"      Bertrand Y, Landais P, Friedrich W, et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the european society for immunodeficiency. J Pediatr 1999; 134:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/24\">",
"      Dror Y, Gallagher R, Wara DW, et al. Immune reconstitution in severe combined immunodeficiency disease after lectin-treated, T-cell-depleted haplocompatible bone marrow transplantation. Blood 1993; 81:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/25\">",
"      Fernandes JF, Rocha V, Labopin M, et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood 2012; 119:2949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/26\">",
"      Stiehm ER, Roberts RL, Hanley-Lopez J, et al. Bone marrow transplantation in severe combined immunodeficiency from a sibling who had received a paternal bone marrow transplant. N Engl J Med 1996; 335:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/27\">",
"      Cohen JM, Rogers V, Gaspar HB, et al. Serial transplantation of mismatched donor hematopoietic cells between HLA-identical sibling pairs with congenital immunodeficiency: in vivo tolerance permits rapid immune reconstitution following T-replete transplantation without GVHD in the secondary recipient. Blood 2006; 108:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/28\">",
"      Burroughs LM, Storb R, Leisenring WM, et al. Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. Bone Marrow Transplant 2007; 40:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/29\">",
"      Nagler A, Ackerstein A, Kapelushnik J, et al. Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplant 1999; 24:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/30\">",
"      Lanfranchi A, Verardi R, Tettoni K, et al. Haploidentical peripheral blood and marrow stem cell transplantation in nine cases of primary immunodeficiency. Haematologica 2000; 85:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/31\">",
"      D&iacute;az de Heredia C, Ortega JJ, D&iacute;az MA, et al. Unrelated cord blood transplantation for severe combined immunodeficiency and other primary immunodeficiencies. Bone Marrow Transplant 2008; 41:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/32\">",
"      Benito AI, Diaz MA, Gonz&aacute;lez-Vicent M, et al. Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results. Bone Marrow Transplant 2004; 33:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/33\">",
"      Knutsen AP, Kelly ME, Wall DA. Umbilical cord blood stem cell transplantion in severe T-cell immundeficiency disorders. Pediatr Asthma Allergy Immunol 2005; 18:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/34\">",
"      Morio T, Atsuta Y, Tomizawa D, et al. Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan. Br J Haematol 2011; 154:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/35\">",
"      Flake AW, Roncarolo MG, Puck JM, et al. Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow. N Engl J Med 1996; 335:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/36\">",
"      Muench MO. In utero transplantation: baby steps towards an effective therapy. Bone Marrow Transplant 2005; 35:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/37\">",
"      Kane L, Gennery AR, Crooks BN, et al. Neonatal bone marrow transplantation for severe combined immunodeficiency. Arch Dis Child Fetal Neonatal Ed 2001; 85:F110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/38\">",
"      Touraine JL. In utero transplantation of fetal liver stem cells into human fetuses. J Hematother 1996; 5:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/39\">",
"      Cowan MJ, Golbus M. In utero hematopoietic stem cell transplants for inherited diseases. Am J Pediatr Hematol Oncol 1994; 16:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/40\">",
"      Gil J, Porta F, Bartolom&eacute; J, et al. Immune reconstitution after in utero bone marrow transplantation in a fetus with severe combined immunodeficiency with natural killer cells. Transplant Proc 1999; 31:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/41\">",
"      Wengler GS, Lanfranchi A, Frusca T, et al. In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI). Lancet 1996; 348:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/42\">",
"      Liuba K, Pronk CJ, Stott SR, Jacobsen SE. Polyclonal T-cell reconstitution of X-SCID recipients after in utero transplantation of lymphoid-primed multipotent progenitors. Blood 2009; 113:4790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/43\">",
"      Leen AM, Heslop HE. Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol 2008; 143:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/44\">",
"      Dvorak CC, Cowan MJ. Radiosensitive severe combined immunodeficiency disease. Immunol Allergy Clin North Am 2010; 30:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/45\">",
"      Patel NC, Chinen J, Rosenblatt HM, et al. Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning. J Allergy Clin Immunol 2009; 124:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/46\">",
"      Ozsahin H, Le Deist F, Benkerrou M, et al. Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center. J Pediatr 1996; 129:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/47\">",
"      Amrolia P, Gaspar HB, Hassan A, et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000; 96:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/48\">",
"      Veys P. Reduced intensity transplantation for primary immunodeficiency disorders. Immunol Allergy Clin North Am 2010; 30:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/49\">",
"      Slatter MA, Rao K, Amrolia P, et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 2011; 117:4367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/50\">",
"      Rao K, Amrolia PJ, Jones A, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005; 105:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/51\">",
"      Straathof KC, Rao K, Eyrich M, et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 2009; 374:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/52\">",
"      Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol 2003; 78:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/53\">",
"      Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981; 2:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/54\">",
"      Slatter MA, Brigham K, Dickinson AM, et al. Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency. J Allergy Clin Immunol 2008; 121:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/55\">",
"      Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/56\">",
"      Petz LD. Immune hemolysis associated with transplantation. Semin Hematol 2005; 42:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/57\">",
"      Patel DD, Gooding ME, Parrott RE, et al. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 2000; 342:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/58\">",
"      Sarzotti-Kelsoe M, Win CM, Parrott RE, et al. Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras. Blood 2009; 114:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/59\">",
"      van Leeuwen JE, van Tol MJ, Joosten AM, et al. Relationship between patterns of engraftment in peripheral blood and immune reconstitution after allogeneic bone marrow transplantation for (severe) combined immunodeficiency. Blood 1994; 84:3936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/60\">",
"      Buckley RH. B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review. J Allergy Clin Immunol 2010; 125:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/61\">",
"      Dvorak CC, Hung GY, Horn B, et al. Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation. Biol Blood Marrow Transplant 2008; 14:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/62\">",
"      Shearer WT, Notarangelo LD, Griffith LM. Treatment of immunodeficiency: long-term outcome and quality of life. J Allergy Clin Immunol 2008; 122:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/63\">",
"      Borghans JA, Bredius RG, Hazenberg MD, et al. Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency. Blood 2006; 108:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/64\">",
"      Cavazzana-Calvo M, Carlier F, Le Deist F, et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood 2007; 109:4575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/65\">",
"      Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 2009; 113:4114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/66\">",
"      Titman P, Pink E, Skucek E, et al. Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood 2008; 112:3907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/67\">",
"      Lin M, Epport K, Azen C, et al. Long-term neurocognitive function of pediatric patients with severe combined immune deficiency (SCID): pre- and post-hematopoietic stem cell transplant (HSCT). J Clin Immunol 2009; 29:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/68\">",
"      Shah AJ, Kohn DB. Neurocognitive function of patients with severe combined immunodeficiency. Immunol Allergy Clin North Am 2010; 30:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/69\">",
"      Pai SY, Levy O, Jabara HH, et al. Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-kappaB essential modulator deficiency. J Allergy Clin Immunol 2008; 122:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/2/1066/abstract/70\">",
"      Tardieu M, Lacroix C, Neven B, et al. Progressive neurologic dysfunctions 20 years after allogeneic bone marrow transplantation for Chediak-Higashi syndrome. Blood 2005; 106:40.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3941 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1066=[""].join("\n");
var outline_f1_2_1066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY IDENTIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DONOR SOURCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HLA-identical donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Matched unrelated donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mismatched related donor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SOURCES OF STEM CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IN UTERO TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMPLICATIONS AFTER HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Graft rejection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pretransplant conditioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Methods to deplete mature T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Posttransplant lymphoproliferative disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Immune hemolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RECONSTITUTION OF IMMUNE FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      LONG-TERM PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Consequences of underlying disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3941\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3941|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/33/21019\" title=\"table 1\">",
"      Disorders treated HCT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2488?source=related_link\">",
"      Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42278?source=related_link\">",
"      Chediak-Higashi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=related_link\">",
"      Chronic granulomatous disease: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=related_link\">",
"      Collection and storage of umbilical cord blood for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=related_link\">",
"      DiGeorge syndrome: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=related_link\">",
"      Evaluation for infection before hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=related_link\">",
"      Gene therapy for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9400?source=related_link\">",
"      General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25850?source=related_link\">",
"      IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22953?source=related_link\">",
"      Leukocyte adhesion deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15176?source=related_link\">",
"      Severe combined immunodeficiency (SCID) with JAK3 deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_2_1067="Actions of cholecystokinin";
var content_f1_2_1067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Actions of cholecystokinin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Contracts the gallbladder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stimulates pancreatic enzyme secretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delays gastric emptying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Induces satiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potentiates insulin secretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regulates intestinal motility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurotransmitter",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1067=[""].join("\n");
var outline_f1_2_1067=null;
var title_f1_2_1068="Initial hx female chronic pelvic pain";
var content_f1_2_1068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial history for women with chronic pelvic pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Characteristics of",
"the pain:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Location and radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intensity, including intensity with menstrual cycle, urination, defecation, and physical activity, if relevant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Timing, especially if only at menses or with intercourse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Quality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Thorough review of systems and past medical/surgical history with particular attention to symptoms or diagnosis of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Endometriosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pelvic inflammatory disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gastrointestinal disease, especially irritable bowel syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Urinary disease, especially interstitial cystitis/painful bladder syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Musculoskeletal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Psychiatric disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any previous diagnostic tests or treatments for pain?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Menstrual, contraceptive, sexual, gynecologic, and obstetric history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is there a history of domestic violence or sexual or other physical abuse?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any history of substance abuse, including alcohol?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of relevant clinical conditions",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Gambone, JC, Mittman, BS, Munro, MG, et al. Fertil Steril 2002; 78:961.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1068=[""].join("\n");
var outline_f1_2_1068=null;
var title_f1_2_1069="Pain scale PI";
var content_f1_2_1069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pain scale",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 228px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1069=[""].join("\n");
var outline_f1_2_1069=null;
var title_f1_2_1070="Common opioids";
var content_f1_2_1070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequently encountered opioids",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"15%\">",
"     </colgroup>",
"     <colgroup width=\"55%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum half-life (hours)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Approximate equivalence to 10 mg morphine injection (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Important clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        IMPORTANT: The doses included here are NOT recommended for the initiation of therapy; they provide equivalents for the purpose of comparing different opioids.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Natural",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Morphine",
"       </td>",
"       <td>",
"        1.9 +/&ndash; 0.5",
"       </td>",
"       <td>",
"        <p>",
"         10 SC/IM/IV",
"        </p>",
"        30 PO",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Codeine",
"       </td>",
"       <td>",
"        2.9 +/&ndash; 0.7",
"       </td>",
"       <td>",
"        <p>",
"         75 SC/IM/IV",
"        </p>",
"        130 to 200 PO",
"       </td>",
"       <td>",
"        Metabolized by CYP2D6 to active drug (morphine). Metabolism and effects are subject to pronounced individual variability. Single oral doses over 65 mg tend to produce disproportionately greater adverse effects than analgesia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Semi-synthetic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydromorphone",
"       </td>",
"       <td>",
"        2.4 +/&ndash; 0.6",
"       </td>",
"       <td>",
"        <p>",
"         1.5 SC/IM/IV",
"        </p>",
"        7.5 PO",
"       </td>",
"       <td>",
"        Hepatically metabolized to metabolites that can accumulate in organ failure and prolong effects. Some metabolites have been linked to neurotoxicity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oxycodone",
"       </td>",
"       <td>",
"        2.6 (2.1-3.1)",
"       </td>",
"       <td>",
"        20 to 30 PO",
"       </td>",
"       <td>",
"        Metabolized by CYP3A4 and 2D6. Prolonged effects and elevated serum concentrations with renal or hepatic insufficiency. May cause QTc prolongation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydrocodone",
"       </td>",
"       <td>",
"        4.24 +/&ndash; 0.99",
"       </td>",
"       <td>",
"        30 PO",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diacetylmorphine (diamorphine, heroin)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        5 SC",
"       </td>",
"       <td>",
"        Highly lipophilic causing more rapid CNS effects than morphine. Largely metabolized to morphine. Due to abuse potential is not available for clinical use in many countries.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Synthetic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meperidine",
"       </td>",
"       <td>",
"        3.2 +/&ndash; 0.8",
"       </td>",
"       <td>",
"        <p>",
"         75 to 100 SC/IM",
"        </p>",
"        300 PO",
"       </td>",
"       <td>",
"        Excitatory neurotoxicity may occur when normeperidine, a renally-eliminated metabolite, accumulates.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methadone",
"       </td>",
"       <td>",
"        27 +/&ndash; 12",
"       </td>",
"       <td>",
"        10 SC/IM/IV Highly variable. See clinical features.",
"       </td>",
"       <td>",
"        Used in opioid substitution therapy. Can cause QTc prolongation. May be far more potent than indicated in this table. Metabolized by CYP3A4. Due to its highly variable and prolonged half-life (up to 150 hours), methadone has the highest risk among opioids of accumulation and toxicity during initial titration and after changes in dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Propoxyphene (dextropropoxyphene)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        65 to 130 PO",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Usual initial dose for mild analgesia shown; NOT equivalent to parenteral morphine 10 mg. Has IA anti-dysrhythmic properties, leading to widened QRS, negative inotropy, and conduction abnormalities. Can cause seizures. Onset of toxic effects is 15 to 60 minutes in overdose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tramadol",
"       </td>",
"       <td>",
"        5.5 (4.5-7.5)",
"       </td>",
"       <td>",
"        50 to 100 PO",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Usual initial dose for mild analgesia shown; NOT equivalent to parenteral morphine 10 mg. Effects NOT completely reversed by naloxone. Noted to cause seizures. Metabolized by CYP2D6 and 3A4. Subject to interactions including serotonin excess.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fentanyl",
"       </td>",
"       <td>",
"        3.7 +/&ndash; 0.4",
"       </td>",
"       <td>",
"        0.05 to 0.1 SC/IM/IV",
"       </td>",
"       <td>",
"        Short acting when administered IV/IM as a single dose. Highly lipophilic. Parent drug accumulates with repeated or prolonged administration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Agonist/antagonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pentazocine",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        <p>",
"         30 to 60 SC/IM",
"        </p>",
"        75 to 150 PO",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Partial agonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Buprenorphine",
"       </td>",
"       <td>",
"        2.33 +/&ndash; 0.24",
"       </td>",
"       <td>",
"        <p>",
"         0.3 to 0.4 IM/IV",
"        </p>",
"        0.4 sublingual",
"       </td>",
"       <td>",
"        Used in opioid substitution therapy. Significantly longer duration of effect than 10 mg parenteral morphine. Metabolized by and subject to interactions involving CYP3A4.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Gastrointestinally insoluble - not analgesic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diphenoxylate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2.5 to 5 PO (anti-diarrheal dose)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Poor solubility limits potential for parenteral injection and abuse. Usually formulated with atropine (US trade name Lomotil&reg;, 0.025 mg atropine and 2.5 mg diphenoxylate) to further decrease abuse potential.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Loperamide",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 to 4 PO (anti-diarrheal dose)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Very low abuse potential due to lack of effect on CNS receptors.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Half-life and equal analgesic dosing approximations apply only to immediate release or SQ/IM preparations, single dose, in opioid naive patients. The actual duration of effect may be longer or shorter than suggested by the serum half-life depending upon the dose, the patient's tolerance, the presence of active metabolites, organ function, and redistribution of the drug.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Not a dose equivalent. Usual initial dose shown.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1070=[""].join("\n");
var outline_f1_2_1070=null;
var title_f1_2_1071="Antibody structure";
var content_f1_2_1071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Antibody (immunoglobulin) structure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 261px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An immunoglobulin molecule is composed of four chains: two identical light chains, shown on the inner aspects of the molecule (in blue and gray), and two identical heavy chains, shown along the outer aspect of the molecule (in red and tan). Each chain is made up of immunoglobulin domains, represented as circles, and contains an internal disulfide bond (not shown). There are usually multiple disulfide bonds linking the two H chains in the hinge region, and also a disulfide linking the H and L chains. Only IgG, IgA, and IgD have distinct hinge regions, and only IgM and IgE have four H chain domains. The points of cleavage of the enzymes pepsin and papain are shown. The combining site (C.S.) is formed by structures contributed by the variable regions of both the heavy chain (VH) and light chain (VL).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_2_1071=[""].join("\n");
var outline_f1_2_1071=null;
      